• Seto, W.-K., Lo, Y.-R., Pawlotsky, J.-M., & Yuen, M.-F. (2018). Chronic hepatitis B virus infection. Lancet, 392(10161), 2313-2324. doi:10.1016/S0140-6736(18)31865-8

• Yuen, M. F., Chen, D. S., Dusheiko, G. M., Janssen, H. L. A., Lau, D. T. Y., Locarnini, S. A., Peters, M. G., & Lai, C. L. (2018). Hepatitis B virus infection. [dsfd]. Nat Rev Dis Primers, 4, 18035. doi:10.1038/nrdp.2018.35

• Chun-Ming, W., Felice Ho-Ching, T., & Irene Oi-Lin, N. (2018). Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nature Reviews Gastroenterology & Hepatology, 15(3). doi:10.1038/nrgastro.2017.169

• Tong, M., Che, N., Zhou, L., Luk, S. T., Kau, P. W., Chai, S., Ngan, E. S., Lo, C.-M., Man, K., Ding, J., Lee, T. K., & Ma, S. (2018). Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib. Journal of Hepatology, 69(4), 826-839. doi:10.1016/j.jhep.2018.05.034

• Brunt, E., Aishima, S., Clavien, P. A., Fowler, K., Goodman, Z., Gores, G., Gouw, A., Kagen, A., Klimstra, D., Komuta, M., Kondo, F., Miksad, R., Nakano, M., Nakanuma, Y., Ng, I., Paradis, V., Nyun Park, Y., Quaglia, A., Roncalli, M., Roskams, T., Sakamoto, M., Saxena, R., Sempoux, C., Sirlin, C., Stueck, A., Thung, S., Tsui, W. M. S., Wang, X. W., Wee, A., Yano, H., Yeh, M., Zen, Y., Zucman‐Rossi, J., & Theise, N. (2018). cHCC‐CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology, 68(1), 113-126. doi:10.1002/hep.29789

• Chen, M., Wei, L., Law, C. T., Tsang, F. H. C., Shen, J., Cheng, C. L. H., Tsang, L. H., Ho, D. W. H., Chiu, D. K. C., Lee, J. M. F., Wong, C. C. L., Ng, I. O. L., & Wong, C. M. (2018). RNA N6‐methyladenosine methyltransferase‐like 3 promotes liver cancer progression through YTHDF2‐dependent posttranscriptional silencing of SOCS2. Hepatology, 67(6), 2254-2270. doi:10.1002/hep.29683

• Fung, J., Cheung, K. S., Wong, D. K. H., Mak, L. Y., To, W. P., Seto, W. K., Lai, C. L., & Yuen, M. F. (2018). Long‐term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e‐antigen seroclearance. Hepatology, 68(2), 462-472. doi:10.1002/hep.29874

• Cheng, B. Y., Lau, E. Y., Leung, H.-W., Leung, C. O.-N., Ho, N. P., Gurung, S., Cheng, L. K., Lin, C. H., Lo, R. C.-L., Ma, S., Ng, I. O.-L., & Lee, T. K. (2018). IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma. Cancer research, 78(9), 2332. doi:10.1158/0008-5472.CAN-17-2445

• Lo, R. C.-L., Leung, C. O.-N., Chan, K. K.-S., Ho, D. W.-H., Wong, C.-M., Lee, T. K.-W., & Ng, I. O.-L. (2018). Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/β-catenin pathway. Cell death and differentiation, 25(8), 1426-1441. doi:10.1038/s41418-018-0059-x

• Seto, W.-K., Hui, R. W. H., Mak, L.-Y., Fung, J., Cheung, K.-S., Liu, K. S. H., Wong, D. K.-H., Lai, C.-L., & Yuen, M.-F. (2018). Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 16(4), 575-583.e572. doi:10.1016/j.cgh.2017.09.044

• Chan, L. H., Zhou, L., Ng, K. Y., Wong, T. L., Lee, T. K., Sharma, R., Loong, J. H., Ching, Y. P., Yuan, Y.-F., Xie, D., Lo, C. M., Man, K., Artegiani, B., Clevers, H., Yan, H. H., Leung, S. Y., Richard, S., Guan, X.-Y., Huen, M. S. Y., & Ma, S. (2018). PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma through CRAF Methylation. Cell Reports, 25(3), 690-701.e698. doi:10.1016/j.celrep.2018.09.053

• Mak, L. Y., Wong, D. K. H., Cheung, K. S., Seto, W. K., Lai, C. L., & Yuen, M. F. (2018). Review article: hepatitis B core‐related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. In Alimentary Pharmacology & Therapeutics (Vol. 47, pp. 43-54).

• Mak, L. Y., & Yuen, M. F. (2018). Letter: serum HBcrAg is a useful marker for disease monitoring, predicting treatment response and disease outcome of chronic hepatitis B virus infection—authors' reply. Alimentary Pharmacology & Therapeutics, 47(12), 1720-1721. doi:10.1111/apt.14684

• Wong, G. L. H., Seto, W. K., Wong, V. W. S., Yuen, M. F., & Chan, H. L. Y. (2018). Review article: long‐term safety of oral anti‐viral treatment for chronic hepatitis B. Alimentary Pharmacology & Therapeutics, 47(6), 730-737. doi:10.1111/apt.14497

• Tse, A. P.-W., Sze, K. M.-F., Shea, Q. T.-K., Chiu, E. Y.-T., Tsang, F. H.-C., Chiu, D. K.-C., Zhang, M. S., Lee, D., Xu, I. M.-J., Chan, C. Y.-K., Koh, H.-Y., Wong, C.-M., Zheng, Y.-P., Ng, I. O.-L., & Wong, C. C.-L. (2018). Hepatitis transactivator protein X promotes extracellular matrix modification through HIF/LOX pathway in liver cancer. Oncogenesis, 7(5), 44-44. doi:10.1038/s41389-018-0052-8

• Ma, K., Chok, K., She, W., Cheung, T., Chan, A., Dai, W., Fung, J., & Lo, C. (2018). Hepatocholangiocarcinoma/intrahepatic cholangiocarcinoma: are they contraindication or indication for liver transplantation? A propensity score-matched analysis. Hepatology International, 12(2), 167-173. doi:10.1007/s12072-018-9847-0

• Mak, K.-H. L.-Y., Wong, K.-H. D., Cheung, K.-H. K.-S., Seto, K.-H. W.-K., Lai, K.-H. C.-L., & Yuen, K.-H. M.-F. (2018). Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. Clinical and Translational Gastroenterology, 9(6), e163-e163. doi:10.1038/s41424-018-0020-9

• Gao, W. W., Tang, H. V., Cheng, Y., Chan, C. P., Chan, C. P., & Jin, D. Y. (2018). Suppression of gluconeogenic gene transcription by SIK1-induced ubiquitination and degradation of CRTC1. Biochim Biophys Acta Gene Regul Mech, 1861(3), 211-223. doi:10.1016/j.bbagrm.2018.01.021

• Chan, K. K.-S., & Lo, R. C.-L. (2018). Deregulation of Frizzled Receptors in Hepatocellular Carcinoma. International journal of molecular sciences, 19(1). doi:10.3390/ijms19010313

• Lo, R. C.-L., Chan, K. K.-S., Chok, K. S.-H., & Ng, I. O.-L. (2018). Liver allograft biopsies with histological cholestasis: a clinicopathological study of 254 cases from a single centre. Journal of Clinical Pathology, 71(1), 72. doi:10.1136/jclinpath-2017-204334

• Ma, K. W., Chok, K. S. H., She, W. H., Chan, A. C. Y., Cheung, T. T., Dai, W. C., Fung, J. Y. Y., & Lo, C. M. (2018). Defining Optimal Surgical Treatment for Recurrent Hepatocellular Carcinoma: A Propensity Score Matched Analysis. Liver Transplantation, 24(8), 1062-1069. doi:10.1002/lt.25033

• Hui, R. W. H., Seto, W. K., Cheung, K. S., Mak, L. Y., Liu, K. S. H., Fung, J., Wong, D. K. H., Lai, C. L., & Yuen, M. F. (2018). Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case‐control study. Journal of Viral Hepatitis, 25(1), 97-104. doi:10.1111/jvh.12766

• Sawai, H., Nishida, N., Khor, S.-S., Honda, M., Sugiyama, M., Baba, N., Yamada, K., Sawada, N., Tsugane, S., Koike, K., Kondo, Y., Yatsuhashi, H., Nagaoka, S., Taketomi, A., Fukai, M., Kurosaki, M., Izumi, N., Kang, J.-H., Murata, K., Hino, K., Nishina, S., Matsumoto, A., Tanaka, E., Sakamoto, N., Ogawa, K., Yamamoto, K., Tamori, A., Yokosuka, O., Kanda, T., Sakaida, I., Itoh, Y., Eguchi, Y., Oeda, S., Mochida, S., Yuen, M.-F., Seto, W.-K., Poovorawan, Y., Posuwan, N., Mizokami, M., & Tokunaga, K. (2018). Genome-wide association study identified new susceptible genetic variants in HLA class I region for hepatitis B virus-related hepatocellular carcinoma. Scientific reports, 8(1), 7958-7958. doi:10.1038/s41598-018-26217-7

• Mak, L.-Y., Seto, W.-K., Lai, C.-L., & Yuen, M.-F. (2018a). An update on the toxicological considerations for protease inhibitors used for hepatitis C infection. Expert Opinion on Drug Metabolism & Toxicology, 14(5), 483-491. doi:10.1080/17425255.2018.1472236

• Mak, L.-Y., Seto, W.-K., Lai, C.-L., & Yuen, M.-F. (2018b). Pharmacokinetic evaluation of besifovir for the treatment of HBV infection. Expert Opinion on Drug Metabolism & Toxicology, 14(1), 101-106. doi:10.1080/17425255.2018.1417983

• Au, K. P., & Chok, K. S. H. (2018). Minimally invasive donor hepatectomy, are we ready for prime time? World journal of gastroenterology, 24(25), 2698-2709. doi:10.3748/wjg.v24.i25.2698

• Burt, A. D., Alves, V., Bedossa, P., Clouston, A., Guido, M., Hübscher, S., Kakar, S., Ng, I., Park, Y. N., Reeves, H., Wyatt, J., Yeh, M. M., & Ellis, D. W. (2018). Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology, 73(3), 369-385. doi:10.1111/his.13520

• Ma, K., Cheung, T., She, W., Chok, K., Chan, A., Dai, W., Chiu, W., & Lo, C. (2018). Diagnostic and Prognostic Role of 18-FDG PET/CT in the Management of Resectable Biliary Tract Cancer. World Journal of Surgery, 42(3), 823-834. doi:10.1007/s00268-017-4192-3

• Lo, R. C. L., Chan, K. K. S., Leung, C. O. N., & Ng, I. O. L. (2018). Expression of hepatic progenitor cell markers in acute cellular rejection of liver allografts—An immunohistochemical study. Clinical Transplantation, 32(3), n/a-n/a. doi:10.1111/ctr.13203

• Dai, W. C., Chok, K. S. H., Sin, S. L., Chan, A. C. Y., Cheung, T. T., Wong, T. C. L., & Lo, C. M. (2018). Impact of intraoperative blood transfusion on long‐term outcomes of liver transplantation for hepatocellular carcinoma. ANZ Journal of Surgery, 88(5), E418-E423. doi:10.1111/ans.13815

• Cheung, C. Y., Chok, K. S. H., Lee, O. J., Lo, K. S., Chan, S. C., & Lo, C. M. (2018). Asia's first combined liver transplant and aortic valve replacement. Hepatobiliary & Pancreatic Diseases International, 17(1), 86-87. doi:10.1016/j.hbpd.2018.01.011

• Ma, K. W., Chan, A. C. Y., She, B. W. H., Chok, K. S. H., Cheung, T. T., Dai, J. W. C., Fung, J. Y. Y., & Lo, C. M. (2018). Changing Paradigm in the Surgical Management of Hepatocellular Carcinoma With Salvage Transplantation. Transplantation Proceedings, 50(4), 1087-1093. doi:10.1016/j.transproceed.2018.01.025

• Sin, S. T. K., Li, Y., Liu, M., Yuan, Y. F., Ma, S., & Guan, X. Y. (2018). Down‐regulation of TROP‐2 Predicts Poor Prognosis of Hepatocellular Carcinoma Patients. Hepatology Communications, 2(11), 1408-1414. doi:10.1002/hep4.1242

• Ma, K. W., Chok, K. S. H., Fung, J. Y. Y., & Lo, C. M. (2018). Liver Transplantation for Hepatitis B Virus-related Hepatocellular Carcinoma in Hong Kong. Journal of clinical and translational hepatology, 6(3), 283-288. doi:10.14218/JCTH.2017.00058

• She, W. H., Chan, A. C. Y., Cheung, T. T., Lo, C. M., & Chok, K. S. H. (2018). Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative alpha-fetoprotein levels. World journal of hepatology, 10(2), 308. doi:10.4254/wjh.v10.i2.308

• Lo RC, Kim H. Histopathological evaluation of liver fibrosis and cirrhosis regression. Clin Mol Hepatol. 2017; 23(4):302-307

• Ng KC, Chok KS, Chan AC, Cheung TT, Wong CL, Fung JY, Yuen J, Poon RTP, Fan ST, Lo CM. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. British Journal of Surgery. 2017; 104(13):1775-1784

• Mak LY, Wong DK, Seto WK, Lai CL, Yuen MF. Hepatitis B core protein as a therapeutic target. Expert Opin Ther Targets. 2017; 21(12):1153-1159

• Tey SK, Tse EYT, Mao X, Ko FCF, Wong AST, Lo RC, Ng IO, Yam JWP. Nuclear Met promotes hepatocellular carcinoma tumorigenesis and metastasis by upregulation of TAK1 and activation of NF-κB pathway. Cancer Lett. 2017; 411:150-161

• Ma KW, Cheung TT, She WH, Chok KS, Chan AC, Dai WC, Lo CM. Risk prediction model for major complication after hepatectomy for malignant tumour - A validated scoring system from a university center. Surg Oncol. 2017; 26(4):446-452

• Cui CP, Wong CC, Kai AK, Ho DW, Lau EY, Tsui YM, Chan LK, Cheung TT, Chok KS, Chan AC, Lo RC, Lee JM, Lee TK, Ng IO. SENP1 promotes hypoxia-induced cancer stemness by HIF-1α deSUMOylation and SENP1/HIF-1α positive feedback loop. Gut. 2017; 66(12):2149-2159

• Jiang L, Yan Q, Fang S, Liu M., Li Y, Yuan YF, Li Y, Zhu Y, Qi J, Yang X, Kwong DL, Guan XY. Calcium Binding Protein 39 Promotes Hepatocellular Carcinoma Growth And Metastasis By Activating Erk Signaling Pathway. Hepatology. 2017; 66(5):1529-1545

• Chok KS, Chan AC, Fung JY, Dai WC, Cheung TT, Lo CM. Comparable short- and long-term outcomes in deceased-donor and living-donor liver retransplantation. Hepatol Int. 2017; 11(6):517-522

• Ma KF, Lau EY, Leung DH, Lo J, Ho NP, CHENG YL, Ma SK, Lin C, Copland JA, Ding J, Lo RC, Ng IO, Lee TK. Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress induced differentiation. Journal of Hepatology. 2017; 67(5):979-990

• Liu AJ, RAO Y, Cheung MP, Hui MN, Wu MH, Chan LK, Ng IO, Niu B, Cheah KS, Sharma R, Hodgson L, Cheung MC. Asymmetric localization of DLC1 defines avian trunk neural crest polarity for directional delamination and migration. Nature Communications. 2017; 8(1):1185

• Lam YF, Seto WK, Wong D, Cheung KS, Fung J, Mak LY, Yuen J, Chong CK, Lai CL, Yuen MF. Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels. Clin Transl Gastroenterol. 2017; 8(10):e125

• Liu XB, Lo CM, Cheng Q, Ng KT, Shao Y, Li CX, Chung SK, Ng IO, Yu J, Man K. Oval Cells Contribute to Fibrogenesis of Marginal Liver Grafts under Stepwise Regulation of Aldose Reductase and Notch Signaling. Theranostics. 2017; 7(19):4879-4893

• Lee D, Wong CC. The folate cycle is a new metabolic weakness of cancer. Molecular & Cellular Oncology. 2017; 4(6):e1327004

• Fung J, Wong T, Chok KS, Chan AC, Sin SL, Cheung TT, Dai WC, Ng K, Ng KT, Man K, Seto WK, Lai CL, Yuen MF, Lo CM. Oral Nucleos(t)ide Analogs Alone After Liver Transplantation in Chronic Hepatitis B With Preexisting rt204 Mutation. Transplantation. 2017; 101(10):2391-2398

• Tong AC, Ng IO, Lo MC. Immunoglobulin G4-related sclerosing disease involving the mandible. Hong Kong Med J. 2017; 23(5):534-6

• Fung JY, Wong T, Chok KS, Chan AC, Cheung TT, Dai JW, Sin SL, Ma KW, Ng K, Ng KT, Seto WK, Lai CL, Yuen MF, Lo CM. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years. Hepatology. 2017; 66(4):1036-1044

• Wei L, Chiu DK, Tsang FH, Law DC, Cheng CL, Au SL, Lee JM, Wong CC, Ng IO#, Wong CM# (# Corresponding author). Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3. J Hepatol. 2017; 67(4):758-769

• Chiu DK, Tse AP, Xu IM, Cui D, Lai RK, Li LL, Koh HY, Tsang FH, Wei LL, Wong CM, Ng IO, Wong CC. Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma. Nat Commun. 2017; 8(1):517
• Ma KW, Chok KS, Chan AC, Tam SC, Dai WC, Cheung TT, Fung JY, Lo CM. A new formula for estimation of standard liver volume using computed tomography-measured body thickness. Liver Transplantation. 2017; 23(9):1113-1122

• Chan KK, Leung CO, Wong CC, Ho DW, Chok KS, Lai CL, Ng IO, Lo RC. Secretory Stanniocalcin 1 promotes metastasis of hepatocellular carcinoma through activation of JNK signaling pathway. Cancer Lett. 2017; 403:330-338

• Ng KY, Chan JL, Chai S, Tong M, Guan X, Lee NP, Yuan YF, Xie D, Lee TK, Dusetti NJ, Carrier A, Ma SK. TP53INP1 down-regulation activates a p73-dependent DUSP10/ERK signaling pathway to promote metastasis of hepatocellular carcinoma. Cancer Research. 2017; 77(17):4602-4612

• Zhang AY, Lai CL, Huang FY, Seto WK, Fung J, Wong DK, Yuen MF. Deep sequencing analysis of quasispecies in the HBV pre-S region and its association with hepatocellular carcinoma. J Gastroenterol. 2017; 52(9): 1064-1074

• Li J, Mak LY, Wong DK, Fung J, Seto WK, Lai CL, Yuen MF. The role of interleukin-27 in predicting spontaneous HBeAg seroconversion in chronic hepatitis B infection. Liver Int. 2017; 37(9):1287-1294

• Cheung KS, Seto WK, Fung J, Lai CL, Yuen MF. Epidemiology and Natural History of Primary Biliary Cholangitis in the Chinese: A Territory-Based Study in Hong Kong between 2000 and 2015. Clin Transl Gastroenterol. 2017; 8(8):e116

• Lo RC, Leung CO, Chok KS, Ng IO. Variation of stemness markers expression in tumor nodules from synchronous multi-focal hepatocellular carcinoma - an immunohistochemical study. Diagn Pathol. 2017; 12(1):56

• Wu CX, Xu A, Zhang CC, Olson P, Chen L, Lee TK, Cheung TT, Lo CM, Wang XQ. Notch inhibitor (PF-03084014) inhibits hepatocellular carcinoma growth and metastasis via suppression cancer stemness due to reduced activation of Notch1-Stat3. Molecular Cancer Therapeutics. 2017; 16(8):1531-1543

• Chong CK, Cheng CY, Tsoi SY, Huang FY, Liu F, Seto WK, Lai CL, Yuen MF, Wong DK. Role of hepatitis B core protein in HBV transcription and recruitment of histone acetyltransferases to cccDNA minichromosome. Antiviral Res. 2017; 144:1-7

• Cheung KS, Seto WK, Wong DK, Lai CL, Yuen MF. Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy. J Viral Hepat. 2017; 24(8):654-661

• Ho DW, Chan LK, Chiu YT, Xu IM, Poon RT, Cheung TT, Tang CN, Tang VW, Lo IL, Lam PW, Yau DT, Li MX, Wong CM#, Ng IO# (# Corresponding author). TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication. Gut. 2017; 66(8):1496-1506

• Yang Y, Zhou Y, Hou J, Bai C, Li Z, Fan J, Ng IO, Zhou W, Sun H, Dong Q, Lee JM, Lo CM, Man K, Yang Y, Li N, Ding G, Yu Y, Cao X. Hepatic IFIT3 predicts interferon-α therapeutic response in patients of hepatocellular carcinoma. Hepatology. 2017; 66(1):152-166

• Wong TL, Che N, Ma S. Reprogramming of Central Carbon Metabolism in Cancer Stem Cells. Biochim Biophys Acata. 2017; 1863(7):1728-1738

• Cheung KS, Seto WK, Wong DK, Mak LY, Lai CL, Yuen MF. Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment. Oncotarget. 2017; 8(29):47507-47517 

• Wong DK, Seto WK, Cheung KS, Chong CK, Huang FY, Fung J, Lai CL, Yuen MF. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int. 2017; 37(7):995-1001

• Cheung KS, Seto WK, Fung J, Lai CL, Yuen MF. Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid. Clin Transl Gastroenterol. 2017; 8(6):e100

• Li WS, Chok KS. Acute hepatitis E virus infection causing acute liver failure requiring living-donor liver transplantation in a non-pregnant immunocompetent woman. Transplant Infectious Disease. 2017; 19(3): e12699

• Tsui YM, Sze KM, Tung EK, Ho DW, Lee TK, Ng IO. Dishevelled-3 phosphorylation is governed by HIPK2/PP1Cα/ITCH axis and the non-phosphorylated form promotes cancer stemness via LGR5 in hepatocellular carcinoma. Oncotarget. 2017; 8(24):39430-39442

• Xia W, Lo CM, Poon RYC, Cheung TT, Chen L, Yang S, Tsao SW, Wang XQ. Smad inhibitor induces CSC differentiation for effective chemosensitization in cyclin D1- and TGF-β/Smad-regulated liver cancer stem cell-like cells. Oncotarget. 2017; 8(24):38811-38824

• Yang S, Wang XQ. XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance. BMC Cancer. 2017; 17(1):344

• Lee D, Xu IM, Chiu DK, Lai RK, Tse AP, Lan Li L, Law CT, Tsang FH, Wei LL, Chan CY, Wong CM, Ng IO, Wong CC. Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma. J Clin Invest. 2017; 127(5):1856-1872

• Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, Gill H, Lam YF, Lau EHY, Cheung KS, Lie AKW, Lai CL, Kwong YL, Yuen MF. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study. Hepatology. 2017; 65(5):1451-1461

• Chu KK, Chan SC, Sin SL, Chan AC, Chok KS, Cheng IK, Lo CM. Lipid profiles of donors and recipients of liver transplant: like father like son. Hepatology International. 2017; 11(3):300-305

• Kotewall CN, Cheung TT, She WH, Ma KW, Tsang HY, Dai WC, Chan AC, Chok KS, Lo CM. The role of radiofrequency ablation to liver transection surface in patients with close tumor margin of HCC during hepatectomy - a case matched study. Translational Gastroenterology and Hepatology. 2017; 2:33

• Deng JJ, Kong KE, Gao WW, Tang HV, Chaudhary V, Cheng Y, Zhou J, Chan CP, Wong DK, Yuen MF, Jin DY. Interplay between SIRT1 and hepatitis B virus X protein in the activation of viral transcription. Biochim Biophys Acta. 2017; 1860(4):491-501

• Ching RH, Sze KM, Lau EY, Chiu YT, Lee JM, Ng IO, Lee TK. C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3/Nanog signaling pathway. Oncotarget. 2017; '8(14):23507-23516

• Chok KS, Chan MM, Dai WC, Chan AC, Cheung TT, Wong CL, She WH, Lo CM. Survival outcomes of hepatocellular carcinoma resection with postoperative complications - a propensity-score-matched analysis. Medicine (Baltimore). 2017; 96(12):e6430

• Leong KW, Cheng CW, Wong CM, Ng IO, Kwong YL, Tse E. miR-874-3p is down-regulated in hepatocellular carcinoma and negatively regulates PIN1 expression. Oncotarget. 2017; 8(7):11343-11355

• Seto WK, Lau EH, Wu JT, Hung IF, Leung WK, Cheung KS, Fung J, Lai CL, Yuen MF. Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study. Aliment Pharmacol Ther. 2017; 45(4):501-509

• Seto WK, Yuen MF. Nonalcoholic fatty liver disease in Asia: emerging perspectives. J Gastroenterol. 2017; 52(2):164-174

• Lai CL, Wong D, Ip P, Kopaniszen M, Seto WK, Fung J, Huang FY, Lee B, Cullaro G, Chong CK, Wu R, Cheng C, Yuen J, Ngai V, Yuen MF. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. Journal of Hepatology. 2017; 66(2):275-281

• Wang XQ, Lo CM, Chen L, Ngan ESW, Xu A, Poon RYC. CDK1-PDK1-PI3K/Akt signaling pathway regulates embryonic and induced pluripotency. Cell Death & Differentiation. 2017; 24(1):38-48

• Chok KS, Fung JY, Chan AC, Dai WC, Sharr WW, Cheung TT, Chan SC, Lo CM. Comparable Short- and Long-term Outcomes in Living Donor and Deceased Donor Liver Transplantations for Patients With Model for End-stage Liver Disease Scores ≥35 in a Hepatitis-B Endemic Area. Ann Surg. 2017; 265(1):173-177

• Chai S, Ng KY, Tong M, Lau EY, Lee TK, Chan KW, Yuan YF, Cheung TT, Cheung ST, Wang XQ, Wong N, Lo CM, Man K, Guan XY, Ma S. Octamer4/microRNA-1246 signaling axis drives Wnt/β-catenin activation in liver cancer stem cells. Hepatology. 2016; 64(6):2062-2076

• Mao XW, Wong SY, Tse EY, Ko FC, Tey SK, Yeung YS, Man K, Lo RC, Ng IO, Yam JW. Mechanisms through Which Hypoxia-Induced Caveolin-1 Drives Tumorigenesis and Metastasis in Hepatocellular Carcinoma.  Cancer Res. 2016; 76(24):7242-7253

• Seto WK, Wong DH, Chan TY, Hwang YY, Fung J, Liu KS, Gill H, Lam YF, Cheung KS, Lie AK, Lai CL, Kwong YL, Yuen MF. Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy. Am J Gastroenterol. 2016; 111(12):1788-1795

• Seto WK, Fung J, Cheung KS, Mak LY, Hui RW, Liu KS, Lai CL, Yuen MF. Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B. Aliment Pharmacol Ther. 2016; 44(10):1071-1079

• Seto WK, Yuen MF. New pharmacological approaches to a functional cure of hepatitis B. Clinical Liver Disease. 2016; 8(4): 83-88

• Chow RK, Sin ST, Liu M, Li Y, Chan TH, Song Y, Chen L, Kwong DL, Guan XY. AKR7A3 suppresses tumorigenicity and chemoresistance in hepatocellular carcinoma through attenuation of ERK, c-Jun and NF-κB signaling pathways. Oncotarget. 2016; 8(48): 83469-83479

• Ma S. Deciphering ZIC2/OCT4 signaling as a vulnerability in liver cancer stem cells. Transl Cancer Res. 2016; 5 Supp 4

• Ho DW, Lo RC, Chan LK, Ng IO. Molecular Pathogenesis of Hepatocellular Carcinoma. Liver Cancer. 2016; 5(4):290-302

• Xu HT, Lai WL, Liu HF, Wong LL, Ng IO, Ching YP. PAK4 Phosphorylates p53 at Serine 215 to Promote Liver Cancer Metastasis. Cancer Res. 2016; 76(19):5732-5742 • Chiu DK, Xu IM, Lai RK, Tse AP, Wei LL, Koh HY, Li LL, Lee D, Lo RC, Wong CM, Ng IO, Wong CC. Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26. Hepatology. 2016; 64(3):797-813

• Zhang AY, Lai CL, Poon RT, Huang FY, Seto WK, Fung J, Wong DK, Yuen MF. Hepatitis B virus full-length genomic mutations and quasispecies in hepatocellular carcinoma. J Gastroenterol Hepatol. 2016; 31(9): 1638-45

• Kai AK, Chan LK, Lo RC, Lee JM, Wong CC, Wong JC, Ng IO. Down-regulation of TIMP2 by HIF-1α/miR-210/HIF-3α regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma.  Hepatology. 2016; 64(2):473-87

• Ma KW, Cheung TT, She WH, Chok KS, Chan AC, Ng IO, Chan SC, Lo CM. The effect of wide resection margin in patients with intrahepatic cholangiocarcinoma: A single-center experience. Medicine (Baltimore). 2016; 95(28):e4133

• Ma W, Sze KM, Chan LK, Lee JM, Wei LL, Wong CM, Lee TK, Wong CC, Ng IO. RhoE/ROCK2 regulates chemoresistance through NF-κB/IL-6/ STAT3 signaling in hepatocellular carcinoma. Oncotarget. 2016; 7(27):41445-41459

• Fung J, Lai CL, Seto WK, Yuen MF. Emerging drugs for the treatment of hepatitis B. Expert Opin Emerg Drugs. 2016; 21(2):183-93

• Wong CC, Wong CM, Ng IO. Hormonal control of the metabolic machinery of hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2016; 5(3):195-7

• Liu SK, Seto WK, Lai CL, Yuen MF. Hepatitis B: treatment choice and monitoring for response. Expert Review of Gastroenterology & Hepatology. 2016; 10(6):697-707

• Chiu YT, Wong JK, Choi SW, Sze KM, Ho DW, Chan LK, Lee JM, Man K, Cherny S, Yang WL, Wong CM, Sham PC, Ng IO. Novel pre-mRNA splicing of intronically integrated HBV generates oncogenic chimera in hepatocellular carcinoma. J Hepatol. 2016; 64(6):1256-64

• Lai RK, Xu IM, Chiu DK, Tse AP, Wei LL, Law CT, Lee D, Wong CM, Wong MP, Ng IO, Wong CC. NDUFA4L2 Fine-tunes Oxidative Stress in Hepatocellular Carcinoma. Clin Cancer Research. 2016; 22(12): 3105-17 • Chiu YT, Ng IO. Gender disparity of hepatocellular carcinoma: role of hepatitis B virus X protein and androgen receptor. Hong Kong Med J. 2016; 22(3 Suppl 4):43-7

• Lau EY, Lo J, Cheng BY, Ma MK, Lee JM, Ng JK, Chai S, Lin CH, Tsang SY, Ma S, Ng IO, Lee TK. Cancer-Associated Fibroblasts Regulate Tumor-Initiating Cell Plasticity in Hepatocellular Carcinoma through c-Met/FRA1/HEY1 Signaling. Cell Rep. 2016; 15(6):1175-89

• Leung CO, Mak WN, Kai AK, Chan KS, Lee TK, Ng IO, Lo RC. Sox9 confers stemness properties in hepatocellular carcinoma through Frizzled-7 mediated Wnt/β-catenin signaling. Oncotarget. 2016; 7(20):29371-86

• Liu M, Chen L, Ma NF, Chow RK, Li Y, Song Y, Chan TH, Fang S, Yang X, Xi S, Jiang L, Li Y, Zeng TT, Li Y, Yuan YF, Guan XY. CHD1L promotes lineage reversion of hepatocellular carcinoma through opening chromatin for key developmental transcription factors. Hepatology. 2016; 63(5):1544-59

• Cheung KS, Seto WK, Lai CL, Yuen MF. Prevention and management of hepatitis B virus reactivation in cancer patients. Hepatol Int. 2016; 10(3):407-14

• Seto WK, Tanaka Y, Wong DK, Shinkai N, Cheung KS, Liu KS, Fung J, Lai CL, Yuen MF. Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance. Liver Int. 2016; 36(5):642-50

• Seto WK, Cheung KS, Wong DK, Huang FY, Fung J, Liu KS, Lai CL, Yuen MF. Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability. J Gastroenterol. 2016; 51(5):487-95

• Lo J, Lau EY, So FT, Lu P, Chan VS, Cheung VC, Ching RH, Cheng BY, Ma MK, Ng IO, Lee TK. Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma. Liver Int. 2016; 36(5):737-45

• Ng KY, Chai S, Tong M, Guan XY, Lin CH, Ching YP, Xie D, Cheng AS, Ma S. C-terminal truncated hepatitis B virus X protein promotes hepatocellular carcinogenesis through induction of cancer and stem cell-like properties. Oncotarget. 2016; 7(17): 24005-24017

• Cheng Y, Gao WW, Tang HM, Deng JJ, Wong CM, Chan CP, Jin DY. β-TrCP-mediated ubiquitination and degradation of liver-enriched transcription factor CREB-H. Scientific Reports. 2016; 6:23938

• Lo RC, Suriawinata AA, Rubin BP. Liver metastasis of meningeal hemangiopericytoma: a study of 5 cases. Clin Mol Hepatol. 2016; 22(1):188-91

• Xiong L, Teng JL, Botelho MG, Lo RC, Lau SK, Woo PC. Arginine Metabolism in Bacterial Pathogenesis and Cancer Therapy. Int J Mol Sci. 2016; 17(3):363

• Wong DK, Fung J, Lee CK, Seto WK, Leung J, Huang FY, Lin CK, Lai CL, Yuen MF. Intrahepatic hepatitis B virus replication and liver histology in subjects with occult hepatitis B infection. Clin Microbiol Infect. 2016; (3):290.e1-3

• Hung IF, Wong DK, Poon RT, Fong DY, Chui AH, Seto WK, Fung JY, Chan AC, Yuen JC, Tiu R, Choi O, Lai CL, Yuen MF. Risk Factors and Post-Resection Independent Predictive Score for the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma. PLoS One. 2016; 11(2):e0148493

• Xu IM, Lai RK, Lin SH, Tse AP, Chiu DK, Koh HY, Law CT, Wong CM, Cai Z, Wong CC, Ng IO. Transketolase counteracts oxidative stress to drive cancer development. Proc Natl Acad Sci U S A. 2016; 113(6):E725-34

• Wong CM, Wei L, Law CT, Ho DW, Tsang FH, Au SL, Sze KM, Lee JM, Wong CC, Ng IO. Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis. Hepatology. 2016; 63(2):474-87

• CHEN Y, Seto WK, Ho LM, Fung JY, Jim MH, Yip WK, Fan KY, ZHEN Z, Liu J, Yuen MF, Lau CP, Tse HF, Yiu KH. Relation of Tricuspid Regurgitation to Liver Stiffness Measured by Transient Elastography in Patients With Left-Sided Cardiac Valve Disease. Am J Cardiol. 2016; 117(4):640-6

• Yuen MF. Need to improve awareness and management of hepatitis B reactivation in patients receiving immunosuppressive therapy. Hepatol Int. 2016; 10(1):102-5

• Ching RH, Lau EY, Ling PM, Lee JM, Ma MK, Cheng BY, Lo RC, Ng IO, Lee TK. Phosphorylation of Nucleophosmin at Threonine 234/237 is associated with HCC metastasis. Oncotarget. 2015; 6(41):43483-95

• Fung J, Lo R, Chan SC, Chok KS, Wong T, Sharr W, Cheung TT, Chan AC, Dai WC, Sin SL, Ng IO, Lai CL, Yuen MF, Lo CM. Outcomes including liver histology after liver transplantation for chronic hepatitis B using oral antiviral therapy alone. Liver Transpl. 2015; 21(12):1504-1510

• She WH, Chan AC, Poon RT, Cheung TT, Chok KS, Chan SC, Lo CM. Defining an optimal surgical strategy for synchronous colorectal liver metastases: staged versus simultaneous resection. ANZ J Surg. 2015; 85(11):829-33

• Jiang L, Kwong DL, Li Y, Liu M, Yuan YF, Li Y, Fu L, Guan XY. HBP21, a chaperone of heat shock protein 70, functions as a tumor suppressor in hepatocellular carcinoma. Carcinogenesis. 2015; 36(10):1111-20

• Song Y, Pan G, Chen L, Ma S, Zeng T, Chan TH, Li L, Lian Q, Chow R, Cai X, Li Y, Li Y, Liu M, Li Y, Zhu Y, Wong N, Yuan YF, Pei D, Guan XY. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells. Gastroenterology. 2015; 149(4):1068-1081

• Huang FY, Wong DK, Seto WK, Lai CL, Yuen MF. Estradiol induces apoptosis via activation of miRNA-23a and p53: implication for gender difference in liver cancer development. Oncotarget. 2015; 6(33):34941-52

• Tsang FH, Au SL, Wei L, Fan DN, Lee JM, Wong CC, Ng IO, Wong CM. MicroRNA-142-3p and microRNA-142-5p are downregulated in hepatocellular carcinoma and exhibit synergistic effects on cell motility. Front Med. 2015; 9(3):331-43 

• Ho DW, Kai AK, Ng IO. TCGA whole-transcriptome sequencing data reveals significantly dysregulated genes and signaling pathways in hepatocellular carcinoma. Front Med. 2015; 9(3):322-30

• Zhang AY, Lai CL, Huang FY, Seto WK, Fung J, Wong DK, Yuen MF. Evolutionary Changes of Hepatitis B Virus Pre-S Mutations Prior to Development of Hepatocellular Carcinoma. PLoS One. 2015; 10(9):e0139478

• Lo J, Lau EY, Ching RH, Cheng BY, Ma MK, Ng IO, Lee TK. NF-κB mediated CD47 upregulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma. Hepatology. 2015; 62(2):534-45

• Ho DW, Sze KM, Ng IO. Virus-Clip: a fast and memory-efficient viral integration site detection tool at single-base resolution with annotation capability. Oncotarget. 2015; 6(25):20959-63

• Chan LK, Chiu YT, Sze KM, Ng IO. Tensin4 is up-regulated by EGF-induced ERK1/2 activity and promotes cell proliferation and migration in hepatocellular carcinoma. Oncotarget. 2015; 6(25):20964-76

• Tong M, Fung TM, Luk ST, Ng KY, Lee TK, Lin CH, Yam JW, Chan KW, Ng F, Zheng BJ, Yuan YF, Xie D, Lo CM, Man K, Guan XY, Ma S. ANXA3/JNK Signaling Promotes Self-Renewal and Tumor Growth, and Its Blockade Provides a Therapeutic Target for Hepatocellular Carcinoma. Stem Cell Reports. 2015; 5(1):45-59

• Ng IO, Sze KM, Chu KY. Role of hepatitis B virus X protein in liver cancer. Hong Kong Med J. 2015; 21 Supppl 4:27-30

• Wong CM, Wei L, Au SL, Fan DN, Zhou Y, Tsang FH, Law CT, Lee JM, He X, Shi J, Wong CC, Ng IO. MiR-200b/200c/429 subfamily negatively regulates Rho/ROCK signaling pathway to suppress hepatocellular carcinoma metastasis. Oncotarget. 2015; 6(15):13658-70

• Leung CO, Wong CC, Fan DN, Kai AK, Tung EK, Xu IM, Ng IO, Lo RC. PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma. Oncotarget. 2015; 6(13):10880-92

• Tsang FH, Au SL, Wei L, Fan DN, Lee JM, Wong CC, Ng IO, Wong CM. Long non-coding RNA HOTTIP is frequently up-regulated in hepatocellular carcinoma and is targeted by tumor suppressive miR-125b. Liver Intl. 2015; 35(5):1597-606

• Seto WK. Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification. World J Hepatol. 2015; 7(6):825-30

• Yung MK, Lo KW, Yip CW, Chung GT, Tong CY, Cheung PF, Cheung TT, Poon RT, So S, Fan ST, Cheung ST. Copy number gain of granulin-epithelin precursor (GEP) at chromosome 17q21 associates with overexpression in human liver cancer. BMC Cancer. 2015; 15:264

• Yau TC, Cheng PN, Chan P, Chan L, Yuen J, Pang R, Fan ST, Wheatley DN, Poon RT. Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2015; 33(2):496-504

• Dai WC, Sharr WW, Chok KS, Cheung TT, Fung JY, Chan AC, Chan SC, Lo CM. Transplantation of a 2-year-old deceased-donor liver to a 61-year-old male recipient. Asian J Surg. 2015; 38(2):113-6

• Chan LH, Luk ST, Ma S. Turning hepatic cancer stem cells inside out--a deeper understanding through multiple perspectives. Mol Cells. 2015; 38(3):202-9

• Fung J, Seto WK, Wong DK, Lai CL, Yuen MF. Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: A longitudinal follow-up study. Liver Intl. 2015; 35(3):854-9

• Zhao H, Davies TJ, Ning J, Chang Y, Sachaitr P, Sattler S, Fairchild PJ, Huang FP. A highly optimized protocol for reprogramming cancer cells to pluripotency using nonviral plasmid vectors. Cell Reprogram. 2015; 17(1):7-18

• Ho DW, Ng IO. uGPA: unified Gene Pathway Analyser package for high-throughput genome-wide screening data provides mechanistic overview on human diseases. Clin Chim Acta. 2015; 441:105-8

• Fung J, Lee CK, Chan M, Seto WK, Lai CL, Yuen MF, The Hong Kong Liver Health Census Study Group. High Prevalence of Non-Alcoholic Fatty Liver Disease in the Chinese - Results from the Hong Kong Liver Health Census. Liver Intl. 2015; 35(2):542-9

• Tang HM, Pan K, Kong KY, Hu L, Chan LC, Siu KL, Sun H, Wong CM, Jin DY. Loss of APD1 in yeast confers hydroxyurea sensitivity suppressed by Yap1p transcription factor. Sci Rep. 2015; 5:7987

• Wang J, Liu M, Chen L, Chan TH, Jiang L, Yuan YF, Guan XY. Overexpression of N-terminal kinase like gene promotes tumorigenicity of hepatocellular carcinoma by regulating cell cycle progression and cell motility. Oncotarget. 2015; 6(3):1619-1630

• Wong CC, Au SL, Tse AP, Xu IM, Lai RK, Chiu DK, Wei LL, Fan DN, Tsang FH, Lo RC, Wong CM, Ng IO. Switching of pyruvate kinase isoform L to m2 promotes metabolic reprogramming in hepatocarcinogenesis. PLoS One. 2014; 9(12):e115036

• Cheung  PF, Yip CW, Wong NC, Fong DY, Ng LW, Wan AM, Wong CK, Cheung TT, Ng IO, Poon RT, Fan ST, Cheung ST. Granulin-epithelin precursor renders hepatocellular carcinoma cells resistant to natural killer cytotoxicity. Cancer Immnuol Res. 2014; 2(12):1209-19

• Wong NC, Cheung PF, Yip CW, Chan KF, Ng IO, Fan ST, Cheung ST. Antibody Against Granulin-Epithelin Precursor Sensitizes Hepatocellular Carcinoma to Chemotherapeutic Agents. Mol Cancer Ther. 2014; 13(12):3001-12

• Ma MK, Ng IO, Lee TK. Roles of Stearoyl-CoA Desaturase-1 in Hepatocellular Carcinoma. J Liver Dis Transplant. 2014; 3:2

• Tang HM, Gao WW, Chan CP, Cheng Y, Chaudhary V, Deng JJ, Yuen KS, Wong CM, Ng IO, Kok KH, Zhou J, Jin DY. Requirement of CRTC1 coactivator for hepatitis B virus transcription. Nucleic Acids Res. 2014; 42(20):12455-68

• Wong CC, Tse AP, Huang YP, Zhu YT, Chiu DK, Lai RK, Au SL, Kai AK, Lee JM, Wei LL, Tsang FH, Lo RC, Shi J, Zheng YP, Wong CM, Ng IO. Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma. Hepatology. 2014; 60(5):1645-58

• Fung J, Wong DK, Seto WK, Kopaniszen M, Lai CL, Yuen MF. Hepatitis B Surface Antigen Seroclearance: Relationship to Hepatitis B e-Antigen Seroclearance and Hepatitis B e-Antigen-Negative Hepatitis. Am J Gastroenterol. 2014; 109(11):1764-70

• Yip CW, Cheung PF, Leung IC, Wong NC, Cheng CK, Fan ST, Cheung ST. Granulin-epithelin precursor interacts with heparan sulfate on liver cancer cells. Carcinogenesis. 2014; 35(11):2485-94

• Seto WK, Wong DK, Fung J, Huang FY, Liu KS, Lai CL, Yuen MF. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. Clin Microbiol Infect. 2014; 20(11):1173-80

• Lai WL, Hung WY, Ching YP. The tumor suppressor, TAX1BP2, is a novel substrate of ATM kinase. Oncogene. 2014; 33(45):5303-9

• Cheung PF, Yip CW, Ng LW, Lo KW, Wong N, Choy KW, Chow C, Chan KF, Cheung TT, Poon RT, Fan ST, Cheung ST. Establishment and characterization of a novel primary hepatocellular carcinoma cell line with metastatic ability in vivo. Cancer Cell Int. 2014; 14(1):103

• Wong DK, Tsoi O, Huang FY, Seto WK, Fung J, Lai CL, Yuen MF. Application of coamplification at lower denaturation temperature-PCR sequencing for early detection of antiviral drug resistance mutations of hepatitis B virus. J Clin Microbiol. 2014; 52(9): 3209-15

• Kido T, Lo RC, Li Y, Lee J, Tabatabai ZL, Ng IO, Lau YF. The potential contributions of a Y-located protooncogene and its X homologue in sexual dimorphisms in hepatocellular carcinoma. Hum Pathol. 2014; 45(9):1847-58

• Wong DK, Kopaniszen M, Omagari K, Tanaka Y, Fong DY, Seto WK, Fung J, Huang FY, Zhang AY, Hung IF, Lai CL, Yuen MF. Effect of hepatitis B virus reverse transcriptase variations on entecavir treatment response. J Infect Dis. 2014; 210(5):701-7

• Chok KS, Cheung TT, Lo RC, Chu FS, Tsang SH, Chan AC, Sharr WW, Fung JY, Dai WC, Chan SC, Fan ST, Lo CM. Pilot study of high-intensity focused ultrasound ablation as a bridging therapy for hepatocellular carcinoma patients wait-listed for liver transplantation. Liver Transpl. 2014; 20(8):912-21

• Tse EY, Ching YP. The role of p21-activated kinases in hepatocellular carcinoma metastasis. J Mol Signal. 2014; 9:7

• Chan AC, Poon RT. Portal Venous Gas and Pneumatosis Intestinalis in Necrotizing Pancreatitis. Clin Gastroenterol Hepatol. 2014; 12(7):e57-8

• Ko FC, Yam JW. Regulation of deleted in liver cancer 1 tumor suppressor by protein-protein interactions and phosphorylation. Int J Cancer. 2014; 135(2):264-9

• Chai S, Tong M, Ng KY, Kwan PS, Chan YP, Fung TM, Lee TK, Wong N, Xie D, Yuan YF, Guan XY, Ma S. Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133. Oncotarget. 2014; 5(14):5725-35

• Shi KQ, Wu FL, Liu WY, Zhao CC, Chen CX, Xie YY, Wu SJ, Lin XF, Chen YP, Wong DK, Yuen MF, Zheng MH. Non-alcoholic fatty liver disease and risk of in-stent restenosis after bare metal stenting in native coronary arteries. Mol Biol Rep. 2014; 41(7):4713-20

• Zheng MH, Seto WK, Shi KQ, Wong DK, Fung J, Hung IF, Fong DY, Yuen JC, Tong T, Lai CL, Yuen MF. Artificial Neural Network Accurately Predicts Hepatitis B Surface Antigen Seroclearance. PLoS One. 2014; 9(6):e99422

• Huang FY, Wong DK, Seto WK, Zhang AY, Lee CK, Lin CK, Fung J, Lai CL, Yuen MF. Sequence Variations of Full-Length Hepatitis B Virus Genomes in Chinese Patients with HBsAg-Negative Hepatitis B Infection. PLoS One. 2014; 9(6):e99028

• Lee TK, Cheung VC, Lu P, Lau EY, Ma S, Tang KH, Tong M, Lo J, Ng IO. Blockade of CD47 mediated CTSS-PAR2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology. 2014; 60(1):179-91

• Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer Staging System With Treatment Stratification for Patients With Hepatocellular Carcinoma. Gastroenterology. 2014; 146(7):1691-700

• Chan AC, Poon RT, Cheung TT, Chok KS, Chiu DW, Chan SC, Lo CM. Laparoscopic versus open liver resection for elderly patients with malignant liver tumors: a single center experience. J Gastroenterol Hepatol. 2014; 29(6):1279-83

• Wang XQ, Chan KK, Ming X, Lui VCh, Poon RY, Lo CM, Norbury C, Poon RT. G1 checkpoint establishment in vivo during embryonic liver development. BMC Dev Biol. 2014; 14:23

• Ng KT, Lo CM, Guo DY, Qi X, Li CX, Geng W, Liu XB, Ling CC, Ma YY, Yeung WH, Shao, Y, Poon RT, Fan ST, Man K. Identification of transmembrane protein 98 as a novel chemoresistance-conferring gene in hepatocellular carcinoma. Mol Cancer Ther. 2014; 13(5):1285-97

• Sze KM, Chu GK, Mak QH, Lee JM, Ng IO. Proline-rich acidic protein 1 (PRAP1) is a novel interacting partner of MAD1 and has a suppressive role in mitotic checkpoint signalling in hepatocellular carcinoma. J Pathol. 2014; 233(1):51-60

• Lin XF, Shi KQ, You J, Liu WY, Luo YW, Wu FL, Chen YP, Wong DK, Yuen MF, Zheng MH. Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study. Mol Biol Rep. 2014; 41(5):2989-97

• Seto WK, Lam YF, Fung J, Wong DK, Huang FY, Hung IF, Lai CL, Yuen MF. Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment. J Gastroenterol Hepatol. 2014; 29(5):1028-34

• Chan AC, Poon RT, Chok KS, Cheung TT, Chan SC, Lo CM. Feasibility of laparoscopic re-resection for patients with recurrent hepatocellular carcinoma. World J Surg. 2014; 38(5):1141-6

• Chan TH, Lin CH, Qi L, Fei J, Li Y, Yong KJ, Liu M, Song Y, Chow RK, Ng VH, Yuan YF, Tenen DG, Guan XY, Chen L. A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut. 2014; 63(5):832-43

• Cheung TT, Yuen WK, Poon RT, Chan SC, Fan ST, Lo CM. Improved anterior hepatic transection for isolated hepatocellular carcinoma in the caudate. Hepatobiliary Pancreat Dis Int. 2014; 13(2):219-22

• Chan SC, Chan AC, Sharr WW, Chok KS, Cheung TT, Fan ST, Lo CM. Perpetuating proficiency in donor right hepatectomy for living donor liver transplantation. Asian J Surg. 2014; 37(2):65-72

• Chok KS, Chan SC, Cheung TT, Sharr WW, Chan AC, Fan ST, Lo CM. A Retrospective Study on Risk Factors Associated With Failed Endoscopic Treatment of Biliary Anastomotic Stricture After Right-Lobe Living Donor Liver Transplantation With Duct-to-Duct Anastomosis. Ann Surg. 2014; 259(4):767-72

• Chan SC. Section 2. Small-for-size liver graft and hepatocellular carcinoma recurrence. Transplantation. 2014; 97 Suppl 8:S7-S10

• Lam YF, Wong DK, Seto WK, To KK, Hung IF, Fung J, Lai CL, Yuen MF. HLA-DP and γ-interferon receptor-2 gene variants and their association with viral hepatitis activity in chronic hepatitis B infection. J Gastroenterol Hepatol. 2014; 29(3):533-9

• Fung J, Seto WK, Lai CL, Yuen MF. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J Gastroenterol Hepatol. 2014; 29(3):428-34

• Jing Y, Jia D, Wong CM, Ng IO, Zhang Z, Liu L, Wang Q, Zhao F, Li J, Yao M, Wu X, He X. SERPINA5 inhibits tumor cell migration by modulating the fibronectin-integrin β1 signaling pathway in hepatocellular carcinoma. Mol Oncol. 2014; 8(2):366-77

• Wong CC, Kai AK, Ng IO. The impact of hypoxia in hepatocellular carcinoma metastasis. Front Med. 2014; 8(1):33-41

• Lam YF, Wong DK, Seto WK, To KK, Hung IF, Fung J, Lai CL, Yuen MF. HLA-DP and interferon gamma receptor-2 gene variants and their association with viral hepatitis activity in chronic hepatitis B infection. J Gastroenterol Hepatol. 2014; 29(3): 533-9

• Chan SC, Chok KS, Sharr WW, Chan AC, Tsang SH, Dai WC, Lo CM. Samaritan donor interchange in living donor liver transplantation. Hepatobiliary Pancreat Dis Int. 2014; 13(1):105-9

• Liu L, Dai Y, Chen J, Zeng T, Li Y, Chen L, Zhu YH, Li Y, Ma S, Xie D, Yuan YF, Guan XY. Maelstrom promotes hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition by way of Akt/GSK-3β/Snail signaling. Hepatology. 2014; 59(2):531-43

• Hou J, Zhou Y, Zheng Y, Fan J, Zhou W, Ng IO, Sun H, Qin L, Qiu S, Lee JM, Lo CM, Man K, Yang Y, Yang Y, Yang Y, Zhang Q, Zhu X, Li N, Wang Z, Ding G, Zhuang SM, Zheng L, Luo X, Xie Y, Liang A, Wang Z, Zhang M, Xia Q, Liang T, Yu Y, Cao X. Hepatic RIG-I Predicts Survival and Interferon-α Therapeutic Response in Hepatocellular Carcinoma. Cancer Cell. 2014; 25(1):49-63

• Fung J, Lee CK, Chan M, Seto WK, Wong DK, Lai CL, Yuen MF. Defining Normal Liver Stiffness Range in a Normal Healthy Chinese Population without Liver Disease. PLoS One. 2013; 8(12):e85067

• Chan SC, Sharr WW, Chok KS, Chan AC, Lo CM. Wait and Transplant for Stage 2 Hepatocellular Carcinoma With Deceased-Donor Liver Grafts. Transplantation. 2013; 96(11):995-9

• Lai CL, Yuen MF. Reply: Reduction of cirrhosis and hepatocellular carcinoma with antiviral therapy in chronic hepatitis B. Hepatology. 2013; 58(5):1857

• Cheung TT, Poon RT, Yuen WK, Chok KS, Tsang SH, Yau T, Chan SC, Lo CM. Outcome of laparoscopic versus open hepatectomy for colorectal liver metastases. ANZ J Surg. 2013; 83(11):847-52

• Chan SC, Sharr WW, Cheung TT, Chan AC, Tsang SH, Chok KS, Leung KC, Lo CM. Retrohepatic vena cava deroofing in living donor liver transplantation for caudate hepacellular carcinoma. Hepatobiliary Pancreat Dis Int. 2013; 12(5):552-5

• Seto WK, Liu K, Wong DK, Fung J, Huang FY, Hung IF, Lai CL, Yuen MF. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol. 2013; 59(4):709-16

• Lo RC. Epithelioid angiomyolipoma of the liver: a clinicopathologic study of 5 cases. Ann Diagn Pathol. 2013; 17(5):412-5

• Chan CP, Kok KH, Tang HM, Wong CM, Jin DY. Internal ribosome entry site-mediated translational regulation of ATF4 splice variant in mammalian unfolded protein response. Biochim Biophys Acta - Mol. Cell Res. 2013; 1833(10):2165-75

• Wang XQ, Ng RK, Ming X, Zhang W, Chen L, Chu AC, Pang R, Lo CM, Tsao SW, Liu X, Poon RT, Fan ST. Epigenetic regulation of pluripotent genes mediates stem cell features in human hepatocellular carcinoma and cancer cell lines. PLoS One. 2013; 8(9):e72435

• Seto WK, Wong DK, Fung J, Huang FY, Lai CL, Yuen MF. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology. 2013; 58(3):923-31

• Lee TK, Cheung VC, Ng IO. Liver tumor-initiating cells as a therapeutic target for hepatocellular carcinoma. Cancer Lett. 2013; 338(1):101-9

• Li Y, Chen L, Chan TH, Guan XY. Hepatocellular carcinoma: transcriptome diversity regulated by RNA editing. Int J Biochem Cell Biol. 2013; 45(8):1843-8

• Chai S, Ma S. Clinical implications of microRNAs in liver cancer stem cells. Chin J Cancer. 2013; 32(8):419-26

• Seto WK, Wong DK, Lai CL, Yuen MF. Reply to Liao et al. Clin Infect Dis. 2013; 57(4):622

• Wong DK, Seto WK, Fung J, Ip P, Huang FY, Lai CL, Yuen MF. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Clin Gastroenterol Hepatol. 2013; 11(8):1004-10

• Cheung TT, Fan ST, Chu FS, Jenkins CR, Chok KS, Tsang SH, Dai WC, Chan AC, Chan SC, Yau TC, Poon RT, Lo CM. Survival analysis of high-intensity focused ultrasound ablation in patients with small hepatocellular carcinoma. HPB (Oxford). 2013; 15(8):567-73 

• Wong LL, Lam IP, Wong TY, Lai WL, Liu HF, Yeung LL, Ching YP. IPA-3 inhibits the growth of liver cancer cells by suppressing PAK1 and NF-κB activation. PLoS One. 2013; 8(7):e68843

• Kok KH, Jin DY. Balance of power in host-virus arms races. Cell Host Microbe. 2013; 14(1):5-6

• Dai Y, Liu L, Zeng T, Zhu YH, Chen L, Li Y, Yuan YF, Ma S, Guan XY. Characterization of the oncogenic function of centromere protein F in hepatocellular carcinoma. Biochem Biophys Res Commun. 2013; 436(4): 711-8

• Seto WK, Tsang OT, Liu K, Chan JM, Wong DK, Fung J, Lai CL, Yuen MF. Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. J Viral Hepat. 2013; 20(7): 470-7

• Gallagher TK, Chan AC, Poon RT, Cheung TT, Chok KS, Chan SC, Lo CM. Outcomes of central bisectionectomy for hepatocellular carcinoma. HPB (Oxford). 2013; 15(7):529-34

• Cheung TT, Poon RT. Synchronous resections of primary colorectal tumor and liver metastasis by laparoscopic approach. World J Hepatol. 2013; 5(6):298-301

• Au SL, Wong CC, Lee JM, Wong CM, Ng IO. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers. PLoS One. 2013; 8(6):e68226

• Wong DK, Watanabe T, Tanaka Y, Seto WK, Lee CK, Fung J, Lin CK, Huang FY, Lai CL, Yuen MF. Role of HLA-DP polymorphisms on chronicity and disease activity of hepatitis B infection in Southern Chinese. PLoS One. 2013; 8(6):e66920

• Chok KS, Chan SC, Fung JY, Cheung TT, Chan AC, Fan ST, Lo CM. Survival outcomes of right-lobe living donor liver transplantation for patients with high Model for End-stage Liver Disease scores. Hepatobiliary Pancreat Dis Int. 2013; 12(3):256-62

• Fong YK, Chan SC, Cheung TT, Dai WC, Chok KS, Chan AC, Sharr WW, Lo CM. Remnant left liver size and recovery of living right liver donors. Hepatol Int. 2013; 7(2):734-740

• Fung J, Chan SC, Cheung C, Yuen MF, Chok KS, Sharr W, Chan AC, Cheung TT, Seto WK, Fan ST, Lai CL, Lo CM. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol. 2013; 108(6):942-8

• Au SL, Ng IO, Wong CM. Epigenetic dysregulation in hepatocellular carcinoma: focus on polycomb group proteins. Front Med. 2013; 7(2):231-41

• Seto WK, Wong DK, Kopaniszen M, Proitsi P, Sham PC, Hung IF, Fung J, Lai CL, Yuen MF. HLA-DP and IL28B polymorphisms: Influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. Clin Infect Dis. 2013; 56(2):1695-703


• Chan AC, Fan ST, Poon RT, Cheung TT, Chok KS, Chan SC, Lo CM. Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system. HPB (Oxford). 2013; 15(6):439-48

• Cheung TT, Fan ST, Chan SC, Chok KS, Chu FS, Jenkins CR, Lo RC, Fung JY, Chan AC, Sharr WW, Tsang SH, Dai WC, Poon RT, Lo CM. High-intensity focused ultrasound ablation: An effective bridging therapy for hepatocellular carcinoma patients. World J Gastroenterol. 2013; 19(20):3083-9

• Lo RC, Chan SC, Chan KL, Chiang AK, Lo CM, Ng IO. Post-transplant lymphoproliferative disorders in liver transplant recipients: a clinicopathological study. J Clin Pathol. 2013; 66(5): 392-8

• Cheung TT, Fan ST. Technical note on complete excision of choledochal cysts. Hepatobiliary Pancreat Dis Int. 2013; 12(2):2118-21

• Lo RC, Ng IO. Hepatic Progenitor Cells: Their Role and Functional Significance in the New Classification of Primary Liver Cancers. Liver Cancer. 2013; 2(2):84-92

• Chan AC, Cheung TT, Fan ST, Chok KS, Chan SC, Poon RT, Lo CM. Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma. Ann Surg. 2013; 257(4):686-92

• Chan SC, Fan ST. Selection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation. Hepatobiliary Surg Nutr. 2013; 2(2):84-88

• Chan AC, Chan SC, Chok KS, Cheung TT, Chiu DW, Poon RT, Fan ST, Lo CM. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation?. Liver Transpl. 2013; 19(4):411-9

• Chan SC, Cheng LC, Ho KL, Chok KS, Sharr WW, Dai WC, Lo CM. Improvising hepatic venous outflow and inferior vena cava reconstruction for combined heart and liver and sequential liver transplantations. Asian J Surg. 2013; 36(2):89-92

• Kim BK, Fung J, Yuen MF, Kim SU. Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectives. World J Gastroenterol. 2013; 19(12):1890-900

• Ko FC, Chan LK, Sze KM, Yeung YS, Tse EY, Lu P, Yu MH, Ng IO, Yam JW. PKA-induced dimerization of the RhoGAP DLC1 promotes its inhibition of tumorigenesis and metastasis. Nat Commun. 2013; 4:1618

• Cheung TT, Poon RT, Yuen WK, Chok KS, Jenkins CR, Chan SC, Fan ST, Lo CM. Long-term survival analysis of pure laparoscopic versus open hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a single-center experience. Ann Surg. 2013; 257(3):506-11

• Seto WK, Wong DK, Fung J, Hung IF, Yuen JC, Tong T, Lai CL, Yuen MF. Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. Hepatol Int. 2013; 7(1):119-126

• Seto WK, Wong DK, Fung J, Huang FY, Lai CL, Yuen MF. Reduction of hepatitis B surface antigen levels and HBsAg seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology. 2013; 58(3):923-31

• Seto WK, Tanaka Y, Wong DK, Lai CL, Shinkai N, Yuen JC, Tong T, Fung J, Hung IF, Yuen MF. Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay. Hepatol Int. 2013; 7(1):98-105

• Chok KS, Chan SC, Cheung TT, Chan AC, Sharr WW, Fan ST, Lo CM. Outcomes of side-to-side conversion hepaticojejunostomy for biliary anastomotic stricture after right-liver living donor liver transplantation. Hepatobiliary Pancreat Dis Int. 2013; 12(1):42-6

• Fung J, Lai CL, Yuen MF, Ng IO. Do statins reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis B?. Hepatobiliary Surg Nutr. 2013; 2(1):34-36

• Cheung TT, Ho CL, Lo CM, Chen S, Chan SC, Fung JY, Chan AC, Sharr W, Yau T, Poon RT, Fan ST. 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon's perspective. J Nucl Med. 54(2):192-200

• Chen L, Li Y, Lin CH, Chan TH, Chow RK, Song Y, Liu M, Yuan YF, Fu L, Kong KL, Qi L, Zhang N, Tong AH, Kwong DL, Man K, Lo CM, Lok S, Tenen DG, Guan XY. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat Med. 2013; 19(2):209-16

• Fan DN, Tsang FH, Au SL, Wong CC, Tam AH, Wei L, Lee JM, He X, Ng IO, Wong CM. Histone lysine methyltransferase, suppressor of variegation 3-9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b. Hepatology. 2013; 57(2):637-47

• Yau T, Cheng PN, Chan P, Chan W, Chen L, Yuen J, Pang R, Fan ST, Poon RT. A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2013; 31(1): 99-107

• Wong CM, Kai AK, Tsang FH, Ng IO. Regulation of hepatocarcinogenesis by microRNAs. Front Biosci (Elite Ed). 2013; 5:49-60

• Fung J, Yuen MF, Lai CL. The role of steatosis in HBsAg seroclearance for patients with chronic hepatitis B infection: fact or fiction?. Dig Dis Sci. 2013; 58(1): 20-2

• Li Y, Chen L, Chan TH, Liu M, Kong KL, Qiu JL, Yuan YF, Guan XY. SPOCK1 is regulated by CHD1L and blocks apoptosis and promotes HCC cell invasiveness and metastasis in mice. Gastroenterology. 2013; 144(1): 179-191

• Ma S. Biology and clinical implications of CD133(+) liver cancer stem cells. Exp Cell Res. 2013; 319(2): 126-32

• Ma W, Wong CC, Tung EK, Wong CM, Ng IO. RhoE is frequently down-regulated in hepatocellular carcinoma (HCC) and suppresses HCC invasion through antagonizing the Rho/Rho-kinase/myosin phosphatase target pathway. Hepatology. 2013; 57(1): 152-61

• Sze KM, Chu GK, Lee JM, Ng IO. C-terminal truncated HBx is associated with metastasis and enhances invasiveness via C-Jun / MMP10 activation in hepatocellular carcinoma. Hepatology. 2013; 57(1): 131-9

• Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology. 2013; 57(1): 399-408


• Chun AC, Kok KH, Jin DY. REV7 is required for anaphase-promoting complex-dependent ubiquitination and degradation of translesion DNA polymerase REV1. Cell Cycle. 2013; 12(2): 365-78

• Chew V, Tow C, Huang C, Bard-Chapeau E, Copeland NG, Jenkins NA, Weber A, Lim KH, Toh HC, Heikenwalder M, Ng IO, Nardin A, Abastado JP. Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patient. J Natl Cancer Inst. 2012; 104(23); 1796-807

• Yau T, Wong H, Chan P, Yao TJ, Pang R, Cheung TT, Fan ST, Poon RT. Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease. Invest New Drugs. 2012; 30(6):2384-90

• Tung EK, Ng IO. Significance of serum DKK1 as a diagnostic biomarker in hepatocellular carcinoma. Future Oncol. 2012; 8(12): 1525-8

• Chow AK, Ng L, Sing Li H, Cheng CW, Lam CS, Yau TC, Cheng PN, Fan ST, Poon RT, Pang RW. Anti-tumor efficacy of a recombinant human arginase in human hepatocellular carcinoma. Curr Cancer Drug Targets. 2012; 12(9): 1233-43

• Lai WL, Hung WY, Wong LL, Zhou Y, Leong VY, Lee JM, Ng IO, Jin DY, Ching YP. The centrosomal protein Tax1 binding protein 2 is a novel tumour suppressor in hepatocellular carcinoma regulated by cyclin-dependent kinase 2. Hepatology. 2012; 56(5): 1770-81

• Chiu J, Tang YF, Yao TJ, Wong A, Wong H, Leung R, Chan P, Cheung TT, Chan AC, Pang R, Fan ST, Poon R, Yau T. The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: A retrospective analysis of efficacy, safety, and survival benefits. Cancer. 2012; 118(21): 5293-301

• Cheung TT, Chu FS, Jenkins CR, Tsang DS, Chok KS, Chan AC, Yau TC, Chan SC, Poon RT, Lo CM, Fan ST. Tolerance of high-intensity focused ultrasound ablation in patients with hepatocellular carcinoma. World J Surg. 2012; 36(10): 2420-7

• Seto WK, Fung J, Yuen MF, Lai CL. Future prevention and treatment of chronic hepatitis B infection. J Clin Gastroenterol. 2012; 46(9):725-34

• Wang XQ, Lo CM, Chen L, Cheung CK, Yang ZF, Chen YX, Ng MN, Yu WC, Ming X, Zhang W, Ho DW, Chan SC, Fan ST. Hematopoietic chimerism in liver transplantation patients and hematopoietic stem/progenitor cells in adult human liver. Hepatology. 2012; 56(4):1557-66

• Tung EK, Ng IO. Considerations in the significance of Dickkopf-1 levels in human hepatocellular carcinoma: authors' reply. Liver Intl. 2012; 32(9):1460-1

• Cheung TT, Chu FS, Jenkins CR, Tsang DS, Chok KS, Chan AC, Yau TC, Chan SC, Poon RT, Lo CM, Fan ST. Tolerance of High-Intensity Focused Ultrasound Ablation in Patients with Hepatocellular Carcinoma. World J Surg. 2012; 36910):2420-7

• Li J, Lau G, Chen L, Yuan YF, Huang J, Luk JM, Xie D, Guan XY. Interleukin 23 promotes hepatocellular carcinoma metastasis via NF-kappa B induced matrix metalloproteinase 9 expression. PLoS One. 2012; 7(9):e46264

• Seto WK, Liu K, Fung J, Wong DK, Yuen JC, Hung IF, Lai CL, Yuen MF. Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir. Antivir Ther. 2012; 17(7): 1255-62

• Chan SC, Fan ST, Chok KS, Sharr WW, Dai WC, Fung JY, Chan KY, Balsarkar DJ, Lo CM. Increasing the recipient benefit/donor risk ratio by lowering the graft size requirement for living donor liver transplantation. Liver Transpl. 2012; 18(9):1078-82

• Seto WK, Wong DK, Fung J, Hung IF, Fong DY, Yuen JC, Tong T, Lai CL, Yuen MF. A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. Hepatology. 2012; 56(3):812-9

• Lee CW, Wong LL, Tse EY, Liu HF, Leong VY, Lee JM, Hardie DG, Ng IO, Ching YP. AMPK Promotes p53 Acetylation via Phosphorylation and Inactivation of SIRT1 in Liver Cancer Cells. Cancer Res. 2012; 72(17):4394-404

• Siriwardana RC, Chan SC, Chok KS, Lo CM, Fan ST. Effects of donor steatosis on liver biochemistry and significance of body mass index in predicting steatosis. HPB (Oxford). 2012; 14(9):619-24

• Seto WK, Wong DK, Fung J, Ip PP, Yuen JC, Hung IF, Lai CL, Yuen MF. High Hepatitis B Surface Antigen Levels Predict Insignificant Fibrosis in Hepatitis B e Antigen Positive Chronic Hepatitis B. PLoS One. 2012; 7(8):e43087

• Au SL, Wong CC, Lee JM, Fan DN, Tsang FH, Ng IO, Wong CM. Enhancer of zeste homolog 2 (EZH2) epigenetically silences multiple tumor suppressor miRNAs to promote liver cancer metastasis. Hepatology. 2012; 56(2): 622-31

• Hu L, Liu M, Chen L, Chan TH, Wang J, Huo KK, Zheng BJ, Xie D, Guan XY. SCYL1 binding protein 1 promotes the ubiquitin-dependent degradation of Pirh2 and has tumor-suppressive function in the development of hepatocellular carcinoma. Carcinogenesis. 2012; 33(8):1581-8

• Mak GW, Lai WL, Zhou Y, Li M, Ng IO, Ching YP. CDK5RAP3 Is a Novel Repressor of p14(ARF) in Hepatocellular Carcinoma Cells. PLoS One. 2012; 7(7):e42210

• Lam CY, Yip CW, Poon TC, Cheng CK, Ng EW, Wong NC, Cheung PF, Lai PB, Ng IO, Fan ST, Cheung ST. Identification and characterization of tropomyosin 3 associated with granulin-epithelin precursor in human hepatocellular carcinoma. PLoS One. 2012; 7(7):e40324

• Chok KS, Chan SC, Chan KL, Sharr WW, Tam PK, Fan ST, Lo CM. Bile duct anastomotic stricture after pediatric living donor liver transplantation. J Pediatr Surg. 2012; 47(7):1399-403

• Chen L, Liu C, Ko FC, Xu N, Ng IO, Yam JW, Zhu G. Solution Structure of the Phosphotyrosine Binding (PTB) Domain of Human Tensin2 Protein in Complex with Deleted in Liver Cancer 1 (DLC1) Peptide Reveals a Novel Peptide Binding Mode. J Biol Chem. 2012; 287(31):26104-14

• Siriwardana RC, Lo CM, Chan SC, Fan ST. Role of portal vein embolization in hepatocellular carcinoma management and its effect on recurrence: a case-control study. World J Surg. 2012; 36(7):1640-6

• Chok KS, Fung JY, Chan SC, Cheung TT, Sharr WW, Chan AC, Fan ST, Lo CM. Outcomes of living donor liver transplantation for patients with preoperative type 1 hepatorenal syndrome and acute hepatic decompensation. Liver Transpl. 2012; 18(7):779-85

• Cheung TT, Chan SC, Chok KS, Chan AC, Yu WC, Poon RT, Lo CM, Fan ST. Rapid measurement of indocyanine green retention by pulse spectrophotometry: a validation study in 70 patients with Child-Pugh A cirrhosis before hepatectomy for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2012; 11(3):267-71

• Wong CM, Ng IO. Reply to: Deregulation of microRNAs expression occurs in stages of multistep hepatocarcinogenesis: Why is it different?. J Hepatol. 2012; 56(6):1426-7

• Chan ST, Fan ST, Chok KS, Cheung TT, Chan AC, Fung JY, Poon RT, Lo CM. Survival advantage of primary liver transplantation for hepatocellular carcinoma within the up-to-7 criteria with microvascular invasion. Hepatol Int. 2012; 6(3):646-656

• Ho DW, Yang ZF, Yi K, Lam CT, Ng MN, Yu WC, Lau J, Wan T, Wang X, Yan Z, Liu H, Zhang Y, Fan ST. Gene expression profiling of liver cancer stem cells by RNA-sequencing. PLoS One. 2012; 7(5):e37159

• Tung EK, Wong BY, Yau TO, Ng IO. Upregulation of the Wnt co-receptor LRP6 promotes hepatocarcinogenesis and enhances cell invasion. PLoS One. 2012; 7(5):e36565

• Wong CM, Wong CC, Lee JM, Fan DN, Au SL, Ng IO. Sequential alterations of miRNA expression in hepatocellular carcinoma development and venous metastasis. Hepatology. 2012; 55(5): 1453-61

• Fan H, Chen L, Zhang F, Quan Y, Su X, Qiu X, Zhao Z, Dong S, Song Y, Chan TH, Guan XY. MTSS1, a novel target of DNA methyltransferase 3B, functions as a tumor suppressor in hepatocellular carcinoma. Oncogene. 2012; 31(18):2298-308

• Chan TH, Chen L, Guan XY. Role of translationally controlled tumor protein in cancer progression. Biochem Res Int. 2012; 2012:369384

• Dai WC, Fan ST, Cheung TT, Chok KS, Chan AC, Tsang SH, Poon RT, Lo CM. The impact of family history of hepatocellular carcinoma on its patients' survival. Hepatobiliary Pancreat Dis Int. 2012; 11(2):160-4

• Seto WK, Lai CL, Yuen MF. Acute-on-chronic liver failure in chronic hepatitis B. J Gastroenterol Hepatol. 2012; 27(4):662-9

• Lei ZQ, Li L, Li GJ, Leung CW, Shi J, Wong CM, Lo KC, Chan KW, Mak CS, Chan SB, Chan NM, Leung CH, La PT, Pong PW. Liver cancer immunoassay with magnetic nanoparticles and MgO-based magnetic tunnel junction sensors. J App Physics. 2012; 111-07E505

• Dai WC, Chan SC, Chok KS, Cheung TT, Sharr WW, Chan AC, Fung JY, Tsang SH, Fan ST, Lo CM. Single-centre experience of liver transplantation for familial amyloidotic polyneuropathy of non-Val30Met variants in Chinese patients. Amyloid. 2012; 19(1):33-6

• Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, Tong CM, Ng IO, Man K, To KF, Lai PB, Lo CM, Guan XY, Chan KW. CD133+ liver tumor-initiating cells promote tumor angiogenesis, growth and self-renewal through neurtensin / IL-8 / CXCL 1 signaling. Hepatology. 2012; 55(3):807-20

• Tse EY, Ko FC, Tung EK, Chan LK, Lee TK, Ngan ES, Man K, Wong AS, Ng IO, Yam JW. Caveolin-1 overexpresion is associated with hepatocellular carinoma tumorigenesis and metastasis. J Pathol. 2012; 226(4):645-53

• Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, Weber A, Slankamenac K, Poon RT, Yang H, Ooi LL, Toh HC, Heikenwalder M, Ng IO, Nardin A, Abastado JP. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut. 2012; 61(3):427-38

• Ng KT, Guo DY, Cheng Q, Geng W, Ling CC, Li CX, Liu XB, Ma YY, Lo CM, Poon RT, Fan ST, Man K. A garlic derivative, S-allylcysteine (SAC), suppresses proliferation and metastasis of hepatocellular carcinoma. PLoS One. 2012; 7(2):e31655

• Seto WK, Lai CL, Ip PP, Fung J, Wong DK, Yuen JC, Hung IF, Yuen MF. A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B. PLoS One. 2012; 7(2):e32622

• Li CX, Shao Y, Ng KT, Liu XB, Ling CC, Ma YY, Geng W, Fan ST, Lo CM, Man K. FTY720 suppresses liver tumor metastasis by reducing the population of circulating endothelial progenitor cells. PLoS One. 2012; 7(2):e32380

• Chan TH, Chen L, Liu M, Hu L, Zheng BJ, Poon VK, Huang P, Yuan YF, Huang JD, Yang J, Tsao GS, Guan XY. Translationally controlled tumor protein induces mitotic defects and chromosome missegregation in hepatocellular carcinoma development. Hepatology. 2012; 55(2):491-505

• Chan AC, Poon RT, Cheung TT, Chok KS, Chan SC, Fan ST, Lo CM. Survival analysis of re-resection versus radiofrequency ablation for ntrahepatic recurrence after hepatectomy for hepatocellular carcinoma. World J Surg. 2012; 36(1):151-6

• Siriwardana RC, Chan SC, Chok KS, Lo CM, Fan ST. Effects of the liver volume and donor steatosis on errors in the estimated standard liver volume. Liver Transpl. 2011; 17(12): 1437-42

• Cheung PF, Cheng CK, Wong NC, Ho JC, Yip CW, Lui VC, Cheung AN, Fan ST, Cheung ST. Granulin-epithelin precursor is an oncofetal protein defining hepatic cancer stem cells. PLoS One. 2011; 6(12): e28246

• Chan KY, Wong CM, Kwan JS, Lee JM, Cheung KW, Yuen MF, Lai CL, Poon RT, Sham PC, Ng IO. Genome-wide association study of hepatocellular carcinoma in southern Chinese patients with chronic hepatitis B virus infection. PLoS One. 2011; 6(12): e28798

• Chan SC, Lo CM, Chok KS, Sharr WW, Cheung TT, Tsang SH, Chan AC, Fan ST. Modulation of graft vascular inflow guided by flowmetry and manometry in liver transplantation. Hepatobiliary Pancreat Dis Int. 2011; 10(6): 649-56

• Chan SC, Lo CM, Chok KS, Sharr WW, Cheung TT, Tsang SH, Chan AC, Fan ST. Validation of graft and standard liver size predictions in right liver living donor liver transplantation. Hepatol Int. 2011; 5(4): 913-917

• Tung EK, Mak CK, Fatima S, Lo RC, Zhao H, Zhang C, Dai H, Poon RT, Yuen MF, Lai CL, Li JJ, Luk JM, Ng IO. Clinicopathological and prognostic significance of serum and tissue Dickkophf-1 levels in human hepatocellular carcinoma. Liver Intl. 2011; 31(10): 1494-504

• Fan ST, Yang ZF, Ho DW, Ng MN, Yu WC, Wong J. Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells: a prospective study. Ann Surg. 2011; 254(4): 569-76

• Cheung TT, Chan SC, Ho CL, Chok KS, Chan AC, Sharr WW, Ng KK, Poon RT, Lo CM, Fan ST. Can PET with the dual tracers [11C]acetate and [18F]FDG predict microvascular invasion in hepatocellular carcinoma. Liver Transpl. 2011; 17(10): 1218-25

• Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, Dai WC, Chan AC, Cheung TT, Tsang S, Lam B, Lai CL, Lo CM. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology. 2011; 141(4): 1212-9

• Chan LK, Ko FC, Sze KM, Ng IO, Yam JW. Nuclear-targeted Deleted in Liver Cancer 1 (DLC1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivo. PLoS One. 2011; 6(9): e25547

• Wong CC, Gilkes DM, Zhang H, Chen J, Wei H, Chaturvedi P, Fraley SI, Wong CM, Khoo US, Ng IO, Wirtz D, Semenza GL. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad USA. 2011; 108(39): 16369-74

• Chok KS, Chan SC, Cheung TT, Chan AC, Fan ST, Lo CM. Late recurrence of hepatocellular carcinoma after liver transplantation. World J Surg. 2011; 35(9): 2058-62

• Wong DK, Huang FY, Lai CL, Poon RT, Seto WK, Fung J, Hung IF, Yuen MF. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology. 2011; 54(3): 829-36

• Tong CM, Ma S, Guan XY. Biology of hepatic cancer stem cells. J Gastroenterol Hepatol. 2011; 26(8): 1229-37

• Li J, Lau GK, Chen L, Dong SS, Lan HY, Huang XR, Li Y, Luk JM, Yuan YF, Guan XY. Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinase 2 and 9 expression. PLoS One. 2011; 6(7): e21816

• Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. CD24+ liver tumor-initiating cells drive self-renewal and tumor initiation through Stat3-mediated NANOG regulation. Cell Stem Cell. 2011; 9(1): 50-63

• Lau CK, Yang ZF, Fan ST. Role of stem cells in normal liver and cancer. Anticancer Agents Med Chem. 2011; 11(6): 522-8

• Chok KS, Chan SC, Lo CM, Fan ST. Emergency re-routing of anterior sector venous outflow for right lobe living donor liver transplantation including the middle hepatic vein. Hepatobiliary Pancreat Dis Int. 2011; 10(3):325-7

• Gao P, Wong CC, Tung EK, Lee JM, Wong CM, Ng IO. Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. J Hepatol. 2011; 54(6): 1177-84

• Sze KM, Wong KL, Chu GK, Lee JM, Yau TO, Ng IO. Loss of PTEN enhances cell invasion and migration through AKT/Sp-1 transcription factor/MMP2 activation in hepatocellular carcinoma and has clinicopathologic significance. Hepatology. 2011; 53(5): 1558-69

• Ng KK, Poon RT, Chan SC, Chok KS, Cheung TT, Tung H, Chu F, Tso WK, Yu WC, Lo CM, Fan ST. High-intensity focused ultrasound for hepatocellular carcinoma: a single-center experience. Ann Surg. 2011; 253(5): 981-7

• Lam CT, Yang ZF, Lau CK, Tam KH, Fan ST, Poon RT. Brain-derived neurotrophic factor promotes tumorigenesis via induction of neovascularization: implication in hepatocellular carcinoma. Clin Cancer Res. 2011; 17(10): 3123-33

• Fung JY, Lai CL, Yuen J, Cheng C, Wu R, Wong DK, Seto WK, Hung IF, Yuen MF. Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: outcome at 2 years. Hepatology. 2011; 53(4): 1148-53

• Kok KH, Lui PY, Ng MHJ, Siu KL, Au SWN, Jin DY. The double-stranded RNA-binding protein PACT functions as a cellular activator of RIG-I to facilitate innate antiviral response. Cell Host Microbe. 2011; 9(4): 299-309

• Fan ST, Lo CM, Poon RT, Yeung C, Liu CL, Yuen WK, Lam CM, Ng KK, Chan SC. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg. 2011; 253(4): 745-58

• Mak GW, Chan MM, Leong VY, Lee JM, Yau TO, Ng IO, Ching YP. Overexpression of a novel activator of PAK4, the CDK5 kinase-associated protein CDK5RAP3, promotes hepatocellular carcinoma metastasis. Cancer Res. 2011; 71(8): 2949-58

• Chen L, Yuan YF, Li Y, Chan TH, Zheng BJ, Huang J, Guan XY. Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion. Gut. 2011; 60(4): 534-43

• Chan J, Ko FC, Ng IO, Yam JW. Integrin-linked kinase overexpression and its oncogenic role in promoting tumorigenicity of hepatocellular carcinoma. PLoS One. 2011; 6(2): e16984

• Wong CM, Wong CC, Ng YL, Au SL, Ko FC, Ng IO. Transcriptional repressive H3K9 and H3K27 methylations contribute to DNMT1-mediated DNA methylation recovery. PLoS One. 2011; 6(2): e16702

• Chan CP, Kok KH, Jin DY. CREB3 subfamily transcription factors are not created equal: Recent insights from global analyses and animal models. Cell Biosci. 2011; 1(1): 6

• Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. Hepatology. 2011; 53(1): 160-70

• Wong CC, Wong CM, Tung EK, Au SL, Lee JM, Poon RT, Man K, Ng IO. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology. 2011; 140(1): 322-31

• Yuen, M. F., Heo, J., Jang, J. W., Yoon, J. H., Kweon, Y. O., Park, S. J., Tami, Y., You, S., Yates, P., Tao, Y., Cremer, J., Campbell, F., Elston, R., Theodore, D., Paff, M., Bennett, C. F., & Kwoh, T. J. (2021). Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. Nature medicine, 27(10), 1725–1734. https://doi.org/10.1038/s41591-021-01513-4

• Yuen M. F. (2021). Biological Gradient of Chronic Hepatitis B. Nature reviews. Gastroenterology & hepatology, 18(9), 593. https://doi.org/10.1038/s41575-021-00504-7

• Lee, T. K., Guan, X. Y., & Ma, S. (2022). Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications. Nature reviews. Gastroenterology & hepatology, 19(1), 26–44. https://doi.org/10.1038/s41575-021-00508-3

• Yang, X. D., Kong, F. E., Qi, L., Lin, J. X., Yan, Q., Loong, J., Xi, S. Y., Zhao, Y., Zhang, Y., Yuan, Y. F., Ma, N. F., Ma, S., Guan, X. Y., & Liu, M. (2021). PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma. Molecular cancer, 20(1), 20. https://doi.org/10.1186/s12943-021-01315-9

• Liu, B., Tey, S. K., Mao, X., Ma, A., Yeung, C., Wong, S., Ng, T. H., Xu, Y., Yao, Y., Fung, E., Tan, K. V., Khong, P. L., Ho, D. W., Ng, I. O., Tang, A., Cai, S. H., Yun, J. P., & Yam, J. (2021). TPI1-reduced extracellular vesicles mediated by Rab20 downregulation promotes aerobic glycolysis to drive hepatocarcinogenesis. Journal of extracellular vesicles, 10(10), e12135. https://doi.org/10.1002/jev2.12135

• Tey, S. K., Wong, S., Tung Chan, J. Y., Mao, X., Ng, T. H., Yeung, C., Leung, Z., Fung, H. L., Tang, A., Wong, D., Mak, L. Y., Yuen, M. F., Sin, C. F., Ng, I. O., Ma, S., Lee, T., Cao, P., Zhong, K., Gao, Y., Yun, J. P., … Ping Yam, J. W. (2021). Patient pIgR-enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma. Journal of hepatology, S0168-8278(21)02245-5. Advance online publication. https://doi.org/10.1016/j.jhep.2021.12.005

• Zhou, L., Yu, K. H., Wong, T. L., Zhang, Z., Chan, C. H., Loong, J. H., Che, N., Yu, H. J., Tan, K. V., Tong, M., Ngan, E. S., Ho, J. W., & Ma, S. (2021). Lineage tracing and single-cell analysis reveal proliferative Prom1+ tumour-propagating cells and their dynamic cellular transition during liver cancer progression. Gut, gutjnl-2021-324321. Advance online publication. https://doi.org/10.1136/gutjnl-2021-324321

• Seto, W. K., Liu, K. S., Mak, L. Y., Cloherty, G., Wong, D. K., Gersch, J., Lam, Y. F., Cheung, K. S., Chow, N., Ko, K. L., To, W. P., Fung, J., & Yuen, M. F. (2021). Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation. Gut, 70(4), 775–783. https://doi.org/10.1136/gutjnl-2020-321116

• Hirode, G., Choi, H., Chen, C. H., Su, T. H., Seto, W. K., Van Hees, S., Papatheodoridi, M., Lens, S., Wong, G., Brakenhoff, S. M., Chien, R. N., Feld, J., Sonneveld, M. J., Chan, H., Forns, X., Papatheodoridis, G. V., Vanwolleghem, T., Yuen, M. F., Hsu, Y. C., Kao, J. H., … RETRACT-B Study Group (2022). Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). Gastroenterology, 162(3), 757–771.e4. https://doi.org/10.1053/j.gastro.2021.11.002

• Lee, C. H., Seto, W. K., Lui, D. T., Fong, C. H., Wan, H. Y., Cheung, C. Y., Chow, W. S., Woo, Y. C., Yuen, M. F., Xu, A., & Lam, K. S. (2021). Circulating Thrombospondin-2 as a Novel Fibrosis Biomarker of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes. Diabetes care, 44(9), 2089–2097. https://doi.org/10.2337/dc21-0131

• Kong, F. E., Li, G. M., Tang, Y. Q., Xi, S. Y., Loong, J., Li, M. M., Li, H. L., Cheng, W., Zhu, W. J., Mo, J. Q., Gong, Y. F., Tang, H., Zhao, Y., Zhang, Y., Ma, S., Guan, X. Y., Ma, N. F., Xie, M. B., & Liu, M. (2021). Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate. Science translational medicine, 13(579), eabb6282. https://doi.org/10.1126/scitranslmed.abb6282

• Cheu, J. W., & Wong, C. C. (2021). Mechanistic Rationales Guiding Combination Hepatocellular Carcinoma Therapies Involving Immune Checkpoint Inhibitors. Hepatology (Baltimore, Md.), 10.1002/hep.31840. Advance online publication. https://doi.org/10.1002/hep.31840

• Lee, D., Zhang, M. S., Tsang, F. H., Bao, M. H., Xu, I. M., Lai, R. K., Chiu, D. K., Tse, A. P., Law, C. T., Chan, C. Y., Yuen, V. W., Chui, N. N., Ng, I. O., Wong, C. M., & Wong, C. C. (2021). Adaptive and Constitutive Activations of Malic Enzymes Confer Liver Cancer Multilayered Protection Against Reactive Oxygen Species. Hepatology (Baltimore, Md.), 74(2), 776–796. https://doi.org/10.1002/hep.31761

• Tian, L., Zhao, L., Sze, K. M., Kam, C. S., Ming, V. S., Wang, X., Zhang, V. X., Ho, D. W., Cheung, T. T., Chan, L. K., & Ng, I. O. (2021). Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma. Hepatology (Baltimore, Md.), 10.1002/hep.32236. Advance online publication. https://doi.org/10.1002/hep.32236

• Ng, K. Y., Shea, Q. T., Wong, T. L., Luk, S. T., Tong, M., Lo, C. M., Man, K., Yun, J. P., Guan, X. Y., Lee, T. K., Zheng, Y. P., & Ma, S. (2021). Chemotherapy-Enriched THBS2-Deficient Cancer Stem Cells Drive Hepatocarcinogenesis through Matrix Softness Induced Histone H3 Modifications. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 8(5), 2002483. https://doi.org/10.1002/advs.202002483

• Yan, Q., Zhang, Y., Fang, X., Liu, B., Wong, T. L., Gong, L., Liu, S., Yu, D., Liu, M., Jiang, L., Wang, X., Wei, T., Jia, Y., Li, L., Sun, L., Tang, Y., Zhou, N., Yuan, Y. F., Li, Y., Ma, S., … Guan, X. Y. (2021). PGC7 promotes tumor oncogenic dedifferentiation through remodeling DNA methylation pattern for key developmental transcription factors. Cell death and differentiation, 28(6), 1955–1970. https://doi.org/10.1038/s41418-020-00726-3

• Chan, L. K., Tsui, Y. M., Ho, D. W., & Ng, I. O. (2021). Cellular heterogeneity and plasticity in liver cancer. Seminars in cancer biology, S1044-579X(21)00050-X. Advance online publication. https://doi.org/10.1016/j.semcancer.2021.02.015

• Wang, X., Wang, J., Tsui, Y. M., Shi, C., Wang, Y., Zhang, X., Yan, Q., Chen, M., Jiang, C., Yuan, Y. F., Wong, C. M., Liu, M., Feng, Z. Y., Chen, H., Ng, I., Jiang, L., & Guan, X. Y. (2021). RALYL increases hepatocellular carcinoma stemness by sustaining the mRNA stability of TGF-β2. Nature communications, 12(1), 1518. https://doi.org/10.1038/s41467-021-21828-7

• Ho, D. W., Tsui, Y. M., Chan, L. K., Sze, K. M., Zhang, X., Cheu, J. W., Chiu, Y. T., Lee, J. M., Chan, A. C., Cheung, E. T., Yau, D. T., Chia, N. H., Lo, I. L., Sham, P. C., Cheung, T. T., Wong, C. C., & Ng, I. O. (2021). Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma. Nature communications, 12(1), 3684. https://doi.org/10.1038/s41467-021-24010-1

• Cheng, W., Li, H. L., Xi, S. Y., Zhang, X. F., Zhu, Y., Le Xing, Mo, Y. X., Li, M. M., Kong, F. E., Zhu, W. J., Chen, X. G., Cui, H. Q., Cao, Z. M., Gong, Y. F., Tang, Y. Q., Zhang, Y., Guan, X. Y., Ma, N. F., & Liu, M. (2021). Growth differentiation factor 1-induced tumour plasticity provides a therapeutic window for immunotherapy in hepatocellular carcinoma. Nature communications, 12(1), 7142. https://doi.org/10.1038/s41467-021-27525-9

• Blanc, V., Riordan, J. D., Soleymanjahi, S., Nadeau, J. H., Nalbantoglu, I., Xie, Y., Molitor, E. A., Madison, B. B., Brunt, E. M., Mills, J. C., Rubin, D. C., Ng, I. O., Ha, Y., Roberts, L. R., & Davidson, N. O. (2021). Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis, and hepatocellular cancer. The Journal of clinical investigation, 131(1), e138699. https://doi.org/10.1172/JCI138699

• Loong, J. H., Wong, T. L., Tong, M., Sharma, R., Zhou, L., Ng, K. Y., Yu, H. J., Li, C. H., Man, K., Lo, C. M., Guan, X. Y., Lee, T. K., Yun, J. P., & Ma, S. K. (2021). Glucose deprivation-induced aberrant FUT1-mediated fucosylation drives cancer stemness in hepatocellular carcinoma. The Journal of clinical investigation, 131(11), e143377. https://doi.org/10.1172/JCI143377

• Leung, H. W., Leung, C., Lau, E. Y., Chung, K., Mok, E. H., Lei, M., Leung, R., Tong, M., Keng, V. W., Ma, C., Zhao, Q., Ng, I., Ma, S., & Lee, T. K. (2021). EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma. Cancer research, 81(12), 3229–3240. https://doi.org/10.1158/0008-5472.CAN-21-0184

• Ma, A., Yeung, C., Tey, S. K., Mao, X., Wong, S., Ng, T. H., Ko, F., Kwong, E., Tang, A., Ng, I. O., Cai, S. H., Yun, J. P., & Yam, J. (2021). Suppression of ACADM-Mediated Fatty Acid Oxidation Promotes Hepatocellular Carcinoma via Aberrant CAV1/SREBP1 Signaling. Cancer research, 81(13), 3679–3692. https://doi.org/10.1158/0008-5472.CAN-20-3944

• Xu, F., Tong, M., Tong, C., Chan, B., Chu, H. Y., Wong, T. L., Fong, J., Cheung, M., Mak, K. H., Pardeshi, L., Huang, Y., Wong, K. H., Choi, G., Ma, S., & Wong, A. (2021). A Combinatorial CRISPR-Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment. Cancer research, 81(24), 6219–6232. https://doi.org/10.1158/0008-5472.CAN-21-1017

• Loh, J. J., Li, T. W., Zhou, L., Wong, T. L., Liu, X., Ma, V., Lo, C. M., Man, K., Lee, T. K., Ning, W., Tong, M., & Ma, S. (2021). FSTL1 Secreted by Activated Fibroblasts Promotes Hepatocellular Carcinoma Metastasis and Stemness. Cancer research, 81(22), 5692–5705. https://doi.org/10.1158/0008-5472.CAN-20-4226

• Wong, D. K., & Yuen, M. F. (2021). Reply. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association, 19(2), 408–409. https://doi.org/10.1016/j.cgh.2020.03.058

• Sun, L., Xi, S., Zhou, Z., Zhang, F., Hu, P., Cui, Y., Wu, S., Wang, Y., Wu, S., Wang, Y., Du, Y., Zheng, J., Yang, H., Chen, M., Yan, Q., Yu, D., Shi, C., Zhang, Y., Xie, D., Guan, X. Y., … Li, Y. (2022). Elevated expression of RIT1 hyperactivates RAS/MAPK signal and sensitizes hepatocellular carcinoma to combined treatment with sorafenib and AKT inhibitor. Oncogene, 10.1038/s41388-021-02130-8. Advance online publication. https://doi.org/10.1038/s41388-021-02130-8

• Zhang, Y., Yan, Q., Gong, L., Xu, H., Liu, B., Fang, X., Yu, D., Li, L., Wei, T., Wang, Y., Wong, C. N., Lyu, Z., Tang, Y., Sham, P. C., & Guan, X. Y. (2021). Correction: C-terminal truncated HBx initiates hepatocarcinogenesis by downregulating TXNIP and reprogramming glucose metabolism. Oncogene, 40(35), 5451–5453. https://doi.org/10.1038/s41388-021-01942-y

• Bao, M. H., Yang, C., Tse, A. P., Wei, L., Lee, D., Zhang, M. S., Goh, C. C., Chiu, D. K., Yuen, V. W., Law, C. T., Chin, W. C., Chui, N. N., Wong, B. P., Chan, C. Y., Ng, I. O., Chung, C. Y., Wong, C. M., & Wong, C. C. (2021). Genome-wide CRISPR-Cas9 knockout library screening identified PTPMT1 in cardiolipin synthesis is crucial to survival in hypoxia in liver cancer. Cell reports, 34(4), 108676. https://doi.org/10.1016/j.celrep.2020.108676

• Tong, M., Wong, T. L., Zhao, H., Zheng, Y., Xie, Y. N., Li, C. H., Zhou, L., Che, N., Yun, J. P., Man, K., Lee, T. K., Cai, Z., & Ma, S. (2021). Loss of tyrosine catabolic enzyme HPD promotes glutamine anaplerosis through mTOR signaling in liver cancer. Cell reports, 36(8), 109617. https://doi.org/10.1016/j.celrep.2021.109617

• Kong, F. E., Tang, Y. Q., Gong, Y. F., Mo, J. Q., Zhao, Y., Li, M. M., Cheng, W., Li, H. L., Zhu, W. J., Liu, S. S., Huang, L., Guan, X. Y., Ma, N. F., & Liu, M. (2020). Identification of prognostic claudins signature in hepatocellular carcinoma from a hepatocyte differentiation model. Hepatology international, 14(4), 521–533. https://doi.org/10.1007/s12072-020-10035-z

• Yeung, S. F., Zhou, Y., Zou, W., Chan, W. L., & Ching, Y. P. (2022). TEC kinase stabilizes PLK4 to promote liver cancer metastasis. Cancer letters, 524, 70–81. https://doi.org/10.1016/j.canlet.2021.08.038

• Ho, N., Leung, C., Wong, T. L., Lau, E., Lei, M., Mok, E., Leung, H. W., Tong, M., Ng, I., Yun, J. P., Ma, S., & Lee, T. (2021). The interplay of UBE2T and Mule in regulating Wnt/β-catenin activation to promote hepatocellular carcinoma progression. Cell death & disease, 12(2), 148. https://doi.org/10.1038/s41419-021-03403-6

• Li, L., Wei, J. R., Song, Y., Fang, S., Du, Y., Li, Z., Zeng, T. T., Zhu, Y. H., Li, Y., & Guan, X. Y. (2021). TROAP switches DYRK1 activity to drive hepatocellular carcinoma progression. Cell death & disease, 12(1), 125. https://doi.org/10.1038/s41419-021-03422-3

• Zhang, X., Bai, Y., Huang, L., Liu, S., Mo, Y., Cheng, W., Wang, G., Cao, Z., Chen, X., Cui, H., Qi, L., Ma, L., Liu, M., Guan, X. Y., & Ma, N. F. (2021). CHD1L augments autophagy-mediated migration of hepatocellular carcinoma through targeting ZKSCAN3. Cell death & disease, 12(10), 950. https://doi.org/10.1038/s41419-021-04254-x

• Mak, L. Y., Huang, Q., Wong, D. K., Stamm, L., Cheung, K. S., Ko, K. L., Yan, R., Ouyang, L., Fung, J., Seto, W. K., & Yuen, M. F. (2021). Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy. Journal of gastroenterology, 56(5), 479–488. https://doi.org/10.1007/s00535-021-01780-5

• Zhang, V. X., Sze, K. M., Chan, L. K., Ho, D. W., Tsui, Y. M., Chiu, Y. T., Lee, E., Husain, A., Huang, H., Tian, L., Wong, C. C., & Ng, I. O. (2021). Antioxidant supplements promote tumor formation and growth and confer drug resistance in hepatocellular carcinoma by reducing intracellular ROS and induction of TMBIM1. Cell & bioscience, 11(1), 217. https://doi.org/10.1186/s13578-021-00731-0

• Loh, J. J., & Ma, S. (2021). The Role of Cancer-Associated Fibroblast as a Dynamic Player in Mediating Cancer Stemness in the Tumor Microenvironment. Frontiers in cell and developmental biology, 9, 727640. https://doi.org/10.3389/fcell.2021.727640

• Bao, M. H., & Wong, C. C. (2021). Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer. Cells, 10(7), 1715. https://doi.org/10.3390/cells10071715

• Cheng, C. L., Tsang, F. H., Wei, L., Chen, M., Chin, D. W., Shen, J., Law, C. T., Lee, D., Wong, C. C., Ng, I. O., & Wong, C. M. (2021). Bromodomain-containing protein BRPF1 is a therapeutic target for liver cancer. Communications biology, 4(1), 888. https://doi.org/10.1038/s42003-021-02405-6

• Cheung, K. S., Mak, L. Y., Lam, L. K., Fung, J., Liu, F., Seto, W. K., & Yuen, M. F. (2021). Statins associate with better clinical outcomes in chronic hepatitis B patients with HBsAg seroclearance. Hepatology international, 15(4), 881–891. https://doi.org/10.1007/s12072-021-10197-4

• Mak, L. Y., & Fung, J. (2021). The clinical and economic burden of non-alcoholic steatohepatitis in the Middle East: behind the scene. Hepatology international, 15(4), 860–862. https://doi.org/10.1007/s12072-021-10215-5

• Mak, L. Y., Hui, R. W., Fung, J., Liu, F., Wong, D. K., Li, B., Cheung, K. S., Yuen, M. F., & Seto, W. K. (2021). Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. Hepatology international, 15(4), 901–911. https://doi.org/10.1007/s12072-021-10218-2

• Mak, L. Y., Hoang, J., Jun, D. W., Chen, C. H., Peng, C. Y., Yeh, M. L., Kim, S. E., Huang, D. Q., Jeong, J. Y., Yoon, E., Oh, H., Tsai, P. C., Huang, C. F., Ahn, S. B., Trinh, H., Xie, Q., Wong, G., Enomoto, M., Shim, J. J., Lee, D. H., … Nguyen, M. H. (2022). Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. Hepatology international, 16(1), 48–58. https://doi.org/10.1007/s12072-021-10271-x

• Wong, D. K., Chen, C., Mak, L. Y., Fung, J., Seto, W. K., & Yuen, M. F. (2021). Detection of the hepatitis B surface antigen in patients with occult hepatitis B using an assay with enhanced sensitivity. Journal of clinical microbiology, jcm0220421. Advance online publication. https://doi.org/10.1128/jcm.02204-21

• Wong, L. S., & Wong, C. M. (2021). Decoding the Roles of Long Noncoding RNAs in Hepatocellular Carcinoma. International journal of molecular sciences, 22(6), 3137. https://doi.org/10.3390/ijms22063137

• Huang, C. F., Tyng-Yuan, J., Jun, D. W., Ahn, S. B., An, J., Enomoto, M., Takahashi, H., Ogawa, E., Yoon, E., Jeong, S. W., Shim, J. J., Jeong, J. Y., Kim, S. E., Oh, H., Kim, H. S., Cho, Y. K., Kozuka, R., Inoue, K., Cheung, K. S., Mak, L. Y., Huang, J.F., Dai C.Y., Yuen, M.F., Nguyen, M.H., Yu, M. L. (2022). On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. Liver international : official journal of the International Association for the Study of the Liver, 42(1), 59–68. https://doi.org/10.1111/liv.15085

• Au, K. P., Fung, J., Dai, W. C., Chan, A., Lo, C. M., & Chok, K. (2022). Verifying the Benefits of Radical Treatment in Posttransplant Hepatocellular Carcinoma Oligo-recurrence: A Propensity Score Analysis. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 28(1), 51–64. https://doi.org/10.1002/lt.26251

• Cable, J., Pei, D., Reid, L. M., Wang, X. W., Bhatia, S., Karras, P., Melenhorst, J. J., Grompe, M., Lathia, J. D., Song, E., Kuo, C. J., Zhang, N., White, R. M., Ma, S. K., Ma, L., Chin, Y. R., Shen, M. M., Ng, I., Kaestner, K. H., Zhou, L., … Weissman, I. L. (2021). Cancer stem cells: advances in biology and clinical translation-a Keystone Symposia report. Annals of the New York Academy of Sciences, 10.1111/nyas.14719. Advance online publication. https://doi.org/10.1111/nyas.14719

• Huang, F. Y., Wong, D. K., Seto, W. K., Mak, L. Y., Cheung, T. T., & Yuen, M. F. (2021). Tumor suppressive role of mitochondrial sirtuin 4 in induction of G2/M cell cycle arrest and apoptosis in hepatitis B virus-related hepatocellular carcinoma. Cell death discovery, 7(1), 88. https://doi.org/10.1038/s41420-021-00470-8

• Li, M. M., Yuan, J., Guan, X. Y., Ma, N. F., & Liu, M. (2021). Molecular subclassification of gastrointestinal cancers based on cancer stem cell traits. Experimental hematology & oncology, 10(1), 53. https://doi.org/10.1186/s40164-021-00246-x

• Khandakar, B., Liu, J. R., Thung, S., Li, Y., Rhee, H., Kagen, A. C., Tong, T. S., Park, Y. N., Theise, N., & Ng, I. O. (2022). Lymphoepithelioma-like neoplasm of the biliary tract with 'probable low malignant potential'. Histopathology, 80(4), 720–728. https://doi.org/10.1111/his.14580

• Chui, N. N., Cheu, J. W., Yuen, V. W., Chiu, D. K., Goh, C. C., Lee, D., Zhang, M. S., Ng, I. O., & Wong, C. C. (2022). Lymphoepithelioma-like neoplasm of the biliary tract with 'probable low malignant potential'. Histopathology, 80(4), 720–728. https://doi.org/10.1111/his.14580

• Mak, L. Y., Seto, W. K., & Yuen, M. F. (2021). Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection. Viruses, 13(6), 1169. https://doi.org/10.3390/v13061169

• Chu, K. K., Wong, K. H., & Chok, K. S. (2021). Expanding Indications for Liver Transplant: Tumor and Patient Factors. Gut and liver, 15(1), 19–30. https://doi.org/10.5009/gnl19265

• Lee, C. H., Seto, W. K., Ieong, K., Lui, D., Fong, C., Wan, H. Y., Chow, W. S., Woo, Y. C., Yuen, M. F., & Lam, K. (2021). Development of a Non-Invasive Liver Fibrosis Score Based on Transient Elastography for Risk Stratification in Patients with Type 2 Diabetes. Endocrinology and metabolism (Seoul, Korea), 36(1), 134–145. https://doi.org/10.3803/EnM.2020.887

• Yu, J. H., & Ma, S. (2022). Organoids as research models for hepatocellular carcinoma. Experimental cell research, 411(1), 112987. https://doi.org/10.1016/j.yexcr.2021.112987

• Seto, W. K., & Mandell, M. S. (2021). Chronic liver disease: Global perspectives and future challenges to delivering quality health care. PloS one, 16(1), e0243607. https://doi.org/10.1371/journal.pone.0243607

• Au, K. Y., & Lo, R. C. (2021). An Immunohistochemical Study of β-catenin Expression and Immune Cell Population in Metastatic Carcinoma to the Liver. Pathology oncology research : POR, 27, 1609752. https://doi.org/10.3389/pore.2021.1609752

• Yuen, M. F., Liu, S. H., Seto, W. K., Mak, L. Y., Corman, S. L., Hsu, D. C., Lee, M., Khan, T. K., & Puenpatom, A. (2021). Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong. Digestive diseases and sciences, 66(4), 1315–1326. https://doi.org/10.1007/s10620-020-06281-8

• Mak, L. Y., Wong, D. K., Cheung, K. S., Seto, W. K., Fung, J., & Yuen, M. F. (2021). First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients. BMC gastroenterology, 21(1), 123. https://doi.org/10.1186/s12876-021-01711-x

• Au, K. P., & Chok, K. (2021). Immunotherapy after liver transplantation: Where are we now?. World journal of gastrointestinal surgery, 13(10), 1267–1278. https://doi.org/10.4240/wjgs.v13.i10.1267

• Au, K. Y., Chan, K. K., & Lo, R. C. (2021). A Clinicopathological Study of Young-onset Hepatocellular Carcinoma. Anticancer research, 41(6), 2933–2944. https://doi.org/10.21873/anticanres.15075

• Ho, D. W., Lyu, X., & Ng, I. O. (2021). Viral integration detection strategies and a technical update on Virus-Clip. BIOCELL 2021; 45: 1495-1500. https://doi:10.32604/biocell.2021.017227

• Au, K. P., Dai, W. C., Chi-Yan Chan, A., Cheung, T. T., Lo, C. M., & Chok, K. S. (2021). Performance of Dual-tracer PET-CT for Staging Post-Liver Transplant Hepatocellular Carcinoma Recurrence. Transplantation direct, 7(10), e769. https://doi.org/10.1097/TXD.0000000000001213

• Ma, H., Lim, T. H., Leerapun, A., Weltman, M., Jia, J., Lim, Y. S., Tangkijvanich, P., Sukeepaisarnjaroen, W., Ji, Y., Le Bert, N., Li, D., Zhang, Y., Hamatake, R., Tan, N., Li, C., Strasser, S. I., Ding, H., Yoon, J. H., Stace, N. H., Ahmed, T., … Yuen, M. F. (2021). Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study. JHEP reports : innovation in hepatology, 3(6), 100361. https://doi.org/10.1016/j.jhepr.2021.100361

•Chiu, Y. T., Sze, K. M., Ho, D. W., Tsui, Y. M., Suarez, E., Zhang, V. X., Chan, L. K., Lee, E., Lee, J. M., Cheung, T. T., Wong, C. C., Chung, C. Y., & Ng, I. O. (2022). Ephrin-A3/EphA2 axis regulates cellular metabolic plasticity to enhance cancer stemness in hypoxic hepatocellular carcinoma. Journal of hepatology, 77(2), 383–396. https://doi.org/10.1016/j.jhep.2022.02.018

• Eslam, M., Fan, J. G., Yu, M. L., Wong, V. W., Cua, I. H., Liu, C. J., Tanwandee, T., Gani, R., Seto, W. K., Alam, S., Young, D. Y., Hamid, S., Zheng, M. H., Kawaguchi, T., Chan, W. K., Payawal, D., Tan, S. S., Goh, G. B., Strasser, S. I., Viet, H. D., … George, J. (2025). The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease. Hepatology international, 19(2), 261–301. https://doi.org/10.1007/s12072-024-10774-3
• Wei, H., Suo, C., Gu, X., Shen, S., Lin, K., Zhu, C., Yan, K., Bian, Z., Chen, L., Zhang, T., Yan, R., Yang, Z., Yu, Y., Li, Z., Liu, R., He, J., He, Q., Zhong, X., Jia, W., Wong, C. M., … Gao, P. (2025). AKR1D1 suppresses liver cancer progression by promoting bile acid metabolism-mediated NK cell cytotoxicity. Cell metabolism, 37(5), 1103–1118.e7. https://doi.org/10.1016/j.cmet.2025.01.011
• Wu, D., Kao, J. H., Piratvisuth, T., Wang, X., Kennedy, P. T. F., Otsuka, M., Ahn, S. H., Tanaka, Y., Wang, G., Yuan, Z., Li, W., Lim, Y. S., Niu, J., Lu, F., Zhang, W., Gao, Z., Kaewdech, A., Han, M., Yan, W., Ren, H., …, Yuen, M.F., Ning, Q. (2025). Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0. Clinical and molecular hepatology, 31(Suppl), S134–S164. https://doi.org/10.3350/cmh.2024.0780
• Ng, L. G., Ballesteros, I., Cassatella, M. A., Egeblad, M., Fridlender, Z. G., Gabrilovich, D., Gao, Q., Granot, Z., Grieshaber-Bouyer, R., Grimes, H. L., Hedrick, C. C., Hidalgo, A., Kaplan, M. J., Kubes, P., Ling, G. S., Lu, L., Luo, H. R., Mayadas, T. N., Moutsopoulos, N. M., Ng, M., … Kwok, I. (2025). From complexity to consensus: A roadmap for neutrophil classification. Immunity, 58(8), 1890–1903. https://doi.org/10.1016/j.immuni.2025.07.011
• Zhang, S., Mak, L. Y., Yuen, M. F., & Seto, W. K. (2025). Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B. Clinical and molecular hepatology, 31(Suppl), S182–S195. https://doi.org/10.3350/cmh.2024.0837
• Teo, J. M. N., Chen, Z., Chen, W., Tan, R. J. Y., Cao, Q., Chu, Y., Ma, D., Chen, L., Yu, H., Lam, K. H., Lee, T. K. W., Chakarov, S., Becher, B., Zhang, N., Li, Z., Ma, S., Xue, R., & Ling, G. S. (2025). Tumor-associated neutrophils attenuate the immunosensitivity of hepatocellular carcinoma. The Journal of experimental medicine, 222(1), e20241442. https://doi.org/10.1084/jem.20241442
• Wu, X. Q., Ying, F., Chung, K. P. S., Leung, C. O. N., Leung, R. W. H., So, K. K. H., Lei, M. M. L., Chau, W. K., Tong, M., Yu, J., Wei, D., Tai, W. C. S., Ma, S., Lu, Y. Y., & Lee, T. K. W. (2025). Intestinal Akkermansia muciniphila complements the efficacy of PD1 therapy in MAFLD-related hepatocellular carcinoma. Cell reports. Medicine, 6(1), 101900. https://doi.org/10.1016/j.xcrm.2024.101900
• Chan, S. L., Sun, H. C., Xu, Y., Zeng, H., El-Serag, H. B., Lee, J. M., Schwartz, M. E., Finn, R. S., Seong, J., Wang, X. W., Paradis, V., Abou-Alfa, G. K., Rimassa, L., Kao, J. H., Zhang, B. H., Llovet, J. M., Bruix, J., Yip, T. C., Wong, V. W., Wong, G. L., …, Ng, O.L., …, Zhou, J. (2025). The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment. Lancet (London, England), 406(10504), 731–778. https://doi.org/10.1016/S0140-6736(25)01042-6
• Hui, R. W., Mak, L. Y., Fung, J., Seto, W. K., & Yuen, M. F. (2025). Prospect of emerging treatments for hepatitis B virus functional cure. Clinical and molecular hepatology, 31(Suppl), S165–S181. https://doi.org/10.3350/cmh.2024.0855

   

• Loh, J. J., Ng, K. Y., Huang, I. B., Deng, M., Wang, Y., Man, K. F., Lam, K. H., Lee, T. K., Tan, J. Y., Cui, Y., Yu, H., Wong, T. L., Gao, Y., Yun, J. P., & Ma, S. (2025). DGKH-mediated phosphatidic acid oncometabolism as a driver of self-renewal and therapy resistance in HCC. Hepatology (Baltimore, Md.), 82(2), 308–325. https://doi.org/10.1097/HEP.0000000000001158
• Zeng, F., Zhang, Q., Tsui, Y. M., Ma, H., Tian, L., Husain, A., Lu, J., Lee, J. M., Zhang, V. X., Li, P. M., Cheung, G. C., Cheung, T. T., Ho, D. W., & Ng, I. O. (2025). Multimodal sequencing of neoadjuvant nivolumab treatment in hepatocellular carcinoma reveals cellular and molecular immune landscape for drug response. Molecular cancer, 24(1), 110. https://doi.org/10.1186/s12943-025-02314-w
• Ng, K. Y., Koo, T. Y., Huang, I. B., Lee, T. K., Fong, T. L., Gao, Y., Wong, T. L., Gao, Y., Yun, J. P., Guan, X. Y., Liu, M., Chung, C. Y., & Ma, S. (2025). AGPAT4 targeted covalent inhibitor potentiates targeted therapy to overcome cancer cell plasticity in hepatocellular carcinoma mouse models. Science translational medicine, 17(809), eadn9472. https://doi.org/10.1126/scitranslmed.adn9472.
• Chen, Y., Lee, D., Kwan, K. K., Wu, M., Wang, G., Zhang, M. S., Deng, H., Cheu, J. W., Lau, M. H., Chan, C. Y., Ooi, Z. Y., Wu, Y., Bao, M. H., Lo, R. C., Ng, I. O., Wong, C. M., & Wong, C. C. (2025). Mevalonate pathway promotes liver cancer by suppressing ferroptosis through CoQ10 production and selenocysteine-tRNA modification. Journal of hepatology, 83(6), 1338–1352. https://doi.org/10.1016/j.jhep.2025.06.034
• Hui, R. W., Chiu, K. W., Lee, I. C., Wang, C., Cheng, H. M., Lu, J., Mao, X., Yu, S., Lam, L. K., Mak, L. Y., Cheung, T. T., Chia, N. H., Cheung, C. C., Kan, W. K., Wong, T. C., Chan, A. C., Huang, Y. H., Yuen, M. F., Yu, P. L., & Seto, W. K. (2025). Multimodal multiphasic preoperative image-based deep-learning predicts HCC outcomes after curative surgery. Hepatology (Baltimore, Md.), 82(2), 344–356. https://doi.org/10.1097/HEP.0000000000001180
• Feng, G., Yilmaz, Y., Valenti, L., Seto, W. K., Pan, C. Q., Méndez-Sánchez, N., Ye, F., Sookoian, S., Targher, G., Byrne, C. D., Chan, W. K., Treeprasertsuk, S., Yu, H. H., Kim, S. U., George, J., Xu, W. J., Sebastiani, G., Ocama, P., Ryan, J. D., Lupșor-Platon, M., … Zheng, M. H. (2025). Global Burden of Major Chronic Liver Diseases in 2021. Liver international : official journal of the International Association for the Study of the Liver, 45(4), e70058. https://doi.org/10.1111/liv.70058
• Teo, J. M. N., Chen, W., & Ling, G. S. (2025). Neutrophil plasticity in liver diseases. Journal of leukocyte biology, 117(3), qiae222. https://doi.org/10.1093/jleuko/qiae222
• Yeung, C. L. S., Ng, T. H., Lai, C. J., Xue, T., Mao, X., Tey, S. K., Lo, R. C. L., Sin, C. F., Ng, K. M., Wong, D. K. H., Mak, L. Y., Yuen, M. F., Ng, I. O., Cao, P., Gao, Y., Yun, J. P., & Yam, J. W. P. (2025). Small Extracellular Vesicle-Derived Nicotinamide Phosphoribosyltransferase (NAMPT) Induces Acyl-Coenzyme A Synthetase SLC27A4-Mediated Glycolysis to Promote Hepatocellular Carcinoma. Journal of extracellular vesicles, 14(4), e70071. https://doi.org/10.1002/jev2.70071.
• Mao, X., Zhang, X., Lai, R., Cheung, K. S., Yuen, M. F., Cheung, R., Seto, W. K., & Nguyen, M. H. (2025). Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study. Clinical and molecular hepatology, 31(3), 1084–1099. https://doi.org/10.3350/cmh.2024.1096
• Lee, T. K. W., & Ma, S. (2025). PROX1: A Key Regulator of Hepatocyte Identity and Tumorigenesis. Cancer research, 85(11), 1957–1959. https://doi.org/10.1158/0008-5472.CAN-25-1377
• Sun, L., Hu, P., Yang, H., Ren, J., Hu, R., Wu, S., Wang, Y., Du, Y., Zheng, J., Wang, F., Gao, H., Yan, J., Yuan, Y. F., Guan, X. Y., Xiao, J., & Li, Y. (2025). ADARp110 promotes hepatocellular carcinoma progression via stabilization of CD24 mRNA. Proceedings of the National Academy of Sciences of the United States of America, 122(3), e2409724122. https://doi.org/10.1073/pnas.2409724122
• Fung J. (2025). Acute-on-chronic liver failure-Prime time for unity. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 44(5), 588–590. https://doi.org/10.1007/s12664-025-01798-0
• Ng, H. Y., Zhang, L., Tan, J. T., Hui, R. W. H., Yuen, M. F., Seto, W. K., Leung, W. K., & Cheung, K. S. (2025). Gut Microbiota Predicts Treatment Response to Empagliflozin Among MASLD Patients Without Diabetes Mellitus. Liver international : official journal of the International Association for the Study of the Liver, 45(3), e70023. https://doi.org/10.1111/liv.70023
• Wu, C., Targher, G., Byrne, C. D., Mao, Y., Cheung, T. T., Yilmaz, Y., Valenti, L., Méndez-Sánchez, N., Sookoian, S., Chan, W. K., Treeprasertsuk, S., Yu, H. H., Kim, S. U., George, J., Hu, D., Sebastiani, G., Ryan, J. D., Oviedo, R. J., Zhong, J. H., Schattenberg, J. M., …, Seto, W. K. , …, Zheng, M. H. (2025). Global, Regional, and National Burden of Primary Liver Cancer Attributable to Metabolic Risks: An Analysis of the Global Burden of Disease Study 1990-2021. The American journal of gastroenterology, 120(10), 2280–2290. https://doi.org/10.14309/ajg.0000000000003288
• Lyu, X., Sze, K. M., Lee, J. M., Husain, A., Tian, L., Imbeaud, S., Zucman-Rossi, J., Ng, I. O., & Ho, D. W. (2025). Disparity landscapes of viral-induced structural variations in HCC: Mechanistic characterization and functional implications. Hepatology (Baltimore, Md.), 81(6), 1805–1821. https://doi.org/10.1097/HEP.0000000000001087
• Hui, R. W., Mak, L. Y., Seto, W. K., & Yuen, M. F. (2025). Investigational RNA Interference Agents for Hepatitis B. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 39(1), 21–32. https://doi.org/10.1007/s40259-024-00694-x
• Zhang, Q., Chan, W. L., Fung, S. Y., Pang, L., Ding, T., Teo, J. M. N., Zhou, Y., Wu, C. M. A., Siu, K. L., Bi, J., Ling, G. S., Jin, D. Y., Man, K., & Ching, Y. P. (2025). Centrosome protein TAX1BP2 mediates STING-dependent immune response and potentiates anti-PD-1 efficacy in hepatocellular carcinoma. Molecular therapy : the journal of the American Society of Gene Therapy, 33(6), 2913–2930. https://doi.org/10.1016/j.ymthe.2025.01.043
• Yu, T. C., Zhao, L., Sze, K. M., Tian, L., Zhang, V. X., Lee, E., Kam, C. S., Lee, J. M., Ho, D. W., Tsui, Y. M., Chan, L. K., & Ng, I. O. (2025). GPD1L supports glycerol-3-phosphate and triacylglycerol synthesis and promotes tumor progression in HCC. Hepatology (Baltimore, Md.), 10.1097/HEP.0000000000001394. Advance online publication. https://doi.org/10.1097/HEP.0000000000001394
• Hui, R. W., Mak, L. Y., Fung, J., Seto, W. K., & Yuen, M. F. (2025). Expanding treatment indications in chronic hepatitis B: Should we treat all patients?. Hepatology international, 19(2), 304–314. https://doi.org/10.1007/s12072-025-10785-8
• Dongelmans, E. J., Hirode, G., Hansen, B. E., Chen, C. H., Su, T. H., Seto, W. K., Furquim d'Almeida, A., van Hees, S., Papatheodoridi, M., Lens, S., Wong, G. L. H., Brakenhoff, S. M., Chien, R. N., Feld, J. J., Chan, H. L. Y., Forns, X., Papatheodoridis, G. V., Vanwolleghem, T., Yuen, M. F., Hsu, Y. C., … RETRACT-B study group (2025). Predictors of hepatic flares after nucleos(t)ide analogue cessation - Results of a global cohort study (RETRACT-B study). Journal of hepatology, 82(3), 446–455. https://doi.org/10.1016/j.jhep.2024.08.015
• Lei, Y., Zhu, Y., Ni, W., Shi, J., Seto, W. K., & Li, J. (2025). Review Article: Impact of Alcohol Consumption on the Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease. Alimentary pharmacology & therapeutics, 62(7), 680–691. https://doi.org/10.1111/apt.70335
• Yu, P. L. H., Chiu, K. W., Lu, J., Lui, G. C. S., Zhou, J., Cheng, H. M., Mao, X., Wu, J., Shen, X. P., Kwok, K. M., Kan, W. K., Ho, Y. C., Chan, H. T., Xiao, P., Mak, L. Y., Tsui, V. W. M., Hui, C., Lam, P. M., Deng, Z., Guo, J., … Yuen, M. F. , & Seto, W. K. (2024). Application of a deep learning algorithm for the diagnosis of HCC. JHEP reports : innovation in hepatology, 7(1), 101219. https://doi.org/10.1016/j.jhepr.2024.101219
• Wan, T. R., Wei, L., Cheng, L. H., Chin, W. C., Shen, J., Chan, F. F., Kuang, Z., Wang, C., Wong, C. C., & Wong, C. M. (2025). Genome-wide CRISPR Screening Identifies NFκB and c-MET as Druggable Targets to Sensitize Lenvatinib Treatment in Hepatocellular Carcinoma. Cellular and molecular gastroenterology and hepatology, 19(7), 101502. https://doi.org/10.1016/j.jcmgh.2025.101502
• Zhang, X. F., Zuo, X. Y., Zhu, Y., Li, J. X., Xian, J. S., Zhang, W. X., Cheng, W., Yuan, J., Gong, Y. F., Tang, H., Yang, X. Q., Su, Y. Y., Zhang, C. Y., Liu, S. S., Huang, L., Wang, H., Li, M. M., Xi, S. Y., Tang, Y. Q., Zhou, L., … , Ma, S., Guan, X.Y., …, Liu, M. (2025). Targeting cell-state plasticity driven by FOXM1/CEBPB axis disrupts developmental heterogeneity and therapeutic resistance in hepatocellular carcinoma. Journal of hepatology, S0168-8278(25)02517-6. Advance online publication. https://doi.org/10.1016/j.jhep.2025.09.022
• Huang, R., Do, A. T., Toyoda, H., Li, J., Yasuda, S., Tsai, P. C., Yeh, M. L., Trinh, H., Chau, A., Huang, D. Q., Ogawa, E., Ito, T., Kozuka, R., Atsukawa, M., Marciano, S., Honda, T., Watanabe, T., Itokawa, N., Preda, C. M., Tseng, C. H., …, Yuen, M. F. , …, Nguyen, M. H. (2025). Distribution, Characteristics, and Natural History of Diverse Types of Indeterminate Chronic Hepatitis B: A REAL-B Study. Alimentary pharmacology & therapeutics, 62(3), 349–358. https://doi.org/10.1111/apt.70194
• Jiang, B., Guan, G., Zhao, K., Gu, Z., Wang, L., Gu, W., Li, M., Xia, Y., Chen, X., Guo, Y., Zhang, J., Cao, Z., Yuen, M. F., & Lu, F. (2025). Mechanisms underlying delayed loss of HBeAg and HBV DNA following HBsAg seroclearance in PEG-IFNα treated patients of chronic hepatitis B. Emerging microbes & infections, 14(1), 2475847. https://doi.org/10.1080/22221751.2025.2475847
• Xie, X., Tsui, Y. M., Zhang, V. X., Yu, T. C., Husain, A., Chiu, Y. T., Tian, L., Lee, E., Lee, J. M., Ma, H. T., Ho, D. W., Sze, K. M., & Ng, I. O. (2025). Nuclear localization of BRCA1-associated protein 1 is important in suppressing hepatocellular carcinoma metastasis via CTCF and NRF1/OGT axis. Cell death & disease, 16(1), 123. https://doi.org/10.1038/s41419-025-07451-0
• Chan, P., Cheung, P. H., Kang, X. Z., Cheng, Y., Wong, C. M., Jin, D. Y., & Chan, C. P. (2025). Cgref1 is a CREB-H-regulated hepatokine that promotes hepatic de novo lipogenesis by mediating epididymal fat insulin resistance. International journal of biological sciences, 21(6), 2568–2588. https://doi.org/10.7150/ijbs.97008.
• Ma, H., Zhang, V. X., Tsui, Y. M., Lee, J. M., Lee, E., Lu, J., Deng, H., Zeng, F., Ho, D. W., Hui, C., Husain, A., Sze, K. M., & Ng, I. O. (2025). Targeting sterol O-acyltransferase 1 rewires fatty acid metabolism and uncovers immune vulnerability in hepatocellular carcinoma. Hepatology (Baltimore, Md.), 10.1097/HEP.0000000000001561. Advance online publication. https://doi.org/10.1097/HEP.0000000000001561
• Chan, K. K., Wong, C. Y., Au, K. Y., Suen, L. H., Yip, W. W., Zhang, J. M., Fung, E. Y., Lee, T. K., Ng, I. O., Cheung, T. T., & Lo, R. C. (2025). Secreted lumican from the tumor microenvironment potentiates HCC stemness and progression. Hepatology communications, 9(9), e0778. https://doi.org/10.1097/HC9.0000000000000778.
• Wong, T. L., Kong, Y., & Ma, S. (2025). Lipid metabolism in cancer cells: Its role in hepatocellular carcinoma progression and therapeutic resistance. Hepatology communications, 9(11), e0837. https://doi.org/10.1097/HC9.0000000000000837
• Liu, X. W., Zhan, Z. B., Li, Z. H., Zhang, Y., Qiao, X. Y., Li, X. M., Liang, X. J., Bai, K. H., Xia, X. F., Zeng, F. H., Gao, Y., & Weng, J. (2025). RAB25/GCN1 Signaling Promotes ER Stress to Mediate Alcohol-associated Liver Disease Progression. Clinical and molecular hepatology, 10.3350/cmh.2025.0559. Advance online publication. https://doi.org/10.3350/cmh.2025.0559
• Zhang, V. X., Tsui, Y. M., & Ng, I. O. (2025). MASLD/MASH-New mechanisms and treatments. Hepatology communications, 9(8), e0770. https://doi.org/10.1097/HC9.0000000000000770.
• Lu, F., Yang, H., She, B., Lu, Q., Bao, Y., Seto, W. K., Wong, W. C. W., Yuen, M. F., He, Y., He, X., Ji, F., & Zhang, L. (2025). Investigating multimorbidity trajectories in people living with MASLD diagnosis: A trajectory analysis using the UK Biobank. Diabetes, obesity & metabolism, 27(12), 6968–6978. https://doi.org/10.1111/dom.70095
• Yang, Z., Yuan, Y., Niu, Y., Zuo, D., Liu, W., Li, K., Shi, Y., Qiu, Z., Li, K., Lin, Z., Zhong, C., Huang, Z., He, W., Guan, X., Yuan, Y., Zeng, W., Qiu, J., & Li, B. (2025). Regulatory factor X1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by transcriptional regulation of BECN1. Cellular oncology (Dordrecht, Netherlands), 48(2), 505–522. https://doi.org/10.1007/s13402-024-01017-6
• Crncec, A., Lau, H. W., Ng, L. Y., Ma, H. T., Mak, J. P. Y., Choi, H. F., Yeung, T. K., & Poon, R. Y. C. (2025). Plasticity of mitotic cyclins in promoting the G2-M transition. The Journal of cell biology, 224(6), e202409219. https://doi.org/10.1083/jcb.202409219
• Wong, D. K., Chow, N., Ma, H. T., Wong, K. Y., Mak, L. Y., Seto, W. K., & Yuen, M. F. (2025). Mechanism of entecavir-induced reduction of HBV DNA integration. Antiviral research, 237, 106120. https://doi.org/10.1016/j.antiviral.2025.106120
• Jiang, M., Alqahtani, S. A., Seto, W. K., Yilmaz, Y., Pan, Z., Valenti, L., & Eslam, M. (2025). Alternative splicing: hallmark and therapeutic opportunity in metabolic liver disease. Gastroenterology report, 13, goaf044. https://doi.org/10.1093/gastro/goaf044
• Lee, C. H., Lui, D. T., Mak, L. Y., Fong, C. H., Chan, K. S., Mak, J. H., Cheung, C. Y., Chow, W. S., Woo, Y. C., Yuen, M. F., Seto, W. K., & Lam, K. S. (2025). Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes-A real-world study. Diabetes, obesity & metabolism, 27(2), 574–582. https://doi.org/10.1111/dom.16049
• Hui, R. W., Fung, J., Seto, W. K., Yuen, M. F., & Mak, L. Y. (2025). Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies. Hepatology international, 19(4), 704–719. https://doi.org/10.1007/s12072-025-10828-0
• Xue, T., Yeung, C. L. S., Mao, X., Tey, S. K., Lo, K. W., Tang, A. H. N., Yun, J. P., & Yam, J. W. P. (2025). Development of a broadly potent neutralizing antibody targeting Nidogen 1 effectively inhibits cancer growth and metastasis in preclinical tumor models. Journal of translational internal medicine, 13(1), 78–92. https://doi.org/10.1515/jtim-2025-0008
• Wong, C. C., & Wong, C. M. (2025). CAD-driven pathways in HCC metastasis. Hepatology (Baltimore, Md.), 10.1097/HEP.0000000000001315. Advance online publication. https://doi.org/10.1097/HEP.0000000000001315
• Peng, C., Yu, P. L. H., Lu, J., Cheng, H. M., Shen, X. P., Chiu, K. W., & Seto, W. K. (2025). Opportunistic Detection of Hepatocellular Carcinoma Using Noncontrast CT and Deep Learning Artificial Intelligence. Journal of the American College of Radiology : JACR, 22(3), 249–259. https://doi.org/10.1016/j.jacr.2024.12.011
• Lei, M. M. L., Leung, C. O. N., Leung, R. W. H., Wu, X. Q., Chung, K. P. S., Gu, C. Y. J., Chan, M. S. M., Chau, W. K., Mu, Q. H., Ng, K. Y., Tong, M., Yun, J. P., Teo, J. M. N., Ling, G. S., Wong, P. P. C., Chan, S. L., Xiong, Z. W., Cheng, A. S. L., Ding, J., Ma, S., … Lee, T. K. W. (2025). Wild-type KRAS activation drives evasion of interferon-mediated immunity and resistance to immunotherapy in hepatocellular carcinoma. Nature communications, 16(1), 9913. https://doi.org/10.1038/s41467-025-64860-7
• Ho, K. C., & Mak, L. Y. (2025). Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol. Alimentary pharmacology & therapeutics, 61(6), 1069–1070. https://doi.org/10.1111/apt.18529
• Ng, T. H., Liang, A., Yeung, M. C., Tey, S. K., Siu, K. L., Fung, S. Y., Jin, D. Y., & Yam, J. W. P. (2025). Integrin β4-Enriched Small Extracellular Vesicle as Drug Delivery Vehicle for Targeting Pulmonary Metastasis of Hepatocellular Carcinoma. Advanced healthcare materials, 14(28), e2502649. https://doi.org/10.1002/adhm.202502649
• Koo, T. Y., Li, J. Y. K., Lee, N. S., Chen, J., Yip, H. Y., Huang, I. B., Ng, K. Y., Yan, H. H. N., Leung, S. Y., Ma, S., Zhou, J., & Chung, C. Y. (2025). A covalent inhibitor targeting Cys16 on RhoA in colorectal cancer. Cell chemical biology, 32(9), 1150–1165.e9. https://doi.org/10.1016/j.chembiol.2025.08.004
• Hui, R. W., Wu, T. K., Ho, K. C., Leung, R. H., Chung, M. S., Wong, D. K., Fung, J., Seto, W. K., Mak, L. Y., & Yuen, M. F. (2025). Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure. Gut, 75(1), 119–130. https://doi.org/10.1136/gutjnl-2025-335219
• Hui, R. W., Wong, D. K., Lyu, X., Mak, L. Y., Fung, J., Seto, W. K., Ho, D. W., & Yuen, M. F. (2025). Profiles of HBV DNA integration in humans with hepatitis B virus infection: Insights for antiviral treatment. JHEP reports : innovation in hepatology, 7(9), 101487. https://doi.org/10.1016/j.jhepr.2025.101487
• Yeung, C. L. S., Lai, C. J., Cui, L., Korani, L., Ng, T. H., Zhang, X., Chen, Z., Ma, R. R., Ng, K. M., & Yam, J. W. P. (2025). Identification of molecular markers and exploration of the oncogenic role of exomeres in hepatocellular carcinoma. Cell reports, 44(11), 116460. https://doi.org/10.1016/j.celrep.2025.116460
• Mak, L. Y., Yip, T. C., Lee, C. H., Lai, J. C., & Wong, V. W. (2025). Underrepresentation of Asians in diagnostic test development and drug trials in MASLD. Journal of hepatology, 83(1), e59–e60. https://doi.org/10.1016/j.jhep.2025.03.005
• Liu, C. X., & Wong, C. C. (2025). Stratifying Cholangiocarcinoma: Tumor Microenvironment, Molecular Drivers, and Novel Immunotherapeutic Approaches. Clinical and molecular hepatology, 10.3350/cmh.2025.0889. Advance online publication. https://doi.org/10.3350/cmh.2025.0889
• Kang, X. Z., Jin, D. Y., & Cheng, Y. (2025). C1orf115 interacts with clathrin adaptors to undergo endocytosis and induces ABCA1 to promote enteric cholesterol efflux. Cellular and molecular life sciences : CMLS, 82(1), 59. https://doi.org/10.1007/s00018-025-05590-3
• Mak, L. Y., Fung, J., Lo, G., Lo, C. S., Wu, T. K., Chung, M. S., Wong, T. C., Seto, W. K., Chan, A. C., & Yuen, M. F. (2025). Impact of liver graft steatosis on long-term post-transplant hepatic steatosis and fibrosis via magnetic resonance quantification. Frontiers in medicine, 11, 1502055. https://doi.org/10.3389/fmed.2024.1502055
• Suoangbaji, T., Long, R., Ng, I. O., Mak, L. L., & Ho, D. W. (2025). LiverSCA 2.0: An Enhanced Comprehensive Cell Atlas for Human Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancers, 17(5), 890. https://doi.org/10.3390/cancers17050890
• Mak, L. Y., & Lok, A. S. (2025). Update on combination therapies against HBV in clinical investigations. Antiviral research, 245, 106321. Advance online publication. https://doi.org/10.1016/j.antiviral.2025.106321
• Mak, L. Y., & Yuen, M. F. (2025). Surveillance for Hepatocellular Carcinoma in Cirrhosis: End of Monopoly for Serum Alpha Fetoprotein. Gastroenterology, 168(2), 217–219. https://doi.org/10.1053/j.gastro.2024.09.027
• Hui, R. W., Chung, M. S., Li, L., Mao, X., Chiang, C. L., Wong, C. K., Wong, I. C., Cheung, K. S., Yuen, M. F., Seto, W. K., & Mak, L. Y. (2025). Disparate patterns of disease time burden in patients with HCC on immunotherapy or tyrosine kinase inhibitors. JHEP reports : innovation in hepatology, 7(11), 101578. https://doi.org/10.1016/j.jhepr.2025.101578
• Hui, R. W., & Mak, L. Y. (2025). MASLD after hepatitis C virus eradication: Do not overlook the cardiometabolic risk factors: Editorial on "Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan". Clinical and molecular hepatology, 31(1), 290–292. https://doi.org/10.3350/cmh.2024.0630
• Seto W. K. (2025). Besifovir: a viable option for long-term disease control in chronic hepatitis B. Clinical and molecular hepatology, 10.3350/cmh.2025.0305. Advance online publication. https://doi.org/10.3350/cmh.2025.0305
• Teo, J. M. N., & Ling, G. S. (2025). Sphingosine Kinase 1 - A Therapeutic Opportunity for Alleviating Liver Fibrosis?. Cellular and molecular gastroenterology and hepatology, 19(2), 101430. https://doi.org/10.1016/j.jcmgh.2024.101430
• Mao, X., Cheung, K. S., Tan, J. T., Mak, L. Y., Lee, C. H., Cheng, H. M., Hui, R. W., Chan, E. W. Y., Yu, P. L., Yuen, M. F., Leung, W. K., & Seto, W. K. (2025). Risk of colorectal cancer and cancer-related mortality in type 2 diabetes patients treated with metformin, SGLT-2 inhibitors, or their combination. Cancer communications (London, England), 45(7), 880–883. https://doi.org/10.1002/cac2.70028
• Ho, K. C., & Mak, L. Y. (2025). The Prevailing Role of Diabetes Mellitus Among Cardiometabolic Risk Factors in Metabolic Dysfunction-associated Steatotic Liver Disease Prognostication. Journal of clinical and experimental hepatology, 15(5), 103119. https://doi.org/10.1016/j.jceh.2025.103119
• Hui, R. W., Wong, D. K., Mak, L. Y., Fung, J., Seto, W. K., & Yuen, M. F. (2025). Development and Validation of a High-Sensitivity Droplet Digital PCR Assay for Serum Hepatitis B Virus DNA Detection. Journal of viral hepatitis, 32(4), e70023. https://doi.org/10.1111/jvh.70023
• Cheng, Y., Kang, X. Z., Fung, S. Y., Siu, K. L., & Jin, D. Y. (2025). PKCα Phosphorylates FACI to Switch Its Function in Clathrin-mediated Endocytosis to a Presumed Role in Macropinocytosis in Intestinal and Hepatic Cells. Cellular and molecular gastroenterology and hepatology, 19(10), 101551. https://doi.org/10.1016/j.jcmgh.2025.101551
• Mak, L. Y., Anderson, M., Stec, M., Chung, M. S., Wong, D. K., Hui, R. W., Seto, W. K., Cloherty, G., & Yuen, M. F. (2025). Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters. Clinical and molecular hepatology, 31(2), 460–473. https://doi.org/10.3350/cmh.2024.0724
• Mao, X., Zhang, X., Henry, L., Cheung, K. S., Yuen, M. F., Cheung, R., Seto, W. K., & Nguyen, M. H. (2025). Association between glucagon-like peptidase 1 receptor agonist and obesity-related cancer in overweight or obese patients with type 2 diabetes: a nationwide cohort study. Journal of the National Cancer Institute, 117(10), 2053–2061. https://doi.org/10.1093/jnci/djaf163
• Ho, K. C., Hui, R. W., Seto, W. K., Yuen, M. F., & Mak, L. Y. (2025). Targeting the innate immune system in treating hepatitis B: Prospects for functional cure. Clinical and molecular hepatology, 10.3350/cmh.2025.0935. Advance online publication. https://doi.org/10.3350/cmh.2025.0935
• Zhan, Z., Liu, X., Zeng, M., Li, Z., Zhang, Y., Qiao, X., Li, X., Xia, X., Bai, K., Zeng, F., Gao, Y., & Weng, J. (2025). CCL2 supports human hepatocytes long-term expansion for bioartificial liver therapy to relieve acute liver failure and extrahepatic complications. International journal of biological sciences, 21(15), 6759–6774. https://doi.org/10.7150/ijbs.115293
• Chan, A. C., Lau, V. W., Wong, G. T., Chan, Y. W., Man, K., Ng, L. Y., Ma, H., Husain, A., & Ng, I. O. (2025). Prospective analysis on the outcomes of histotripsy for primary and metastatic liver tumours. International journal of surgery (London, England), 10.1097/JS9.0000000000003856. Advance online publication. https://doi.org/10.1097/JS9.0000000000003856
• Lyu, X., Mok, R. W., Chan, H. Y., Suoangbaji, T., Li, Q., Zeng, F., Long, R., Ng, I. O., Mak, L. L., & Ho, D. W. (2025). AVID enables sensitive and accurate viral integration detection across human cancers. Cell reports methods, 5(3), 101007. https://doi.org/10.1016/j.crmeth.2025.101007
• Zhang, X., Cheung, K. S., Mak, L. Y., Tan, K. C. B., Kung, A. W. C., Wong, I. C., & Cheung, C. L. (2025). Low Bone Mineral Density as a Risk Factor for Liver Cirrhosis. The Journal of clinical endocrinology and metabolism, 110(2), e276–e282. https://doi.org/10.1210/clinem/dgae223
• Wooddell, C. I., Mak, L. Y., Seto, W. K., Given, B. D., & Yuen, M. F. (2025). Virological Insights from ARC-520 siRNA and Entecavir Treated Chronically HBV-Infected Patients and Chimpanzees. Microorganisms, 13(8), 1787. https://doi.org/10.3390/microorganisms13081787
• Gao, D., & Yam, J. W. P. (2025). Reversal of lipid metabolism as a therapeutic approach for HCC. Hepatology (Baltimore, Md.), 81(4), 1113–1115. https://doi.org/10.1097/HEP.0000000000001000
• Hui, R. W., Mak, L. Y., & Yuen, M. F. (2025). Reply to: "Prediction of HBsAg loss after cessation of entecavir therapy". Journal of hepatology, 82(3), e130–e131. https://doi.org/10.1016/j.jhep.2024.10.041
• Lu, Z., & Wong, C. M. (2025). The impact of LRP4 mutations on HCC recurrence and immunotherapy response. Hepatology (Baltimore, Md.), 82(5), 1048–1050. https://doi.org/10.1097/HEP.0000000000001235
• Clevers, H., Sharma, A., Mani, S. A., Golebiewska, A., Behrens, A., Tam, W. L., Deleyrolle, L. P., Liu, H., Ganesh, K., Khaled, W. T., Sikandar, S., Lee, T. K., Miller, T. E., Tang, D. G., Singh, S., Li, V. S. W., Lathia, J. D., & Ma, S. (2025). Advancing Cancer Biology: Highlights from the 2025 FASEB SRC on Cellular Plasticity in Cancer. Cancer heterogeneity and plasticity, 2(4), 10.47248/chp2502040018. https://doi.org/10.47248/chp2502040018
• Zhang, Y., Tsui, Y. M., Lee, J. M., Cheung, T. T., Ho, D. W., & Ng, I. O. (2025). Spatiotemporal dynamics of T cells in peripheral blood and tumor underlying differential responses to neoadjuvant PD-1 blockade in hepatocellular carcinoma. Journal for immunotherapy of cancer, 13(12), e013516. https://doi.org/10.1136/jitc-2025-013516
• Tam, C. W. L., & Yam, J. W. P. (2025). Harnessing the potential of small extracellular vesicle biomarkers for cancer diagnosis and prognosis with advanced analytical technologies. Journal of translational internal medicine, 13(3), 187–200. https://doi.org/10.1515/jtim-2025-0019
• Zheng, S., Liu, Y., Zhang, B., Huang, J., Fang, X., Huang, C., Gong, L., Luo, J., Yang, Y., Liu, S., Wong, C. N., Huang, J., Li, S., Tan, Y., Chen, Q., Qin, Y., & Guan, X. Y. (2025). Targeting FTL regulates ferroptosis and remodels lymph node metastasis microenvironment in esophageal squamous cell carcinoma. International journal of biological sciences, 21(15), 6616–6632. https://doi.org/10.7150/ijbs.112017.
• Long, R., Suoangbaji, T., & Ho, D. W. (2025). OmniCellX: A Versatile and Comprehensive Browser-Based Tool for Single-Cell RNA Sequencing Analysis. Biology, 14(10), 1437. https://doi.org/10.3390/biology14101437
• Kong, N., Chen, K., Chanboonyasitt, P., Jiang, H., Wong, K. Y., Ma, H. T., & Chan, Y. W. (2025). The interplay of the translocase activity and protein recruitment function of PICH in ultrafine anaphase bridge resolution and genomic stability. Nucleic acids research, 53(3), gkae1249. https://doi.org/10.1093/nar/gkae1249
• Hui, R. W., Chiu, K. W., Yu, P. L., & Seto, W. K. (2025). Reply: Technical considerations in the development of a multimodal deep learning model for predicting hepatocellular carcinoma outcomes. Hepatology (Baltimore, Md.), 10.1097/HEP.0000000000001540. Advance online publication. https://doi.org/10.1097/HEP.0000000000001540
• Choi, W. M., & Seto, W. K. (2025). Unraveling the metabolic thread: Type 2 diabetes and fibrosis in chronic hepatitis B with steatosis. Hepatology (Baltimore, Md.), 10.1097/HEP.0000000000001469. Advance online publication. https://doi.org/10.1097/HEP.0000000000001469
• Hui, R. W., Mak, L. Y., & Yuen, M. F. (2025). Reply to: "Community health strategies for chronic hepatitis B: Advancing care with the ALT/qHBsAg ratio". Journal of hepatology, 82(3), e133–e134.>https://doi.org/10.1016/j.jhep.2024.10.042
• Hui, R. W., Mak, L. Y., & Yuen, M. F. (2025). Reply to: "ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative patients receiving Peg-IFNα based therapy". Journal of hepatology, 82(5), e228–e229. https://doi.org/10.1016/j.jhep.2024.12.036
• Ngan, H. L., Zhang, J., Kwan, K. K., Cheu, J. W., Zhong, L., Guo, Y., Yang, X., Wong, C. C., Yan, H., & Cai, Z. (2025). Resolution-Adaptive Binning Enhances Machine Learning Modeling by Interbatch and Multiplatform Orbitrap-Based Shotgun Mass Spectrometry Data Integration. Analytical chemistry, 97(48), 26877–26885. https://doi.org/10.1021/acs.analchem.5c05874

• Chan, F., Kwan, K. K., Seoung, D., Chin, D. W., Ng, I. O., Wong, C. C., & Wong, C. (2024). N6-Methyladenosine (m6A) modification activates serine synthesis pathway to mediate therapeutic resistance in liver cancer. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.10.025
• Chan, F., Yuen, V. W., Shen, J., Chin, D. W., Law, C., Wong, B. P., Chan, C. Y., Cheu, J. W., Ng, I. O., Wong, C. C., & Wong, C. (2023). Inhibition of CAF-1 histone chaperone complex triggers cytosolic DNA and dsRNA sensing pathways and induces intrinsic immunity of hepatocellular carcinoma. Hepatology, 80(2), 295–311. https://doi.org/10.1097/hep.0000000000000709
• Chen, A., Zhang, V. X., Zhang, Q., Sze, K. M., Tian, L., Huang, H., Wang, X., Lee, E., Lu, J., Lyu, X., Lee, M. J., Wong, C. M., Ho, D. W., & Ng, I. O. (2024). Targeting the oncogenic m6A demethylase FTO suppresses tumourigenesis and potentiates immune response in hepatocellular carcinoma. Gut, 74(1), 90–102. https://doi.org/10.1136/gutjnl-2024-331903
• Chen, Y., & Wong, C. C. (2024). The mechanistic insights behind the anticancer effects of statins in liver cancer. Hepatology Communications, 8(9). https://doi.org/10.1097/hc9.0000000000000519
• Cheng, T., Cheng, Y., & Jin, D. (2023). Oncostatin M for Anti-HBV therapy: Can a foe be turned into a friend? Cellular and Molecular Gastroenterology and Hepatology. https://doi.org/10.1016/j.jcmgh.2023.11.005
• Cheu, J. W., & Wong, C. C. (2024). The immune microenvironment of steatotic hepatocellular carcinoma: Current findings and future prospects. Hepatology Communications, 8(9). https://doi.org/10.1097/hc9.0000000000000516
• Cheung, K. S., Ng, H. Y., Hui, R. W. H., Lam, L. K., Mak, L. Y., Ho, Y. C., Tan, J. T., Chan, E. W., Seto, W. K., Yuen, M. F., & Leung, W. K. (2024). Effects of empagliflozin on liver fat in patients with metabolic dysfunction–associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial. Hepatology, 80(4), 916–927. https://doi.org/10.1097/hep.0000000000000855
• Cheung, T., Ho, D. W., Lyu, S. X., Zhang, Q., Tsui, Y., Yu, T. C., Sze, K. M., Lee, J. M., Lau, V. W., Chu, E. Y., Tsang, S. H., She, W., Leung, R. C., Yau, T. C., & Ng, I. O. (2023). Multimodal integrative genomics and pathology analyses in neoadjuvant nivolumab treatment for intermediate and locally advanced hepatocellular carcinoma. Liver Cancer, 13(1), 70–88. https://doi.org/10.1159/000531176
• Chiang, C. L., Chan, K. S. K., Chiu, K. W. H., Lee, F. a. S., Chen, W., Wong, N. S. M., Ho, R. L. M., Lee, V. W. Y., Man, K., Kong, F. M., & Chan, A. C. Y. (2024). Complete response to locoregional therapy plus immunotherapy for hepatocellular carcinoma. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2024.4085
• Dong, W., Da Roza, C. C., Cheng, D., Zhang, D., Xiang, Y., Seto, W. K., & Wong, W. C. W. (2024). Development and validation of HBV surveillance models using big data and machine learning. Annals of Medicine, 56(1). https://doi.org/10.1080/07853890.2024.2314237
• Dongelmans, E. J., Hirode, G., Hansen, B. E., Chen, C., Su, T., Seto, W., D’Almeida, A. F., Van Hees, S., Papatheodoridi, M., Lens, S., Wong, G. L., Brakenhoff, S. M., Chien, R., Feld, J. J., Chan, H. L., Forns, X., Papatheodoridis, G. V., Vanwolleghem, T., Yuen, M., . . . Janssen, H. L. (2024). Predictors of hepatic flares after nucleos(t)ide analogue cessation - Results of a global cohort study (RETRACT-B study). Journal of Hepatology. https://doi.org/10.1016/j.jhep.2024.08.015
• Fung, S. K., Pan, C. Q., Wong, G. L., Seto, W., Ahn, S. H., Chen, C., Hann, H. L., Jablkowski, M. S., Kim, Y. J., Yurdaydin, C., Peng, C., Nguyen, T., Yatsuhashi, H., Flaherty, J. F., Yee, L. J., Abramov, F., Wang, H., Abdurakhmanov, D., Lim, Y., & Buti, M. (2023). Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks. Alimentary Pharmacology & Therapeutics, 59(2), 217–229. https://doi.org/10.1111/apt.17764
• Gao, D., & Yam, J. W. P. (2024). Reversal of lipid metabolism as a therapeutic approach for hepatocellular carcinoma. Hepatology. https://doi.org/10.1097/hep.0000000000001000
• Gao, F., Seto, W., & Zheng, M. (2023). Preventing overdiagnosis of nonalcoholic fatty liver disease: established cutoff values for transient elastography are needed. Gastroenterology, 166(3), 541–542. https://doi.org/10.1053/j.gastro.2023.08.016
• Hirode, G., Hansen, B. E., Chen, C., Su, T., Wong, G. L., Seto, W., D’Almeida, A. F., Papatheodoridi, M., Brakenhoff, S. M., Lens, S., Choi, H. S., Chien, R., Feld, J. J., Forns, X., Sonneveld, M. J., Papatheodoridis, G. V., Vanwolleghem, T., Yuen, M., Chan, H. L., . . . Janssen, H. L. (2024). Limited Sustained Remission After Nucleos(t)ide Analog Withdrawal: Results From a Large, Global, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study). The American Journal of Gastroenterology, 119(9), 1849–1856. https://doi.org/10.14309/ajg.0000000000002759
• Hirode, G., Hansen, B. E., Chen, C., Su, T., Wong, G., Seto, W., Van Hees, S., Papatheodoridi, M., Brakenhoff, S. M., Lens, S., Choi, H. S., Chien, R., Feld, J. J., Forns, X., Sonneveld, M. J., Papatheodoridis, G. V., Vanwolleghem, T., Yuen, M., Chan, H. L., . . . Janssen, H. L. (2024). Erratum: Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study). The American Journal of Gastroenterology, 119(10), 2145. https://doi.org/10.14309/ajg.0000000000002718
• Ho, K. C., & Mak, L. (2024). Editorial: Decoding the enigma—Navigating complexity in MASLD management. Alimentary Pharmacology & Therapeutics, 60(6), 815–816. https://doi.org/10.1111/apt.18169
• Ho, K. K., Sin, S. L., Au, K. P., Lee, H. H., Chan, D. T., & Chan, A. (2024). Inferior vena cava reconstruction in extended right hepatectomy: A case report. Hepatobiliary & Pancreatic Diseases International, 23(5), 533–534. https://doi.org/10.1016/j.hbpd.2024.05.003
• Hou, J., Gane, E., Balabanska, R., Zhang, W., Zhang, J., Lim, T. H., Xie, Q., Yeh, C., Yang, S., Liang, X., Komolmit, P., Leerapun, A., Xue, Z., Chen, E., Zhang, Y., Xie, Q., Chang, T., Hu, T., Lim, S. G., . . . Yuen, M. (2024). Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients. Clinical and Molecular Hepatology, 30(2), 191–205. https://doi.org/10.3350/cmh.2023.0422
• Hou, J., Zhang, W., Xie, Q., Hua, R., Tang, H., Amado, L. E. M., Yang, S., Peng, C., Su, W., Chuang, W., Kim, D. J., Avihingsanon, A., Kao, J., Leerapun, A., Yuen, M., Asselah, T., Liang, X., Bo, Q., Canducci, F., . . . Gane, E. (2024). Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B. New England Journal of Medicine, 391(22), 2098–2109. https://doi.org/10.1056/nejmoa2405485
• Huang, H., Tsui, Y., Ho, D. W., Chung, C. Y., Sze, K. M., Lee, E., Cheung, G. C., Zhang, V. X., Wang, X., Lyu, X., & Ng, I. O. (2023). LANCL1, a cell surface protein, promotes liver tumor initiation through FAM49B-Rac1 axis to suppress oxidative stress. Hepatology, 79(2), 323–340. https://doi.org/10.1097/hep.0000000000000523
• Huang, J., Tsang, W. Y., Fang, X., Zhang, Y., Luo, J., Gong, L., Zhang, B., Wong, C. N., Li, Z., Liu, B., Huang, J., Yang, Y., Liu, S., Ban, L., Chan, Y. H., & Guan, X. (2024). FASN Inhibition Decreases MHC-I Degradation and Synergizes with PD-L1 Checkpoint Blockade in Hepatocellular Carcinoma. Cancer Research, 84(6), 855–871. https://doi.org/10.1158/0008-5472.can-23-0966
• Hui, R. W., Chiu, K. W., Lee, I., Wang, C., Cheng, H., Lu, J., Mao, X., Yu, S., Lam, L., Mak, L., Cheung, T., Chia, N., Cheung, C., Kan, W., Wong, T. C., Chan, A. C., Huang, Y., Yuen, M., Yu, P. L., & Seto, W. (2024). Multimodal multiphasic pre-operative image-based deep-learning predicts hepatocellular carcinoma outcomes after curative surgery. Hepatology. https://doi.org/10.1097/hep.0000000000001180
• Hui, R. W., Mak, L., Fung, J., Seto, W., & Yuen, M. (2024a). Prospect of emerging treatments for HBV functional cure. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2024.0855
• Hui, R. W., Mak, L., Seto, W., & Yuen, M. (2024b). Therapeutic advances in HBV cure. Clinical Liver Disease, 23(1). https://doi.org/10.1097/cld.0000000000000161
• Hui, R. W., Mak, L., Seto, W., & Yuen, M. (2024c). Investigational RNA interference agents for hepatitis B. BioDrugs. https://doi.org/10.1007/s40259-024-00694-x
• Hui, R. W., Mak, L., & Yuen, M. (2024a). Reply to: “Community health strategies for chronic hepatitis B: Advancing care with the ALT/qHBsAg ratio.” Journal of Hepatology. https://doi.org/10.1016/j.jhep.2024.10.042
• Hui, R. W., Mak, L., & Yuen, M. (2024b). Reply to: “Prediction of HBsAg loss after cessation of entecavir therapy.” Journal of Hepatology. https://doi.org/10.1016/j.jhep.2024.10.041
• Hui, R. W., Mak, L., & Yuen, M. (2024c). Reply to: “ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative hepatitis B patients with Peg-IFNα based therapy.” Journal of Hepatology. https://doi.org/10.1016/j.jhep.2024.12.036
• Jang, T., Liang, P., Jun, D. W., Jung, J. H., Toyoda, H., Wang, C., Yuen, M., Cheung, K. S., Yasuda, S., Kim, S. E., Yoon, E. L., An, J., Enomoto, M., Kozuka, R., Chuma, M., Nozaki, A., Ishikawa, T., Watanabe, T., Atsukawa, M., . . . Yu, M. (2023). Pretreatment gamma‐glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs.The Kaohsiung Journal of Medical Sciences, 40(2), 188–197. https://doi.org/10.1002/kjm2.12771
• Ji, F., Tran, S., Ogawa, E., Huang, C., Suzuki, T., Wong, Y. J., Toyoda, H., Jun, D. W., Li, L., Uojima, H., Nozaki, A., Chuma, M., Tseng, C., Hsu, Y., Ishigami, M., Honda, T., Atsukawa, M., Haga, H., Enomoto, M., . . . Nguyen, M. H. (2024). Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study. Journal of Clinical and Translational Hepatology, 000(000), 000. https://doi.org/10.14218/jcth.2024.00089
• Kan, K., Wong, D. K., Hui, R. W., Seto, W. K., Yuen, M., & Mak, L. (2023). Plasma interferon‐gamma‐inducible‐protein 10 level as a predictive factor of spontaneous hepatitis B surface antigen seroclearance in chronic hepatitis B patients.Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16371
• Kim, S., Lau, T. T., Liao, M. K., Tang, H., MA, & Poon, R. Y. (2024). Coregulation of NDC80 complex subunits determines the fidelity of the Spindle-Assembly checkpoint and mitosis. Molecular Cancer Research, 22(5), 423–439. https://doi.org/10.1158/1541-7786.mcr-23-0828
• Kong, N., Chen, K., Chanboonyasitt, P., Jiang, H., Wong, K. Y., Tang, H., MA, & Chan, Y. W. (2024). The interplay of the translocase activity and protein recruitment function of PICH in ultrafine anaphase bridge resolution and genomic stability. Nucleic Acids Research. https://doi.org/10.1093/nar/gkae1249
• Kwok, T., Hui, R. W., Mao, X., Ling, G., Wong, D. K., Huang, F., Fung, J., Seto, W., Yuen, M., & Mak, L. (2024). Cigarette smoking is associated with lower chance of hepatitis B surface antigen seroclearance and altered host immunity. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.14007
• Lam, L. K., Tan, J. T., Ooi, P. H., Zhang, R., Chan, K. H., Mao, X., Hung, I. F. N., Seto, W. K., Yuen, M. F., & Cheung, K. S. (2024). Effect of metabolic dysfunction‐associated steatotic liver disease on BNT162b2 immunogenicity against the severe acute respiratory syndrome coronavirus 2 omicron variant.Journal of Gastroenterology and Hepatology, 39(11), 2386–2393. https://doi.org/10.1111/jgh.16716
• Lau, T. T., Tang, H., MA, & Poon, R. Y. (2024). Kinesins regulate the heterogeneity in centrosome clustering after whole-genome duplication. Life Science Alliance, 7(10), e202402670. https://doi.org/10.26508/lsa.202402670
• Leung, R. H., Hui, R. W., Mak, L., Mao, X., Liu, K. S., Wong, D. K., Fung, J., Seto, W., & Yuen, M. (2024). ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis B. Journal of Hepatology, 81(2), 218–226. https://doi.org/10.1016/j.jhep.2024.03.022
• Ling, G. S. (2024). Tolerogenic PDCs turn the inflammatory tide and protect against acute liver failure. Cellular and Molecular Gastroenterology and Hepatology, 18(3), 101370. https://doi.org/10.1016/j.jcmgh.2024.101370
• Loh, J. J., Ng, K. Y., Huang, I. B., Deng, M., Wang, Y., Man, K. F., Lam, K. H., Lee, T. K., Tan, J. Y., Cui, Y., Yu, H., Wong, T. L., Gao, Y., Yun, J., & Ma, S. (2024). DGKH-mediated phosphatidic acid oncometabolism as a driver of self-renewal and therapy resistance in hepatocellular carcinoma. Hepatology. https://doi.org/10.1097/hep.0000000000001158
• Loh, J., & Ma, S. (2024). Hallmarks of cancer stemness. Cell Stem Cell, 31(5), 617–639. https://doi.org/10.1016/j.stem.2024.04.004
• Long, R., Suoangbaji, N., Ng, I. O., & Ho, D. W. (2024). LiverSCA: A comprehensive and user-friendly cell atlas in human hepatocellular carcinoma. Computational and Structural Biotechnology Journal, 23, 2740–2745. https://doi.org/10.1016/j.csbj.2024.06.031
• Lui, R. N., Mak, L. L., Kung, K., Leung, C., St Li, R., Ma, Y., Ng, C. K., Chan, H. L., Yuen, M., Wong, G. L., & Fung, J. (2024). Protein induced by vitamin K absence-II for the surveillance and monitoring of hepatocellular carcinoma in Hong Kong. Hong Kong Medical Journal. https://doi.org/10.12809/hkmj2411783
• Luo, J., Gong, L., Yang, Y., Zhang, Y., Liu, Q., Bai, L., Fang, X., Zhang, B., Huang, J., Liu, M., Liu, B., Tang, Y., Wong, C. N., Huang, J., Liu, S., Li, S., Ding, T., Man, K., Lee, V. H., . . . Guan, X. (2023). Enhanced mitophagy driven by ADAR1-GLI1 editing supports the self-renewal of cancer stem cells in HCC. Hepatology, 79(1), 61–78. https://doi.org/10.1097/hep.0000000000000299
• Lyu, X., Sze, K. M., Lee, J. M., Husain, A., Tian, L., Imbeaud, S., Zucman-Rossi, J., Ng, I. O., & Ho, D. W. (2024). Disparity landscapes of viral-induced structural variations in hepatocellular carcinoma: Mechanistic characterization and functional implications. Hepatology. https://doi.org/10.1097/hep.0000000000001087
• Lyu, X., Tsui, Y., Tam, I. K., Li, P., Cheung, G. C., Lee, J. M., Ng, I. O., & Ho, D. W. (2024). Resolution of optimal mitochondrial and nuclear DNA enrichment in Target-Panel sequencing and physiological mitochondrial DNA copy number estimation in liver Cancer and Non-Liver cancer subjects. Cancers, 16(17), 3012. https://doi.org/10.3390/cancers16173012
• Ma, S., & Chew, V. (2023). Unlocking the immune microenvironment of nonalcoholic steatohepatitis-associated HCC. Hepatology. https://doi.org/10.1097/hep.0000000000000626
• Mak, L. (2024a). Steatotic liver disease: Know your enemies. Clinical and Molecular Hepatology, 30(2), 171–173. https://doi.org/10.3350/cmh.2024.0078
• Mak, L. (2024b). Broadening clinical indications of tenofovir alafenamide in chronic hepatitis B. ˜the œLancet. Gastroenterology & Hepatology, 9(8), 681–682. https://doi.org/10.1016/s2468-1253(24)00116-x
• Mak, L. (2024c). Disease modifiers and novel markers in HBV-related HCC. Journal of Liver Cancer, 24(2), 145–154. https://doi.org/10.17998/jlc.2024.08.03
• Mak, L. (2024d). Disease modifiers and novel markers in HBV-related HCC. Journal of Liver Cancer, 24(2), 145–154. https://doi.org/10.17998/jlc.2024.08.03
• Mak, L., Anderson, M., Stec, M., Chung, M. S., Wong, D. K., Hui, R. W., Seto, W., Cloherty, G., & Yuen, M. (2024). Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2024.0724
• Mak, L., Chung, M. S. H., Li, X., Lai, F. T. T., Wan, E. Y. F., Chui, C. S. L., Cheng, F. W. T., Chan, E. W. Y., Cheung, C. L., Au, I. C. H., Xiong, X., Seto, W., Yuen, M., Wong, C. K. H., & Wong, I. C. K. (2024). Effects of SARS-CoV-2 infection on incidence and treatment strategies of hepatocellular carcinoma in people with chronic liver disease. World Journal of Hepatology, 16(2), 211–228. https://doi.org/10.4254/wjh.v16.i2.211
• Mak, L., Hui, R. W., Chung, M. S. H., Wong, D. K., Fung, J., Seto, W., & Yuen, M. (2024). Regression of liver fibrosis after HBsAg loss: A prospective matched case–control evaluation using transient elastography and serum enhanced liver fibrosis test. Journal of Gastroenterology and Hepatology, 39(12), 2826–2834. https://doi.org/10.1111/jgh.16728
• Mak, L., To, W., Tsui, V., Chung, M. S., Hui, K., Wu, T. K., Kwok, A., Ko, K., Wong, D. K., Wong, S., Liu, K. S., Seto, W., & Yuen, M. (2024). Pilot model of hepatitis C virus micro-elimination in high-risk populations in Hong Kong: Barriers and facilitators. International Journal of Drug Policy, 132, 104568. https://doi.org/10.1016/j.drugpo.2024.104568
• Mak, L., & Yuen, M. (2024). Surveillance for hepatocellular carcinoma in cirrhosis: End of monopoly for serum alpha fetoprotein. Gastroenterology. https://doi.org/10.1053/j.gastro.2024.09.027
• Mao, X., Cheung, K., Tan, J., Mak, L., Lee, C., Chiang, C., Cheng, H., Hui, R. W., Leung, W. K., Yuen, M., & Seto, W. (2024). Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver‐related mortality in patients with diabetes.Alimentary Pharmacology & Therapeutics, 60(10), 1398–1408. https://doi.org/10.1111/apt.18254
• Mao, X., Zhang, X., Kam, L., Chien, N., Lai, R., Cheung, K., Yuen, M., Cheung, R., Seto, W., & Nguyen, M. H. (2024). Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease. Gut, 73(12), 2054–2061. https://doi.org/10.1136/gutjnl-2024-332481
• Ng, K. T., Pang, L., Wang, J., She, W. H., Tsang, S. H., Lo, C. M., Man, K., & Cheung, T. T. (2023). Indications of pro-inflammatory cytokines in laparoscopic and open liver resection for early-stage hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases International, 23(3), 257–264. https://doi.org/10.1016/j.hbpd.2023.10.006
• Pan, Z., Seto, W., Liu, C., Mao, Y., Alqahtani, S. A., & Eslam, M. (2024). A literature review of genetics and epigenetics of HCV-related hepatocellular carcinoma: translational impact. HepatoBiliary Surgery and Nutrition, 13(4), 650–661. https://doi.org/10.21037/hbsn-23-562
• Peters, M. G., Yuen, M., Terrault, N., Fry, J., Lampertico, P., Gane, E., Hwang, C., Stamm, L. M., Leus, M., Maini, M. K., Mendez, P., Lonjon-Domanec, I., Berg, T., Wang, S., Mishra, P., Donaldson, E., Buchholz, S., Miller, V., & Lenz, O. (2023). Chronic hepatitis B finite treatment: similar and different concerns with new drug classes. Clinical Infectious Diseases, 78(4), 983–990. https://doi.org/10.1093/cid/ciad506
• Teo, J. M. N., Chen, W., & Ling, G. S. (2024). Neutrophil plasticity in liver diseases. Journal of Leukocyte Biology. https://doi.org/10.1093/jleuko/qiae222
• Teo, J. M. N., & Ling, G. S. (2024). Sphingosine kinase 1 – a therapeutic opportunity for alleviating liver fibrosis? Cellular and Molecular Gastroenterology and Hepatology, 19(2), 101430. https://doi.org/10.1016/j.jcmgh.2024.101430
• Tian, L., Lu, J., & Ng, I. O. (2024). Extracellular vesicles and cancer stemness in hepatocellular carcinoma – is there a link? Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1368898
• Tsui, Y., Ho, D. W., Sze, K. M., Lee, J. M., Lee, E., Zhang, Q., Cheung, G. C., Tang, C., Tang, V. W., Cheung, E. T., Lo, I. L., Chan, A. C., Cheung, T., & Ng, I. O. (2024). Sorted-Cell sequencing on HCC specimens reveals EPS8L3 as a key player in CD24/CD13/EPCAM-Triple Positive, Stemness-Related HCC cells. Cellular and Molecular Gastroenterology and Hepatology, 18(3), 101358. https://doi.org/10.1016/j.jcmgh.2024.05.006
• Tsui, Y. M., Ho, D. W., & Ng, I. O. (2024). Unraveling the tumor-initiating cells in hepatocellular carcinoma. Cancer Cell. https://doi.org/10.1016/j.ccell.2024.10.018
• Tsui, Y., Tian, L., Lu, J., Ma, H., & Ng, I. O. (2024). Interplay among extracellular vesicles, cancer stemness and immune regulation in driving hepatocellular carcinoma progression. Cancer Letters, 597, 217084. https://doi.org/10.1016/j.canlet.2024.217084
• Wong, C. C., Tapper, E. B., Malhi, H., & Gores, G. J. (2024). Manuscript best practices: Takeaways from a community conversation. Hepatology, 79(6), 1243–1245. https://doi.org/10.1097/hep.0000000000000849
• Wong, P. Y., Chan, C. Y. K., Xue, H. D. G., Goh, C. C., Cheu, J. W. S., Tse, A. P. W., Zhang, M. S., Zhang, Y., & Wong, C. C. L. (2024). Cell cycle inhibitors activate hypoxia-induced DDX41-STING pathway to mediate anti-tumor immune response in liver cancer. JCI Insight, 9(22). https://doi.org/10.1172/jci.insight.170532
• Wooddell, C. I., Sanders, D., Xu, Z., Mak, L., Schluep, T., Seto, W., Given, B. D., & Yuen, M. (2024). Characterization of Hepatitis B Virus Transcripts in Chronically HBV-Infected Chimpanzees and Patients Treated with ARC-520 siRNA Demonstrates Transcriptional Silencing of cccDNA. Viruses, 16(12), 1943. https://doi.org/10.3390/v16121943
• Wu, C., Targher, G., Byrne, C. D., Mao, Y., Cheung, T. T., Yilmaz, Y., Valenti, L., Méndez-Sánchez, N., Sookoian, S., Chan, W., Treeprasertsuk, S., Yu, H. H., Kim, S. U., George, J., Hu, D., Sebastiani, G., Ryan, J. D., Oviedo, R. J., Zhong, J., . . . Zheng, M. (2025). Global, regional, and national burden of primary liver cancer attributable to metabolic risks: an analysis of the Global Burden of Disease Study 1990-2021. The American Journal of Gastroenterology. https://doi.org/10.14309/ajg.0000000000003288
• Wu, T. K., Hui, R. W., Mak, L., Fung, J., Seto, W., & Yuen, M. (2024). Hepatocellular carcinoma: Advances in systemic therapies. F1000Research, 13, 104. https://doi.org/10.12688/f1000research.145493.2
• Wu, X. Q., Ying, F., Chung, K. P. S., Leung, C. O. N., Leung, R. W. H., So, K. K. H., Lei, M. M. L., Chau, W. K., Tong, M., Yu, J., Wei, D., Tai, W. C. S., Ma, S., Lu, Y. Y., & Lee, T. K. W. (2025). Intestinal Akkermansia muciniphila complements the efficacy of PD1 therapy in MAFLD-related hepatocellular carcinoma. Cell Reports Medicine, 101900. https://doi.org/10.1016/j.xcrm.2024.101900
• Xie, Y., Wu, H., He, Y., Liu, L., Huang, I. B., Zhou, L., Lin, C., Leung, R. W., Loh, J., Lee, T. K., Ding, J., Man, K., Ma, S., & Tong, M. (2024). Targeting AXL induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancer. Cell Death and Disease, 15(2). https://doi.org/10.1038/s41419-024-06493-0
• Yang, N., Seto, W., & Zheng, M. (2024). Functional cure of chronic hepatitis B encounters resmetirom. Clinical and Molecular Hepatology, 30(3), 580–581. https://doi.org/10.3350/cmh.2024.0301
• Yang, Z., Yuan, Y., Niu, Y., Zuo, D., Liu, W., Li, K., Shi, Y., Qiu, Z., Li, K., Lin, Z., Zhong, C., Huang, Z., He, W., Guan, X., Yuan, Y., Zeng, W., Qiu, J., & Li, B. (2024). Regulatory factor X1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by transcriptional regulation of BECN1. Cellular Oncology. https://doi.org/10.1007/s13402-024-01017-6
• Yao, Y., Xu, Y., Yu, L., Xue, T., Xiao, Z., Tin, P., Fung, H., Ma, H., Yun, J., & Yam, J. W. P. (2023). NHE7 upregulation potentiates the uptake of small extracellular vesicles by enhancing maturation of macropinosomes in hepatocellular carcinoma. Cancer Communications, 44(2), 251–272. https://doi.org/10.1002/cac2.12515
• Yip, R. P. H., Kwok, D. C. Y., Lai, L. T. F., Ho, S., Wong, I. C. K., Chan, C., Lau, W. C. Y., & Ngo, J. C. K. (2024). SRPK2 mediates HBV core protein phosphorylation and capsid assembly via docking interaction. PLoS Pathogens, 20(2), e1011978. https://doi.org/10.1371/journal.ppat.1011978
• Yu, P. L. H., Chiu, K. W., Lu, J., Lui, G. C. S., Zhou, J., Cheng, H., Mao, X., Wu, J., Shen, X., Kwok, K. M., Kan, W. K., Ho, Y. C., Chan, H. T., Xiao, P., Mak, L., Tsui, V. W. M., Hui, C., Lam, P. M., Deng, Z., . . . Seto, W. (2024). Application of a deep learning algorithm for the diagnosis of HCC. JHEP Reports, 7(1), 101219. https://doi.org/10.1016/j.jhepr.2024.101219
• Yuen, M., Fung, S., Ma, X., Nguyen, T. T., Hassanein, T., Hann, H., Elkhashab, M., Nahass, R. G., Park, J. S., Jacobson, I. M., Ayoub, W. S., Han, S., Gane, E. J., Zomorodi, K., Yan, R., Ma, J., Knox, S. J., Stamm, L. M., Bonacini, M., . . . Sulkowski, M. S. (2024). Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses. JHEP Reports, 6(4), 100999. https://doi.org/10.1016/j.jhepr.2023.100999
• Yuen, M., Lim, Y., Yoon, K. T., Lim, T., Heo, J., Tangkijvanich, P., Tak, W. Y., Thanawala, V., Cloutier, D., Mao, S., Arizpe, A., Cathcart, A. L., Gupta, S. V., Hwang, C., & Gane, E. (2024). VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study. ˜the œLancet. Gastroenterology & Hepatology, 9(12), 1121–1132. https://doi.org/10.1016/s2468-1253(24)00237-1
• Zhang, H., Targher, G., Byrne, C. D., Kim, S. U., Wong, V. W., Valenti, L., Glickman, M., Ponce, J., Mantzoros, C. S., Crespo, J., Gronbaek, H., Yang, W., Eslam, M., Wong, R. J., Machado, M. V., Yu, M., Ghanem, O. M., Okanoue, T., Liu, J., . . . Zou, Z. (2024). A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease. Hepatology International, 18(4), 1178–1201. https://doi.org/10.1007/s12072-024-10702-5
• Zhang, Q., Tsui, Y., Zhang, V. X., Lu, A. J., Lee, J. M., Lee, E., Cheung, G. C., Li, P., Cheung, E. T., Chia, N., Lo, I. L., Chan, A. C., Cheung, T., Ng, I. O., & Ho, D. W. (2024). Reciprocal interactions between malignant cells and macrophages enhance cancer stemness and M2 polarization in HBV-associated hepatocellular carcinoma. Theranostics, 14(2), 892–910. https://doi.org/10.7150/thno.87962
• Zhang, S., Chau, H., Tun, H. M., Huang, F., Wong, D. K., Mak, L., Yuen, M., & Seto, W. (2024). Virological response to nucleos(t)ide analogues treatment in chronic hepatitis B patients is associated with Bacteroides-dominant gut microbiome. EBioMedicine, 103, 105101. https://doi.org/10.1016/j.ebiom.2024.105101
• Zhang, S., Mak, L., Yuen, M., & Seto, W. (2024). Mechanisms of HCC and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2024.0837
• Zhang, X., Cheung, K., Mak, L., Tan, K. C. B., Kung, A. W. C., Wong, I. C., & Cheung, C. (2024). Low bone mineral density as a risk factor for liver cirrhosis. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae223
• Zhao, L., Wang, G., Qi, H., Yu, L., Yin, H., Sun, R., Wang, H., Zhu, X., & Yang, A. (2024). LINC00330/CCL2 axis-mediated ESCC TAM reprogramming affects tumor progression. Cellular & Molecular Biology Letters, 29(1). https://doi.org/10.1186/s11658-024-00592-8
• Zhou, Y., Pang, L., Ding, T., Chen, K., Liu, J., Wu, M., Wang, W., & Man, K. (2024). Precise in situ delivery of a photo-enhanceable Inflammasome-Activating nanovaccine activates anti-cancer immunity. Cancer Research. https://doi.org/10.1158/0008-5472.can-24-0220

 

• Yeung, T. K., Kim, S., Tang, H., MA, & Poon, R. Y. C. (2023). A robust dual gene ON–OFF toggle directed by two independent promoter–degron pairs. Journal of Cell Science, 136(8). https://doi.org/10.1242/jcs.260754
• Yu, H., Zhou, L., Loong, J. H., Lam, K., Wong, T., Ng, K., Tong, M., WS, V., MA, Wang, Y., Zhang, X., Lee, T. K., Yun, J., Yu, J., & Ma, S. (2023). SERPINA12 promotes the tumorigenic capacity of HCC stem cells through hyperactivation of AKT/β-catenin signaling. Hepatology, 78(6), 1711–1726. https://doi.org/10.1097/hep.0000000000000269
• Yuen, M., Asselah, T., Jacobson, I. M., Brunetto, M. R., Janssen, H. L. A., Takehara, T., Hou, J. L., Kakuda, T. N., Lambrecht, T., Beumont, M., Kalmeijer, R., Guinard-Azadian, C., Mayer, C., Jezorwski, J., Verbinnen, T., Lenz, O., Shukla, U., Biermer, M., Bourgeois, S., . . . Gitlin, N. (2023). Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial. the Lancet. Gastroenterology & Hepatology, 8(9), 790–802. https://doi.org/10.1016/s2468-1253(23)00148-6
• Yuen, M., Balabanska, R., Cottreel, E., Chen, E., Duan, D., Jiang, Q., Patil, A., Triyatni, M., Upmanyu, R., Zhu, Y., Canducci, F., & Gane, E. J. (2022). TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trial. The Lancet Infectious Diseases, 23(4), 496–507. https://doi.org/10.1016/s1473-3099(22)00727-7
• Yuen, M., Chen, C., Liu, C., Jeng, W., Elkhashab, M., Coffin, C. S., Kim, W., Greenbloom, S., Ramji, A., Lim, Y. S., Kim, Y. J., Fung, S. K., Kim, D. J., Jang, J., Lee, K. S., Iyer, R. P., Macfarlane, C., Jackson, K., Locarnini, S. A., . . . Afdhal, N. H. (2022). A phase 2, open‐label, randomized, multiple‐dose study evaluating Inarigivir in treatment‐naïve patients with chronic hepatitis B.Liver International, 43(1), 77–89. https://doi.org/10.1111/liv.15465
• Yuen, V. W., Chiu, D. K., Law, C., Cheu, J. W., Chan, C. Y., Wong, B. P., Goh, C., Zhang, M. S., Xue, H. D., Tse, A. P., Zhang, Y., Lau, H. Y., Lee, D., Au-Yeung, R. K., Wong, C., & Wong, C. C. (2022). Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses. Journal of Hepatology, 78(2), 376–389. https://doi.org/10.1016/j.jhep.2022.10.037
• Zhang, L., Liu, H., Zou, Z., Su, S., Ong, J. J., Ji, F., Cui, F., Chan, P., Ning, Q., Li, R., Shen, M., Fairley, C. K., Liu, L., Seto, W., & Wong, W. C. W. (2023). Shared-care models are highly effective and cost-effective for managing chronic hepatitis B in China: reinterpreting the primary care and specialty divide. The Lancet Regional Health - Western Pacific, 35, 100737. https://doi.org/10.1016/j.lanwpc.2023.100737
• Zhang, S., Mak, L., Yuen, M., & Seto, W. (2022). Screening strategy for non-alcoholic fatty liver disease. Clinical and Molecular Hepatology, 29(Suppl), S103–S122. https://doi.org/10.3350/cmh.2022.0336
• Zhang, W., Huang, Y., Xiang, H., Zhang, L., Yuan, L., Wang, X., Dang, T., Zhang, G., Hu, S., Liu, C., Zhang, X., Peng, L., Gao, M., Xia, D., Li, J., Song, Y., Zhou, X., Qi, X., Zeng, J., . . . Qi, X. (2023). Timing of endoscopy for acute variceal bleeding in patients with cirrhosis (CHESS1905): A nationwide cohort study. Hepatology Communications, 7(5). https://doi.org/10.1097/hc9.0000000000000152
• Zhu, Y., Liu, C., Xu, X., Ma, X., Liu, J., Zhang, Z., Li, F., Wong, D., Fan, Z., Wu, C., Qi, X., & Li, J. (2023). Association of Diabetes Mellitus with All-Cause and Cause-Specific Mortality among Patients with Metabolic-Dysfunction-Associated Fatty Liver Disease: A Longitudinal Cohort Study. Journal of Personalized Medicine, 13(3), 554. https://doi.org/10.3390/jpm13030554
• Ma, S., & Chew, V. (2023). Unlocking the immune microenvironment of nonalcoholic steatohepatitis-associated HCC. Hepatology. https://doi.org/10.1097/hep.0000000000000626
• Malhi, H., Brown, R. S., Lim, J. K., Reau, N., Tapper, E. B., Wong, C. C., & Gores, G. J. (2023). Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals. Clinical Liver Disease, 22(6), 193–194. https://doi.org/10.1097/cld.0000000000000094
• Man, C., Lam, W., Dang, C., Zeng, X., Zheng, L., Chan, N. N., Ng, K., Chan, K., Kwok, T., Ng, T. C., Leung, W., Huen, M. S., Wong, C. C., So, C. W. E., Dou, Z., Goyama, S., Bray, M. R., Mak, T. W., & Leung, A. Y. (2023). Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML. Blood, 142(23), 2002–2015. https://doi.org/10.1182/blood.2023019782
• Man, K., Zhou, L., Yu, H., Lam, K., Cheng, W., Yu, J., Lee, T. K., Yun, J., Guan, X., Liu, M., & Ma, S. (2023). SPINK1-induced tumor plasticity provides a therapeutic window for chemotherapy in hepatocellular carcinoma. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-43670-9
• Mao, X., Cheung, K. S., Peng, C., Mak, L., Cheng, H. M., Fung, J., Peleg, N., Leung, H. H., Kumar, R., Lee, J., Shlomai, A., Yuen, M., & Seto, W. (2022). Steatosis, HBV‐related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta‐analysis.Hepatology, 77(5), 1735–1745. https://doi.org/10.1002/hep.32792
• Mao, X., Mak, L. Y., & Seto, W. (2023). The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B. Clinical and Molecular Hepatology, 29(3), 690–692. https://doi.org/10.3350/cmh.2023.0173
• Ng, K. T., Pang, L., Wang, J., She, W. H., Tsang, S. H., Lo, C. M., Man, K., & Cheung, T. T. (2023). Indications of pro-inflammatory cytokines in laparoscopic and open liver resection for early-stage hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases International, 23(3), 257–264. https://doi.org/10.1016/j.hbpd.2023.10.006
• Ng, L. Y., Tang, H., MA, & Poon, R. Y. (2023). Cyclin A–CDK1 suppresses the expression of the CDK1 activator CDC25A to safeguard timely mitotic entry. Journal of Biological Chemistry, 299(3), 102957. https://doi.org/10.1016/j.jbc.2023.102957
• Suoangbaji, T., Zhang, V. X., Ng, I. O., & Ho, D. W. (2023). Single-Cell analysis of primary liver cancer in mouse models. Cells, 12(3), 477. https://doi.org/10.3390/cells12030477
• Tapper, E. B., & Wong, C. C. (2023). The future of Hepatology Communications. Hepatology Communications, 7(4). https://doi.org/10.1097/hc9.0000000000000085
• Tian, L. L., & Ng, I. O. (2023). Novel role for ceramides in colorectal cancer liver metastases. Cellular and Molecular Gastroenterology and Hepatology, 16(3), 499–500. https://doi.org/10.1016/j.jcmgh.2023.06.004
• Wang, X., Huang, H., Sze, K. M., Wang, J., Tian, L., Lu, J., Tsui, Y., Tang, H., MA, Lee, E., Chen, A., Lee, J., Wang, Y., Yam, J. W. P., Cheung, T., Guan, X., & Ng, I. O. (2023). S100A10 promotes HCC development and progression via transfer in extracellular vesicles and regulating their protein cargos. Gut, 72(7), 1370–1384. https://doi.org/10.1136/gutjnl-2022-327998
• Wong, C. K. H., Mak, L. Y., Au, I. C. H., Cheng, W. Y., So, C. H., Lau, K. T. K., Lau, E. H. Y., Cowling, B. J., Leung, G. M., & Yuen, M. F. (2023). Risk of acute liver injury following the nirmatrelvir/ritonavir use. Liver International, 43(12), 2657–2667. https://doi.org/10.1111/liv.15673
• Wong, D. K., Inoue, T., Mak, L., Hui, R. W., Fung, J., Cheung, K., Seto, W., Tanaka, Y., & Yuen, M. (2022). A longitudinal study to detect hepatitis B surface and core-related antigens in chronic hepatitis B patients with hepatitis B surface antigen seroclearance using highly sensitive assays. Journal of Clinical Virology, 160, 105375. https://doi.org/10.1016/j.jcv.2022.105375
• Wong, S. W. K., Tey, S. K., Mao, X., Fung, H. L., Xiao, Z., Wong, D. K. H., Mak, L., Yuen, M., Ng, I. O., Yun, J. P., Gao, Y., & Yam, J. W. P. (2023). Small Extracellular Vesicle‐Derived vWF Induces a Positive Feedback Loop between Tumor and Endothelial Cells to Promote Angiogenesis and Metastasis in Hepatocellular Carcinoma.Advanced Science, 10(26). https://doi.org/10.1002/advs.202302677
• Wong, T. L. M., Wong, T., Zhou, L., Man, K., Purcell, J., Lee, T. K., Yun, J., & Ma, S. (2022). Protein tyrosine kinase 7 (PTK7) promotes metastasis in hepatocellular carcinoma via SOX9 regulation and TGF-Β signaling. Cellular and Molecular Gastroenterology and Hepatology, 15(1), 13–37. https://doi.org/10.1016/j.jcmgh.2022.09.015
• Wong, Y. J., Tran, S., Huang, C., Hsu, Y., Preda, C., Toyoda, H., Liu, J., Jun, D. W., Landis, C., Huang, D. Q., Gila, A., Negoita, L., Yasuda, S., Tseng, C., Tsai, P., Uojima, H., Nozaki, A., Chuma, M., Atsukawa, M., . . . Nguyen, M. H. (2023). Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study. Hepatology International, 17(5), 1150–1161. https://doi.org/10.1007/s12072-023-10547-4
• Xu, Y., Yao, Y., Yu, L., Fung, H. L., Tang, A. H. N., Ng, I. O., Wong, M. Y. M., Che, C., Yun, J. P., Cui, Y., & Yam, J. W. P. (2023). Clathrin light chain A facilitates small extracellular vesicle uptake to promote hepatocellular carcinoma progression. Hepatology International, 17(6), 1490–1499. https://doi.org/10.1007/s12072-023-10562-5
• Xu, Y., Yao, Y., Yu, L., Zhang, X., Mao, X., Tey, S. K., Wong, S. W. K., Yeung, C. L. S., Ng, T. H., Wong, M. Y., Che, C., Lee, T. K. W., Gao, Y., Cui, Y., & Yam, J. W. P. (2023). Clathrin light chain A‐enriched small extracellular vesicles remodel microvascular niche to induce hepatocellular carcinoma metastasis.Journal of Extracellular Vesicles, 12(8). https://doi.org/10.1002/jev2.12359
• Yao, Y., Xu, Y., Yu, L., Xue, T., Xiao, Z., Tin, P., Fung, H., Ma, H., Yun, J., & Yam, J. W. P. (2023). NHE7 upregulation potentiates the uptake of small extracellular vesicles by enhancing maturation of macropinosomes in hepatocellular carcinoma. Cancer Communications, 44(2), 251–272. https://doi.org/10.1002/cac2.12515
• Lee, K., Yam, J. W. P., & Mao, X. (2023). Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations. Cells, 12(17), 2147. https://doi.org/10.3390/cells12172147
• Lei, M. M. L., Leung, C. O. N., Lau, E. Y. T., Leung, R. W. H., San, V. W., MA, Tong, M., Lu, Y. Y., Huang, C. Y., Zhu, Q. H., Ng, I. O. L., Ma, S., & Lee, T. K. W. (2022). SCYL3, as a novel binding partner and regulator of ROCK2, promotes hepatocellular carcinoma progression. JHEP Reports, 5(1), 100604. https://doi.org/10.1016/j.jhepr.2022.100604
• Leow, W., Chan, A. W., Mendoza, P. G. L., Lo, R., Yap, K., & Kim, H. (2022). Non-alcoholic fatty liver disease: the pathologist’s perspective. Clinical and Molecular Hepatology, 29(Suppl), S302–S318. https://doi.org/10.3350/cmh.2022.0329
• Leung, C. O. N., Yang, Y., Leung, R. W. H., So, K. K. H., Guo, H. J., Lei, M. M. L., Muliawan, G. K., Gao, Y., Yu, Q. Q., Yun, J. P., Ma, S., Zhao, Q., & Lee, T. K. W. (2023). Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-42360-w
• Li, J., Li, J., Zhang, W., Wang, G., & Qu, Z. (2023). Effectiveness of a school-based, lay counselor-delivered cognitive behavioral therapy for Chinese children with posttraumatic stress symptoms: a randomized controlled trial. The Lancet Regional Health - Western Pacific, 33, 100699. https://doi.org/10.1016/j.lanwpc.2023.100699
• Li, R., Shen, M., Ong, J. J., Cui, F., Hu, W., Chan, P., Zou, Z., Su, S., Liu, H., Zhang, L., Seto, W., & Wong, W. C. (2023). Blueprint to hepatitis B elimination in China: A modelling analysis of clinical strategies. JHEP Reports, 5(10), 100833. https://doi.org/10.1016/j.jhepr.2023.100833
• Luo, J., Gong, L., Yang, Y., Zhang, Y., Liu, Q., Bai, L., Fang, X., Zhang, B., Huang, J., Liu, M., Liu, B., Tang, Y., Wong, C. N., Huang, J., Liu, S., Li, S., Ding, T., Man, K., Lee, V. H., . . . Guan, X. (2023). Enhanced mitophagy driven by ADAR1-GLI1 editing supports the self-renewal of cancer stem cells in HCC. Hepatology, 79(1), 61–78. https://doi.org/10.1097/hep.0000000000000299
• Mak, L., & Fung, J. (2023). Editorial: Mitigating the risk of severe hepatitis flare following nucleoside analogue discontinuation—Insights from a real‐world study.Alimentary Pharmacology & Therapeutics, 58(5), 548–549. https://doi.org/10.1111/apt.17630
• Mak, L., Gane, E., Schwabe, C., Yoon, K. T., Heo, J., Scott, R., Lee, J., Lee, J. I., Kweon, Y. O., Weltman, M., Harrison, S. A., Neuschwander-Tetri, B. A., Cusi, K., Loomba, R., Given, B. D., Christianson, D. R., Garcia-Medel, E., Yi, M., Hamilton, J., & Yuen, M. (2022). A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis. Journal of Hepatology, 78(4), 684–692. https://doi.org/10.1016/j.jhep.2022.11.025
• Mak, L., Hui, R. W., Cheung, K., Fung, J., Seto, W., & Yuen, M. (2023). Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers. Expert Opinion on Drug Discovery, 18(4), 401–416. https://doi.org/10.1080/17460441.2023.2192920
• Mak, L., Hui, R. W., Fung, J., Seto, W. K., & Yuen, M. (2023a). The role of different viral biomarkers on the management of chronic hepatitis B. Clinical and Molecular Hepatology, 29(2), 263–276. https://doi.org/10.3350/cmh.2022.0448
• Mak, L., Hui, R. W., Fung, J., Seto, W., & Yuen, M. (2023b). Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress. Expert Opinion on Investigational Drugs, 32(11), 971–983. https://doi.org/10.1080/13543784.2023.2277389
• Mak, L., Hui, R. W., Lee, C., Mao, X., Cheung, K., Wong, D. K., Lui, D. T., Fung, J., Yuen, M., & Seto, W. (2022). Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes. Hepatology, 77(2), 606–618. https://doi.org/10.1002/hep.32716
• Mak, L., Hui, R. W., Seto, W., & Yuen, M. (2023). Novel drug development in chronic hepatitis B infection: CaPSID assembly modulators and nucleic acid polymers. Clinics in Liver Disease, 27(4), 877–893. https://doi.org/10.1016/j.cld.2023.05.004
• Mak, L., Seto, W., & Yuen, M. (2022). Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB.” Clinical and Molecular Hepatology, 29(1), 191–193. https://doi.org/10.3350/cmh.2022.0410
• Mak, L., Wong, D., Kuchta, A., Hilfiker, M., Hamilton, A., Chow, N., Mao, X., Seto, W. K., & Yuen, M. (2022). Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B. Clinical and Molecular Hepatology, 29(1), 146–162. https://doi.org/10.3350/cmh.2022.0172
• Mak, L., Yuen, M., & Seto, W. (2023). Reply: Hepatic steatosis and glycemic burden in chronic hepatitis B. Hepatology, 78(1), E12–E13. https://doi.org/10.1097/hep.0000000000000374
• Malhi, H., Brown, R. S., Lim, J. K., Reau, N., Tapper, E. B., Wong, C. C., & Gores, G. J. (2023a). Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals. Hepatology Communications, 7(11). https://doi.org/10.1097/hc9.0000000000000318
• Malhi, H., Brown, R. S., Lim, J. K., Reau, N., Tapper, E. B., Wong, C. C., & Gores, G. J. (2023b). Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals. Hepatology, 78(6), 1680–1681. https://doi.org/10.1097/hep.0000000000000619
• Malhi, H., Brown, R. S., Lim, J. K., Reau, N., Tapper, E. B., Wong, C. C., & Gores, G. J. (2023c). Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals. Liver Transplantation. https://doi.org/10.1097/lvt.0000000000000279
• Fung, J., & Hui, R. (2023). World Hepatitis Day 2023: Are we close to the target? The Indian Journal of Medical Research, 158(1), 1. https://doi.org/10.4103/ijmr.ijmr_1250_23
• Gane, E., Lim, Y., Kim, J. B., Jadhav, V., Shen, L., Bakardjiev, A. I., Huang, S. A., Cathcart, A. L., Lempp, F. A., Janas, M. M., Cloutier, D. J., Kaittanis, C., Sepp-Lorenzino, L., Hinkle, G., Taubel, J., Haslett, P., Milstein, S., Anglero-Rodriguez, Y. I., Hebner, C. M., . . . Yuen, M. (2023). Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials. Journal of Hepatology, 79(4), 924–932. https://doi.org/10.1016/j.jhep.2023.05.023
• Gao, F., Seto, W., & Zheng, M. (2023). Preventing overdiagnosis of nonalcoholic fatty liver disease: established cutoff values for transient elastography are needed. Gastroenterology, 166(3), 541–542. https://doi.org/10.1053/j.gastro.2023.08.016
• Gao, Y., Tong, M., Wong, T., Ng, K., Xie, Y., Wang, Z., Yu, H., Loh, J., Li, M., & Ma, S. (2023). Long noncoding RNA URB1-Antisense RNA 1 (AS1) suppresses Sorafenib-Induced ferroptosis in hepatocellular carcinoma by driving ferritin phase separation. ACS Nano, 17(22), 22240–22258. https://doi.org/10.1021/acsnano.3c01199
• Hirode, G., Hansen, B. E., Chen, C., Su, T., Wong, G., Seto, W., Van Hees, S., Papatheodoridi, M., Brakenhoff, S. M., Lens, S., Choi, H. S., Chien, R., Feld, J. J., Forns, X., Sonneveld, M. J., Papatheodoridis, G. V., Vanwolleghem, T., Yuen, M., Chan, H. L., . . . Janssen, H. L. (2023). Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study). The American Journal of Gastroenterology, 118(9), 1601–1608. https://doi.org/10.14309/ajg.0000000000002203
• Huang, F., Wong, D. K., Mak, L., Cheung, T., Zhang, S., Chau, H., Hui, R. W., Seto, W., & Yuen, M. (2023). FAT4 loss initiates hepatocarcinogenesis through the switching of canonical to noncanonical WNT signaling pathways. Hepatology Communications, 7(12). https://doi.org/10.1097/hc9.0000000000000338
• Huang, H., Tsui, Y., Ho, D. W., Chung, C. Y., Sze, K. M., Lee, E., Cheung, G. C., Zhang, V. X., Wang, X., Lyu, X., & Ng, I. O. (2023). LANCL1, a cell surface protein, promotes liver tumor initiation through FAM49B-Rac1 axis to suppress oxidative stress. Hepatology, 79(2), 323–340. https://doi.org/10.1097/hep.0000000000000523
• Huang, H., Tsui, Y., & Ng, I. O. (2023). Fueling HCC dynamics: interplay between tumor microenvironment and tumor initiating cells. Cellular and Molecular Gastroenterology and Hepatology, 15(5), 1105–1116. https://doi.org/10.1016/j.jcmgh.2023.01.007
• Hui, K., Fung, J., Cheung, K., Mak, L., Seto, W., & Yuen, M. (2022). Long-term Hepatitis B Surface Antigen Profile and Seroclearance after Severe Acute Flares of Chronic Hepatitis B. Gut And Liver, 17(2), 280–287. https://doi.org/10.5009/gnl220122
• Hui, R. W., Mak, L., Cheung, T., Lee, V. H., Seto, W., & Yuen, M. (2022). Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective. Clinical and Molecular Hepatology, 29(2), 217–229. https://doi.org/10.3350/cmh.2022.0399
• Hui, R. W., Mak, L., Seto, W., Yuen, M., & Fung, J. (2023). Chronic hepatitis B: a scoping review on the guidelines for stopping nucleos(t)ide analogue therapy. Expert Review of Gastroenterology & Hepatology, 17(5), 443–450. https://doi.org/10.1080/17474124.2023.2196405
• Jang, T., Liang, P., Jun, D. W., Jung, J. H., Toyoda, H., Wang, C., Yuen, M., Cheung, K. S., Yasuda, S., Kim, S. E., Yoon, E. L., An, J., Enomoto, M., Kozuka, R., Chuma, M., Nozaki, A., Ishikawa, T., Watanabe, T., Atsukawa, M., . . . Yu, M. (2023). Pretreatment gamma‐glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs.The Kaohsiung Journal of Medical Sciences, 40(2), 188–197. https://doi.org/10.1002/kjm2.12771
• Kam, C. S., Ho, D. W., Ming, V. S., Tian, L., Sze, K. M., Zhang, V. X., Tsui, Y., Husain, A., Lee, J. M., Wong, C. C., Chan, A. C., Cheung, T., Chan, L., & Ng, I. O. (2023). PFKFB4 drives the oncogenicity in TP53-Mutated hepatocellular carcinoma in a Phosphatase-Dependent manner. Cellular and Molecular Gastroenterology and Hepatology, 15(6), 1325–1350. https://doi.org/10.1016/j.jcmgh.2023.02.004
• Kan, K., Wong, D. K., Hui, R. W., Seto, W. K., Yuen, M., & Mak, L. (2023a). Plasma interferon‐gamma‐inducible‐protein 10 level as a predictive factor of spontaneous hepatitis B surface antigen seroclearance in chronic hepatitis B patients.Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16371
• Kan, K., Wong, D. K., Hui, R. W., Seto, W. K., Yuen, M., & Mak, L. (2023b). Anti-HBc: a significant host predictor of spontaneous HBsAg seroclearance in chronic hepatitis B patients - a retrospective longitudinal study. BMC Gastroenterology, 23(1). https://doi.org/10.1186/s12876-023-02983-1
• Lam, K., & Ma, S. (2022). Noncellular components in the liver cancer stem cell niche: Biology and potential clinical implications. Hepatology, 78(3), 991–1005. https://doi.org/10.1002/hep.32629
• Lam, L., Chan, T. S. Y., Hwang, Y., Mak, L., Seto, W., Kwong, Y., & Yuen, M. (2023). Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy. Virology Journal, 20(1). https://doi.org/10.1186/s12985-023-02140-w
• Lau, N. C. H., & Yam, J. W. P. (2023). From exosome biogenesis to absorption: Key takeaways for cancer research. Cancers, 15(7), 1992. https://doi.org/10.3390/cancers15071992
• Lee, C., Lui, D. T., Li, R. H., Yuen, M. M., Fong, C. H., Leung, A. P., Chu, J. C., Mak, L. L., Lam, T., Woo, J., Woo, Y., Xu, A., Tse, H., Tan, K. C., Cheung, B. M., Yuen, M., & Lam, K. S. (2023). Sequential algorithm to stratify liver fibrosis risk in overweight/obese metabolic dysfunction-associated fatty liver disease. Frontiers in Endocrinology, 13. https://doi.org/10.3389/fendo.2022.1056562
• Lee, C., Mak, L., Tang, E. H., Lui, D. T., Mak, J. H., Li, L., Wu, T., Chan, W. L., Yuen, M., Lam, K. S., & Wong, C. K. H. (2023). SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: A territory-wide cohort study in Hong Kong. Hepatology. https://doi.org/10.1097/hep.0000000000000404
• Calderaro, J., Laleh, N. G., Zeng, Q., Maille, P., Favre, L., Pujals, A., Klein, C., Bazille, C., Heij, L. R., Uguen, A., Luedde, T., Di Tommaso, L., Beaufrère, A., Chatain, A., Gastineau, D., Nguyen, C. T., Nguyen-Canh, H., Thi, K. N., Gnemmi, V., . . . Kather, J. N. (2023). Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-43749-3

• Yeung, T. K., Kim, S., Tang, H., MA, & Poon, R. Y. C. (2023). A robust dual gene ON–OFF toggle directed by two independent promoter–degron pairs. Journal of Cell Science, 136(8). https://doi.org/10.1242/jcs.260754
• Yu, H., Zhou, L., Loong, J. H., Lam, K., Wong, T., Ng, K., Tong, M., WS, V., MA, Wang, Y., Zhang, X., Lee, T. K., Yun, J., Yu, J., & Ma, S. (2023). SERPINA12 promotes the tumorigenic capacity of HCC stem cells through hyperactivation of AKT/β-catenin signaling. Hepatology, 78(6), 1711–1726. https://doi.org/10.1097/hep.0000000000000269
• Yuen, M., Asselah, T., Jacobson, I. M., Brunetto, M. R., Janssen, H. L. A., Takehara, T., Hou, J. L., Kakuda, T. N., Lambrecht, T., Beumont, M., Kalmeijer, R., Guinard-Azadian, C., Mayer, C., Jezorwski, J., Verbinnen, T., Lenz, O., Shukla, U., Biermer, M., Bourgeois, S., . . . Gitlin, N. (2023). Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial. the Lancet. Gastroenterology & Hepatology, 8(9), 790–802. https://doi.org/10.1016/s2468-1253(23)00148-6
• Yuen, M., Balabanska, R., Cottreel, E., Chen, E., Duan, D., Jiang, Q., Patil, A., Triyatni, M., Upmanyu, R., Zhu, Y., Canducci, F., & Gane, E. J. (2022). TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trial. The Lancet Infectious Diseases, 23(4), 496–507. https://doi.org/10.1016/s1473-3099(22)00727-7
• Yuen, M., Chen, C., Liu, C., Jeng, W., Elkhashab, M., Coffin, C. S., Kim, W., Greenbloom, S., Ramji, A., Lim, Y. S., Kim, Y. J., Fung, S. K., Kim, D. J., Jang, J., Lee, K. S., Iyer, R. P., Macfarlane, C., Jackson, K., Locarnini, S. A., . . . Afdhal, N. H. (2022). A phase 2, open‐label, randomized, multiple‐dose study evaluating Inarigivir in treatment‐naïve patients with chronic hepatitis B.Liver International, 43(1), 77–89. https://doi.org/10.1111/liv.15465
• Yuen, V. W., Chiu, D. K., Law, C., Cheu, J. W., Chan, C. Y., Wong, B. P., Goh, C., Zhang, M. S., Xue, H. D., Tse, A. P., Zhang, Y., Lau, H. Y., Lee, D., Au-Yeung, R. K., Wong, C., & Wong, C. C. (2022). Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses. Journal of Hepatology, 78(2), 376–389. https://doi.org/10.1016/j.jhep.2022.10.037
• Zhang, L., Liu, H., Zou, Z., Su, S., Ong, J. J., Ji, F., Cui, F., Chan, P., Ning, Q., Li, R., Shen, M., Fairley, C. K., Liu, L., Seto, W., & Wong, W. C. W. (2023). Shared-care models are highly effective and cost-effective for managing chronic hepatitis B in China: reinterpreting the primary care and specialty divide. The Lancet Regional Health - Western Pacific, 35, 100737. https://doi.org/10.1016/j.lanwpc.2023.100737
• Zhang, S., Mak, L., Yuen, M., & Seto, W. (2022). Screening strategy for non-alcoholic fatty liver disease. Clinical and Molecular Hepatology, 29(Suppl), S103–S122. https://doi.org/10.3350/cmh.2022.0336
• Zhang, W., Huang, Y., Xiang, H., Zhang, L., Yuan, L., Wang, X., Dang, T., Zhang, G., Hu, S., Liu, C., Zhang, X., Peng, L., Gao, M., Xia, D., Li, J., Song, Y., Zhou, X., Qi, X., Zeng, J., . . . Qi, X. (2023). Timing of endoscopy for acute variceal bleeding in patients with cirrhosis (CHESS1905): A nationwide cohort study. Hepatology Communications, 7(5). https://doi.org/10.1097/hc9.0000000000000152
• Zhu, Y., Liu, C., Xu, X., Ma, X., Liu, J., Zhang, Z., Li, F., Wong, D., Fan, Z., Wu, C., Qi, X., & Li, J. (2023). Association of Diabetes Mellitus with All-Cause and Cause-Specific Mortality among Patients with Metabolic-Dysfunction-Associated Fatty Liver Disease: A Longitudinal Cohort Study. Journal of Personalized Medicine, 13(3), 554. https://doi.org/10.3390/jpm13030554
• Ma, S., & Chew, V. (2023). Unlocking the immune microenvironment of nonalcoholic steatohepatitis-associated HCC. Hepatology. https://doi.org/10.1097/hep.0000000000000626
• Malhi, H., Brown, R. S., Lim, J. K., Reau, N., Tapper, E. B., Wong, C. C., & Gores, G. J. (2023). Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals. Clinical Liver Disease, 22(6), 193–194. https://doi.org/10.1097/cld.0000000000000094
• Man, C., Lam, W., Dang, C., Zeng, X., Zheng, L., Chan, N. N., Ng, K., Chan, K., Kwok, T., Ng, T. C., Leung, W., Huen, M. S., Wong, C. C., So, C. W. E., Dou, Z., Goyama, S., Bray, M. R., Mak, T. W., & Leung, A. Y. (2023). Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML. Blood, 142(23), 2002–2015. https://doi.org/10.1182/blood.2023019782
• Man, K., Zhou, L., Yu, H., Lam, K., Cheng, W., Yu, J., Lee, T. K., Yun, J., Guan, X., Liu, M., & Ma, S. (2023). SPINK1-induced tumor plasticity provides a therapeutic window for chemotherapy in hepatocellular carcinoma. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-43670-9
• Mao, X., Cheung, K. S., Peng, C., Mak, L., Cheng, H. M., Fung, J., Peleg, N., Leung, H. H., Kumar, R., Lee, J., Shlomai, A., Yuen, M., & Seto, W. (2022). Steatosis, HBV‐related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta‐analysis.Hepatology, 77(5), 1735–1745. https://doi.org/10.1002/hep.32792
• Mao, X., Mak, L. Y., & Seto, W. (2023). The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B. Clinical and Molecular Hepatology, 29(3), 690–692. https://doi.org/10.3350/cmh.2023.0173
• Ng, K. T., Pang, L., Wang, J., She, W. H., Tsang, S. H., Lo, C. M., Man, K., & Cheung, T. T. (2023). Indications of pro-inflammatory cytokines in laparoscopic and open liver resection for early-stage hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases International, 23(3), 257–264. https://doi.org/10.1016/j.hbpd.2023.10.006
• Ng, L. Y., Tang, H., MA, & Poon, R. Y. (2023). Cyclin A–CDK1 suppresses the expression of the CDK1 activator CDC25A to safeguard timely mitotic entry. Journal of Biological Chemistry, 299(3), 102957. https://doi.org/10.1016/j.jbc.2023.102957
• Suoangbaji, T., Zhang, V. X., Ng, I. O., & Ho, D. W. (2023). Single-Cell analysis of primary liver cancer in mouse models. Cells, 12(3), 477. https://doi.org/10.3390/cells12030477
• Tapper, E. B., & Wong, C. C. (2023). The future of Hepatology Communications. Hepatology Communications, 7(4). https://doi.org/10.1097/hc9.0000000000000085
• Tian, L. L., & Ng, I. O. (2023). Novel role for ceramides in colorectal cancer liver metastases. Cellular and Molecular Gastroenterology and Hepatology, 16(3), 499–500. https://doi.org/10.1016/j.jcmgh.2023.06.004
• Wang, X., Huang, H., Sze, K. M., Wang, J., Tian, L., Lu, J., Tsui, Y., Tang, H., MA, Lee, E., Chen, A., Lee, J., Wang, Y., Yam, J. W. P., Cheung, T., Guan, X., & Ng, I. O. (2023). S100A10 promotes HCC development and progression via transfer in extracellular vesicles and regulating their protein cargos. Gut, 72(7), 1370–1384. https://doi.org/10.1136/gutjnl-2022-327998
• Wong, C. K. H., Mak, L. Y., Au, I. C. H., Cheng, W. Y., So, C. H., Lau, K. T. K., Lau, E. H. Y., Cowling, B. J., Leung, G. M., & Yuen, M. F. (2023). Risk of acute liver injury following the nirmatrelvir/ritonavir use. Liver International, 43(12), 2657–2667. https://doi.org/10.1111/liv.15673
• Wong, D. K., Inoue, T., Mak, L., Hui, R. W., Fung, J., Cheung, K., Seto, W., Tanaka, Y., & Yuen, M. (2022). A longitudinal study to detect hepatitis B surface and core-related antigens in chronic hepatitis B patients with hepatitis B surface antigen seroclearance using highly sensitive assays. Journal of Clinical Virology, 160, 105375. https://doi.org/10.1016/j.jcv.2022.105375
• Wong, S. W. K., Tey, S. K., Mao, X., Fung, H. L., Xiao, Z., Wong, D. K. H., Mak, L., Yuen, M., Ng, I. O., Yun, J. P., Gao, Y., & Yam, J. W. P. (2023). Small Extracellular Vesicle‐Derived vWF Induces a Positive Feedback Loop between Tumor and Endothelial Cells to Promote Angiogenesis and Metastasis in Hepatocellular Carcinoma.Advanced Science, 10(26). https://doi.org/10.1002/advs.202302677
• Wong, T. L. M., Wong, T., Zhou, L., Man, K., Purcell, J., Lee, T. K., Yun, J., & Ma, S. (2022). Protein tyrosine kinase 7 (PTK7) promotes metastasis in hepatocellular carcinoma via SOX9 regulation and TGF-Β signaling. Cellular and Molecular Gastroenterology and Hepatology, 15(1), 13–37. https://doi.org/10.1016/j.jcmgh.2022.09.015
• Wong, Y. J., Tran, S., Huang, C., Hsu, Y., Preda, C., Toyoda, H., Liu, J., Jun, D. W., Landis, C., Huang, D. Q., Gila, A., Negoita, L., Yasuda, S., Tseng, C., Tsai, P., Uojima, H., Nozaki, A., Chuma, M., Atsukawa, M., . . . Nguyen, M. H. (2023). Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study. Hepatology International, 17(5), 1150–1161. https://doi.org/10.1007/s12072-023-10547-4
• Xu, Y., Yao, Y., Yu, L., Fung, H. L., Tang, A. H. N., Ng, I. O., Wong, M. Y. M., Che, C., Yun, J. P., Cui, Y., & Yam, J. W. P. (2023). Clathrin light chain A facilitates small extracellular vesicle uptake to promote hepatocellular carcinoma progression. Hepatology International, 17(6), 1490–1499. https://doi.org/10.1007/s12072-023-10562-5
• Xu, Y., Yao, Y., Yu, L., Zhang, X., Mao, X., Tey, S. K., Wong, S. W. K., Yeung, C. L. S., Ng, T. H., Wong, M. Y., Che, C., Lee, T. K. W., Gao, Y., Cui, Y., & Yam, J. W. P. (2023). Clathrin light chain A‐enriched small extracellular vesicles remodel microvascular niche to induce hepatocellular carcinoma metastasis.Journal of Extracellular Vesicles, 12(8). https://doi.org/10.1002/jev2.12359
• Yao, Y., Xu, Y., Yu, L., Xue, T., Xiao, Z., Tin, P., Fung, H., Ma, H., Yun, J., & Yam, J. W. P. (2023). NHE7 upregulation potentiates the uptake of small extracellular vesicles by enhancing maturation of macropinosomes in hepatocellular carcinoma. Cancer Communications, 44(2), 251–272. https://doi.org/10.1002/cac2.12515
• Lee, K., Yam, J. W. P., & Mao, X. (2023). Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations. Cells, 12(17), 2147. https://doi.org/10.3390/cells12172147
• Lei, M. M. L., Leung, C. O. N., Lau, E. Y. T., Leung, R. W. H., San, V. W., MA, Tong, M., Lu, Y. Y., Huang, C. Y., Zhu, Q. H., Ng, I. O. L., Ma, S., & Lee, T. K. W. (2022). SCYL3, as a novel binding partner and regulator of ROCK2, promotes hepatocellular carcinoma progression. JHEP Reports, 5(1), 100604. https://doi.org/10.1016/j.jhepr.2022.100604
• Leow, W., Chan, A. W., Mendoza, P. G. L., Lo, R., Yap, K., & Kim, H. (2022). Non-alcoholic fatty liver disease: the pathologist’s perspective. Clinical and Molecular Hepatology, 29(Suppl), S302–S318. https://doi.org/10.3350/cmh.2022.0329
• Leung, C. O. N., Yang, Y., Leung, R. W. H., So, K. K. H., Guo, H. J., Lei, M. M. L., Muliawan, G. K., Gao, Y., Yu, Q. Q., Yun, J. P., Ma, S., Zhao, Q., & Lee, T. K. W. (2023). Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-42360-w
• Li, J., Li, J., Zhang, W., Wang, G., & Qu, Z. (2023). Effectiveness of a school-based, lay counselor-delivered cognitive behavioral therapy for Chinese children with posttraumatic stress symptoms: a randomized controlled trial. The Lancet Regional Health - Western Pacific, 33, 100699. https://doi.org/10.1016/j.lanwpc.2023.100699
• Li, R., Shen, M., Ong, J. J., Cui, F., Hu, W., Chan, P., Zou, Z., Su, S., Liu, H., Zhang, L., Seto, W., & Wong, W. C. (2023). Blueprint to hepatitis B elimination in China: A modelling analysis of clinical strategies. JHEP Reports, 5(10), 100833. https://doi.org/10.1016/j.jhepr.2023.100833
• Luo, J., Gong, L., Yang, Y., Zhang, Y., Liu, Q., Bai, L., Fang, X., Zhang, B., Huang, J., Liu, M., Liu, B., Tang, Y., Wong, C. N., Huang, J., Liu, S., Li, S., Ding, T., Man, K., Lee, V. H., . . . Guan, X. (2023). Enhanced mitophagy driven by ADAR1-GLI1 editing supports the self-renewal of cancer stem cells in HCC. Hepatology, 79(1), 61–78. https://doi.org/10.1097/hep.0000000000000299
• Mak, L., & Fung, J. (2023). Editorial: Mitigating the risk of severe hepatitis flare following nucleoside analogue discontinuation—Insights from a real‐world study.Alimentary Pharmacology & Therapeutics, 58(5), 548–549. https://doi.org/10.1111/apt.17630
• Mak, L., Gane, E., Schwabe, C., Yoon, K. T., Heo, J., Scott, R., Lee, J., Lee, J. I., Kweon, Y. O., Weltman, M., Harrison, S. A., Neuschwander-Tetri, B. A., Cusi, K., Loomba, R., Given, B. D., Christianson, D. R., Garcia-Medel, E., Yi, M., Hamilton, J., & Yuen, M. (2022). A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis. Journal of Hepatology, 78(4), 684–692. https://doi.org/10.1016/j.jhep.2022.11.025
• Mak, L., Hui, R. W., Cheung, K., Fung, J., Seto, W., & Yuen, M. (2023). Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers. Expert Opinion on Drug Discovery, 18(4), 401–416. https://doi.org/10.1080/17460441.2023.2192920
• Mak, L., Hui, R. W., Fung, J., Seto, W. K., & Yuen, M. (2023a). The role of different viral biomarkers on the management of chronic hepatitis B. Clinical and Molecular Hepatology, 29(2), 263–276. https://doi.org/10.3350/cmh.2022.0448
• Mak, L., Hui, R. W., Fung, J., Seto, W., & Yuen, M. (2023b). Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress. Expert Opinion on Investigational Drugs, 32(11), 971–983. https://doi.org/10.1080/13543784.2023.2277389
• Mak, L., Hui, R. W., Lee, C., Mao, X., Cheung, K., Wong, D. K., Lui, D. T., Fung, J., Yuen, M., & Seto, W. (2022). Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes. Hepatology, 77(2), 606–618. https://doi.org/10.1002/hep.32716
• Mak, L., Hui, R. W., Seto, W., & Yuen, M. (2023). Novel drug development in chronic hepatitis B infection: CaPSID assembly modulators and nucleic acid polymers. Clinics in Liver Disease, 27(4), 877–893. https://doi.org/10.1016/j.cld.2023.05.004
• Mak, L., Seto, W., & Yuen, M. (2022). Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB.” Clinical and Molecular Hepatology, 29(1), 191–193. https://doi.org/10.3350/cmh.2022.0410
• Mak, L., Wong, D., Kuchta, A., Hilfiker, M., Hamilton, A., Chow, N., Mao, X., Seto, W. K., & Yuen, M. (2022). Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B. Clinical and Molecular Hepatology, 29(1), 146–162. https://doi.org/10.3350/cmh.2022.0172
• Mak, L., Yuen, M., & Seto, W. (2023). Reply: Hepatic steatosis and glycemic burden in chronic hepatitis B. Hepatology, 78(1), E12–E13. https://doi.org/10.1097/hep.0000000000000374
• Malhi, H., Brown, R. S., Lim, J. K., Reau, N., Tapper, E. B., Wong, C. C., & Gores, G. J. (2023a). Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals. Hepatology Communications, 7(11). https://doi.org/10.1097/hc9.0000000000000318
• Malhi, H., Brown, R. S., Lim, J. K., Reau, N., Tapper, E. B., Wong, C. C., & Gores, G. J. (2023b). Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals. Hepatology, 78(6), 1680–1681. https://doi.org/10.1097/hep.0000000000000619
• Malhi, H., Brown, R. S., Lim, J. K., Reau, N., Tapper, E. B., Wong, C. C., & Gores, G. J. (2023c). Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals. Liver Transplantation. https://doi.org/10.1097/lvt.0000000000000279
• Fung, J., & Hui, R. (2023). World Hepatitis Day 2023: Are we close to the target? The Indian Journal of Medical Research, 158(1), 1. https://doi.org/10.4103/ijmr.ijmr_1250_23
• Gane, E., Lim, Y., Kim, J. B., Jadhav, V., Shen, L., Bakardjiev, A. I., Huang, S. A., Cathcart, A. L., Lempp, F. A., Janas, M. M., Cloutier, D. J., Kaittanis, C., Sepp-Lorenzino, L., Hinkle, G., Taubel, J., Haslett, P., Milstein, S., Anglero-Rodriguez, Y. I., Hebner, C. M., . . . Yuen, M. (2023). Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials. Journal of Hepatology, 79(4), 924–932. https://doi.org/10.1016/j.jhep.2023.05.023
• Gao, F., Seto, W., & Zheng, M. (2023). Preventing overdiagnosis of nonalcoholic fatty liver disease: established cutoff values for transient elastography are needed. Gastroenterology, 166(3), 541–542. https://doi.org/10.1053/j.gastro.2023.08.016
• Gao, Y., Tong, M., Wong, T., Ng, K., Xie, Y., Wang, Z., Yu, H., Loh, J., Li, M., & Ma, S. (2023). Long noncoding RNA URB1-Antisense RNA 1 (AS1) suppresses Sorafenib-Induced ferroptosis in hepatocellular carcinoma by driving ferritin phase separation. ACS Nano, 17(22), 22240–22258. https://doi.org/10.1021/acsnano.3c01199
• Hirode, G., Hansen, B. E., Chen, C., Su, T., Wong, G., Seto, W., Van Hees, S., Papatheodoridi, M., Brakenhoff, S. M., Lens, S., Choi, H. S., Chien, R., Feld, J. J., Forns, X., Sonneveld, M. J., Papatheodoridis, G. V., Vanwolleghem, T., Yuen, M., Chan, H. L., . . . Janssen, H. L. (2023). Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study). The American Journal of Gastroenterology, 118(9), 1601–1608. https://doi.org/10.14309/ajg.0000000000002203
• Huang, F., Wong, D. K., Mak, L., Cheung, T., Zhang, S., Chau, H., Hui, R. W., Seto, W., & Yuen, M. (2023). FAT4 loss initiates hepatocarcinogenesis through the switching of canonical to noncanonical WNT signaling pathways. Hepatology Communications, 7(12). https://doi.org/10.1097/hc9.0000000000000338
• Huang, H., Tsui, Y., Ho, D. W., Chung, C. Y., Sze, K. M., Lee, E., Cheung, G. C., Zhang, V. X., Wang, X., Lyu, X., & Ng, I. O. (2023). LANCL1, a cell surface protein, promotes liver tumor initiation through FAM49B-Rac1 axis to suppress oxidative stress. Hepatology, 79(2), 323–340. https://doi.org/10.1097/hep.0000000000000523
• Huang, H., Tsui, Y., & Ng, I. O. (2023). Fueling HCC dynamics: interplay between tumor microenvironment and tumor initiating cells. Cellular and Molecular Gastroenterology and Hepatology, 15(5), 1105–1116. https://doi.org/10.1016/j.jcmgh.2023.01.007
• Hui, K., Fung, J., Cheung, K., Mak, L., Seto, W., & Yuen, M. (2022). Long-term Hepatitis B Surface Antigen Profile and Seroclearance after Severe Acute Flares of Chronic Hepatitis B. Gut And Liver, 17(2), 280–287. https://doi.org/10.5009/gnl220122
• Hui, R. W., Mak, L., Cheung, T., Lee, V. H., Seto, W., & Yuen, M. (2022). Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective. Clinical and Molecular Hepatology, 29(2), 217–229. https://doi.org/10.3350/cmh.2022.0399
• Hui, R. W., Mak, L., Seto, W., Yuen, M., & Fung, J. (2023). Chronic hepatitis B: a scoping review on the guidelines for stopping nucleos(t)ide analogue therapy. Expert Review of Gastroenterology & Hepatology, 17(5), 443–450. https://doi.org/10.1080/17474124.2023.2196405
• Jang, T., Liang, P., Jun, D. W., Jung, J. H., Toyoda, H., Wang, C., Yuen, M., Cheung, K. S., Yasuda, S., Kim, S. E., Yoon, E. L., An, J., Enomoto, M., Kozuka, R., Chuma, M., Nozaki, A., Ishikawa, T., Watanabe, T., Atsukawa, M., . . . Yu, M. (2023). Pretreatment gamma‐glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs.The Kaohsiung Journal of Medical Sciences, 40(2), 188–197. https://doi.org/10.1002/kjm2.12771
• Kam, C. S., Ho, D. W., Ming, V. S., Tian, L., Sze, K. M., Zhang, V. X., Tsui, Y., Husain, A., Lee, J. M., Wong, C. C., Chan, A. C., Cheung, T., Chan, L., & Ng, I. O. (2023). PFKFB4 drives the oncogenicity in TP53-Mutated hepatocellular carcinoma in a Phosphatase-Dependent manner. Cellular and Molecular Gastroenterology and Hepatology, 15(6), 1325–1350. https://doi.org/10.1016/j.jcmgh.2023.02.004
• Kan, K., Wong, D. K., Hui, R. W., Seto, W. K., Yuen, M., & Mak, L. (2023a). Plasma interferon‐gamma‐inducible‐protein 10 level as a predictive factor of spontaneous hepatitis B surface antigen seroclearance in chronic hepatitis B patients.Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16371
• Kan, K., Wong, D. K., Hui, R. W., Seto, W. K., Yuen, M., & Mak, L. (2023b). Anti-HBc: a significant host predictor of spontaneous HBsAg seroclearance in chronic hepatitis B patients - a retrospective longitudinal study. BMC Gastroenterology, 23(1). https://doi.org/10.1186/s12876-023-02983-1
• Lam, K., & Ma, S. (2022). Noncellular components in the liver cancer stem cell niche: Biology and potential clinical implications. Hepatology, 78(3), 991–1005. https://doi.org/10.1002/hep.32629
• Lam, L., Chan, T. S. Y., Hwang, Y., Mak, L., Seto, W., Kwong, Y., & Yuen, M. (2023). Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy. Virology Journal, 20(1). https://doi.org/10.1186/s12985-023-02140-w
• Lau, N. C. H., & Yam, J. W. P. (2023). From exosome biogenesis to absorption: Key takeaways for cancer research. Cancers, 15(7), 1992. https://doi.org/10.3390/cancers15071992
• Lee, C., Lui, D. T., Li, R. H., Yuen, M. M., Fong, C. H., Leung, A. P., Chu, J. C., Mak, L. L., Lam, T., Woo, J., Woo, Y., Xu, A., Tse, H., Tan, K. C., Cheung, B. M., Yuen, M., & Lam, K. S. (2023). Sequential algorithm to stratify liver fibrosis risk in overweight/obese metabolic dysfunction-associated fatty liver disease. Frontiers in Endocrinology, 13. https://doi.org/10.3389/fendo.2022.1056562
• Lee, C., Mak, L., Tang, E. H., Lui, D. T., Mak, J. H., Li, L., Wu, T., Chan, W. L., Yuen, M., Lam, K. S., & Wong, C. K. H. (2023). SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: A territory-wide cohort study in Hong Kong. Hepatology. https://doi.org/10.1097/hep.0000000000000404
• Calderaro, J., Laleh, N. G., Zeng, Q., Maille, P., Favre, L., Pujals, A., Klein, C., Bazille, C., Heij, L. R., Uguen, A., Luedde, T., Di Tommaso, L., Beaufrère, A., Chatain, A., Gastineau, D., Nguyen, C. T., Nguyen-Canh, H., Thi, K. N., Gnemmi, V., . . . Kather, J. N. (2023). Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-43749-3
• Chan, C. Y., Yuen, V. W., Chiu, D. K., Goh, C., Thu, K. L., Cescon, D. W., Soria‐Bretones, I., Law, C., Cheu, J. W., Lee, D., Tse, A. P., Tan, K. V., Zhang, M. S., Wong, B. P., Wong, C., Khong, P., Ng, I. O., Bray, M. R., Mak, T. W., . . . Wong, C. C. (2022). Polo‐like kinase 4 inhibitor CFI‐400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity.Hepatology, 77(3), 729–744. https://doi.org/10.1002/hep.32461
• Chan, F., & Wong, C. (2023). ZEB1 fuels serine metabolism to promote HCC metastasis. Cellular and Molecular Gastroenterology and Hepatology, 16(4), 646–647. https://doi.org/10.1016/j.jcmgh.2023.07.002
• Chan, F., Yuen, V. W., Shen, J., Chin, D. W., Law, C., Wong, B. P., Chan, C. Y., Cheu, J. W., Ng, I. O., Wong, C. C., & Wong, C. (2023). Inhibition of CAF-1 histone chaperone complex triggers cytosolic DNA and dsRNA sensing pathways and induces intrinsic immunity of hepatocellular carcinoma. Hepatology, 80(2), 295–311. https://doi.org/10.1097/hep.0000000000000709
• Chan, K. K., Au, K., Suen, L., Leung, B., Wong, C., Leow, W., Lim, T. K., Ng, I. O., Chung, C. Y., & Lo, R. C. (2023). Sortilin-Driven Cancer Secretome Enhances Tumorigenic Properties of Hepatocellular Carcinoma via de Novo Lipogenesis. American Journal of Pathology, 193(12), 2156–2171. https://doi.org/10.1016/j.ajpath.2023.08.005
• Cheng, T., Cheng, Y., & Jin, D. (2023). Oncostatin M for Anti-HBV therapy: Can a foe be turned into a friend? Cellular and Molecular Gastroenterology and Hepatology. https://doi.org/10.1016/j.jcmgh.2023.11.005
• Cheng, Y., Kang, X., Chan, P., Cheung, P. H., Cheng, T., Ye, Z., Chan, C., Yu, C., & Jin, D. (2023). FACI is a novel clathrin adaptor protein 2-binding protein that facilitates low-density lipoprotein endocytosis. Cell & Bioscience, 13(1). https://doi.org/10.1186/s13578-023-01023-5
• Cheu, J. W., Chiu, D. K., Kwan, K. K., Yang, C., Yuen, V. W., Goh, C. C., Chui, N. N., Shen, W., Law, C., Li, Q., Zhang, M. S., Bao, M. H., Wong, B. P., Chan, C. Y., Liu, C. X., Sit, G. F., Ooi, Z. Y., Deng, H., Tse, A. P., . . . Wong, C. C. (2023). Hypoxia-inducible factor orchestrates adenosine metabolism to promote liver cancer development. Science Advances, 9(18). https://doi.org/10.1126/sciadv.ade5111
• Cheu, J. W., Lee, D., Li, Q., Goh, C. C., Bao, M. H., Yuen, V. W., Zhang, M. S., Yang, C., Chan, C. Y., Tse, A. P., Sit, G. F., Liu, C. X., Ng, I. O., Wong, C., & Wong, C. C. (2023). Ferroptosis suppressor protein 1 inhibition promotes tumor ferroptosis and anti-tumor immune responses in liver cancer. Cellular and Molecular Gastroenterology and Hepatology, 16(1), 133–159. https://doi.org/10.1016/j.jcmgh.2023.03.001
• Cheung, K., Mok, C., Lam, L., Mao, X., Mak, L., Seto, W., & Yuen, M. (2023). Carvedilol versus other nonselective beta blockers for variceal bleeding prophylaxis and Death: A network Meta-analysis. Journal of Clinical and Translational Hepatology, 000(000), 000. https://doi.org/10.14218/jcth.2022.00130s
• Cheung, K. S., Lam, L. K., Mao, X., Tan, J. T., Ooi, P. H., Zhang, R., Chan, K. H., Hung, I. F. N., Seto, W. K., & Yuen, M. F. (2023). Effect of Moderate to Severe Hepatic Steatosis on Vaccine Immunogenicity against Wild-Type and Mutant Virus and COVID-19 Infection among BNT162b2 Recipients. Vaccines, 11(3), 497. https://doi.org/10.3390/vaccines11030497
• Cheung, K. S., Mok, C. H., Seto, W. K., & Yuen, M. F. (2022). Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis.” Clinical and Molecular Hepatology, 29(1), 176–178. https://doi.org/10.3350/cmh.2022.0377
• Cheung, T., Ho, D. W., Lyu, S. X., Zhang, Q., Tsui, Y., Yu, T. C., Sze, K. M., Lee, J. M., Lau, V. W., Chu, E. Y., Tsang, S. H., She, W., Leung, R. C., Yau, T. C., & Ng, I. O. (2023). Multimodal integrative genomics and pathology analyses in neoadjuvant nivolumab treatment for intermediate and locally advanced hepatocellular carcinoma. Liver Cancer, 13(1), 70–88. https://doi.org/10.1159/000531176
• Cheung, T., Lee, Y. T., Tang, R. S., She, W. H., Cheng, K. C., Cheung, C. C., Chiu, K. W. H., Chok, K. S. H., Chow, W. S., Lai, T. W., Seto, W., & Yau, T. (2023). The Hong Kong consensus recommendations on the diagnosis and management of pancreatic cystic lesions. HepatoBiliary Surgery and Nutrition, 12(5), 715–735. https://doi.org/10.21037/hbsn-22-471
• Chiu, Y., Husain, A., Sze, K. M., Ho, D. W., Suarez, E. M. S., Wang, X., Lee, E., Ma, H., Lee, J. M., Chan, L., & Ng, I. O. (2023). Midline 1 interacting protein 1 promotes cancer metastasis through FOS-like 1-mediated matrix metalloproteinase 9 signaling in HCC. Hepatology, 78(5), 1368–1383. https://doi.org/10.1097/hep.0000000000000266
• Chow, N., Wong, D., Lai, C., Mak, L., Fung, J., Ma, H., Lei, M., Seto, W., & Yuen, M. (2022). Effect of antiviral treatment on hepatitis B virus integration and hepatocyte clonal expansion. Clinical Infectious Diseases, 76(3), e801–e809. https://doi.org/10.1093/cid/ciac383
• Cortesi, P. A., Viganò, R., Conti, S., Lenci, I., Volpes, R., Martini, S., Angelico, M., Fung, J., Buti, M., Coilly, A., Durand, F., Fondevila, C., Lebray, P., Nevens, F., Polak, W. G., Rizzetto, M., Zoulim, F., Perricone, G., Berenguer, M., . . . Belli, L. S. (2023). Economic Impact of European Liver and Intestine Transplantation Association (ELITA) recommendations for Hepatitis B prophylaxis after liver transplantation. Transplant International, 36. https://doi.org/10.3389/ti.2023.10954
• Fung, J. (2022). Role of pharmacogenetics and tacrolimus dosing in liver transplantation. Hepatology International, 17(1), 1–3. https://doi.org/10.1007/s12072-022-10437-1
• Fung, S. K., Pan, C. Q., Wong, G. L., Seto, W., Ahn, S. H., Chen, C., Hann, H. L., Jablkowski, M. S., Kim, Y. J., Yurdaydin, C., Peng, C., Nguyen, T., Yatsuhashi, H., Flaherty, J. F., Yee, L. J., Abramov, F., Wang, H., Abdurakhmanov, D., Lim, Y., & Buti, M. (2023). Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks. Alimentary Pharmacology & Therapeutics, 59(2), 217–229. https://doi.org/10.1111/apt.17764
• Gane, E. J., Kim, W., Lim, T. H., Tangkijvanich, P., Yoon, J., Sievert, W., Sukeepaisarnjaroen, W., Thompson, A. J., Pavlovic, V., Surujbally, B., Wat, C., Brown, B. D., Achneck, H. E., & Yuen, M. (2023). First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection. Journal of Hepatology, 79(5), 1139–1149. https://doi.org/10.1016/j.jhep.2023.07.026

• Lim, C. J., Lee, Y. H., Pan, L., Lai, L., Chua, C., Wasser, M., Lim, T., Yeong, J., Toh, H. C., Lee, S. Y., Chan, C. Y., Goh, B. K., Chung, A., Heikenwälder, M., Ng, I. O., Chow, P., Albani, S., & Chew, V. (2019). Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut, 68(5), 916–927. https://doi.org/10.1136/gutjnl-2018-316510

• Tsang, F. H., Law, C. T., Tang, T. C., Cheng, C. L., Chin, D. W., Tam, W. V., Wei, L., Wong, C. C., Ng, I. O., & Wong, C. M. (2019). Aberrant Super-Enhancer Landscape in Human Hepatocellular Carcinoma. Hepatology (Baltimore, Md.), 69(6), 2502–2517. https://doi.org/10.1002/hep.30544

• Wong, T. L., Ng, K. Y., Tan, K. V., Chan, L. H., Zhou, L., Che, N., Hoo, R., Lee, T. K., Richard, S., Lo, C. M., Man, K., Khong, P. L., & Ma, S. (2020). CRAF Methylation by PRMT6 Regulates Aerobic Glycolysis-Driven Hepatocarcinogenesis via ERK-Dependent PKM2 Nuclear Relocalization and Activation. Hepatology (Baltimore, Md.), 71(4), 1279–1296. https://doi.org/10.1002/hep.30923

• Luk, S. T., Ng, K. Y., Zhou, L., Tong, M., Wong, T. L., Yu, H., Lo, C. M., Man, K., Guan, X. Y., Lee, T. K., & Ma, S. (2020). Deficiency in Embryonic Stem Cell Marker Reduced Expression 1 Activates Mitogen-Activated Protein Kinase Kinase 6-Dependent p38 Mitogen-Activated Protein Kinase Signaling to Drive Hepatocarcinogenesis. Hepatology (Baltimore, Md.), 72(1), 183–197. https://doi.org/10.1002/hep.31020

• Law, C. T., Wei, L., Tsang, F. H., Chan, C. Y., Xu, I. M., Lai, R. K., Ho, D. W., Lee, J. M., Wong, C. C., Ng, I. O., & Wong, C. M. (2019). HELLS Regulates Chromatin Remodeling and Epigenetic Silencing of Multiple Tumor Suppressor Genes in Human Hepatocellular Carcinoma. Hepatology (Baltimore, Md.), 69(5), 2013–2030. https://doi.org/10.1002/hep.30414

• Lee, D., Xu, I. M., Chiu, D. K., Leibold, J., Tse, A. P., Bao, M. H., Yuen, V. W., Chan, C. Y., Lai, R. K., Chin, D. W., Chan, D. F., Cheung, T. T., Chok, S. H., Wong, C. M., Lowe, S. W., Ng, I. O., & Wong, C. C. (2019). Induction of Oxidative Stress Through Inhibition of Thioredoxin Reductase 1 Is an Effective Therapeutic Approach for Hepatocellular Carcinoma. Hepatology (Baltimore, Md.), 69(4), 1768–1786. https://doi.org/10.1002/hep.30467

• Fung, J., Mak, L. Y., Chan, A. C., Chok, K. S., Wong, T. C., Cheung, T. T., Dai, W. C., Sin, S. L., She, W. H., Ma, K. W., Seto, W. K., Lai, C. L., Lo, C. M., & Yuen, M. F. (2020). Model for End-Stage Liver Disease With Additional Criteria to Predict Short-Term Mortality in Severe Flares of Chronic Hepatitis B. Hepatology (Baltimore, Md.), 72(3), 818–828. https://doi.org/10.1002/hep.31086

• Leung, C., Tong, M., Chung, K., Zhou, L., Che, N., Tang, K. H., Ding, J., Lau, E., Ng, I., Ma, S., & Lee, T. (2020). Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma. Hepatology (Baltimore, Md.), 72(1), 155–168. https://doi.org/10.1002/hep.30989

• Wei, L., Lee, D., Law, C. T., Zhang, M. S., Shen, J., Chin, D. W., Zhang, A., Tsang, F. H., Wong, C. L., Ng, I. O., Wong, C. C., & Wong, C. M. (2019). Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. Nature communications, 10(1), 4681. https://doi.org/10.1038/s41467-019-12606-7

• Seto, W. K., Chan, T. S., Hwang, Y. Y., Mak, L. Y., Wong, D. K., Fung, J., Liu, K. S., Cheung, K. S., Lai, C. L., Kwong, Y. L., & Yuen, M. F. (2019). Monitoring and Treatment of Patients Undergoing Immunotherapy With Anti-CD20 Who are Exposed to HBV. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 17(7), 1410–1412. https://doi.org/10.1016/j.cgh.2018.09.020

• Fang, S., Liu, M., Li, L., Zhang, F. F., Li, Y., Yan, Q., Cui, Y. Z., Zhu, Y. H., Yuan, Y. F., & Guan, X. Y. (2019). Lymphoid enhancer-binding factor-1 promotes stemness and poor differentiation of hepatocellular carcinoma by directly activating the NOTCH pathway. Oncogene, 38(21), 4061–4074. https://doi.org/10.1038/s41388-019-0704-y

• Mao, X., Tey, S. K., Ko, F., Kwong, E., Gao, Y., Ng, I. O., Cheung, S. T., Guan, X. Y., & Yam, J. (2019). C-terminal truncated HBx protein activates caveolin-1/LRP6/β-catenin/FRMD5 axis in promoting hepatocarcinogenesis. Cancer letters, 444, 60–69. https://doi.org/10.1016/j.canlet.2018.12.003

• Ho, D. W., Tsui, Y. M., Sze, K. M., Chan, L. K., Cheung, T. T., Lee, E., Sham, P. C., Tsui, S. K., Lee, T. K., & Ng, I. O. (2019). Single-cell transcriptomics reveals the landscape of intra-tumoral heterogeneity and stemness-related subpopulations in liver cancer. Cancer letters, 459, 176–185. https://doi.org/10.1016/j.canlet.2019.06.002

• Kung-Chun Chiu, D., Pui-Wah Tse, A., Law, C. T., Ming-Jing Xu, I., Lee, D., Chen, M., Kit-Ho Lai, R., Wai-Hin Yuen, V., Wing-Sum Cheu, J., Wai-Hung Ho, D., Wong, C. M., Zhang, H., Oi-Lin Ng, I., & Chak-Lui Wong, C. (2019). Hypoxia regulates the mitochondrial activity of hepatocellular carcinoma cells through HIF/HEY1/PINK1 pathway. Cell death & disease, 10(12), 934. https://doi.org/10.1038/s41419-019-2155-3

• Leung, Z., Ko, F., Tey, S. K., Kwong, E., Mao, X., Liu, B., Ma, A., Fung, Y., Che, C. M., Wong, D., Lai, C. L., Ng, I. O., & Yam, J. (2019). Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells. Journal of experimental & clinical cancer research : CR, 38(1), 423. https://doi.org/10.1186/s13046-019-1402-x

• Mak, L. Y., Lee, C. H., Cheung, K. S., Wong, D. K., Liu, F., Hui, R. W., Fung, J., Xu, A., Lam, K. S., Yuen, M. F., & Seto, W. K. (2019). Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogue. Liver international : official journal of the International Association for the Study of the Liver, 39(7), 1217–1225. https://doi.org/10.1111/liv.14104

• Mak, L. Y., Wong, D. K., Seto, W. K., Ning, Q., Cheung, K. S., Fung, J., Lai, C. L., & Yuen, M. F. (2019). Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection. Hepatology international, 13(2), 148–156. https://doi.org/10.1007/s12072-019-09928-5

• Liu, K., Seto, W. K., Lau, E., Wong, D. K., Lam, Y. F., Cheung, K. S., Mak, L. Y., Ko, K. L., To, W. P., Law, M., Wu, J. T., Lai, C. L., & Yuen, M. F. (2019). A Territorywide Prevalence Study on Blood-Borne and Enteric Viral Hepatitis in Hong Kong. The Journal of infectious diseases, 219(12), 1924–1933. https://doi.org/10.1093/infdis/jiz038

• Liu, F., Seto, W. K., Wong, D. K., Huang, F. Y., Cheung, K. S., Mak, L. Y., Sharma, R., Zhang, S., Fung, J., Lai, C. L., & Yuen, M. F. (2019). Plasma Fibronectin Levels Identified via Quantitative Proteomics Profiling Predicts Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. The Journal of infectious diseases, 220(6), 940–950. https://doi.org/10.1093/infdis/jiz223

• Tan, H. W., Leung, C. O., Chan, K. K., Ho, D. W., Leung, M. S., Wong, C. M., Ng, I. O., & Lo, R. C. (2019). Deregulated GATA6 modulates stem cell-like properties and metabolic phenotype in hepatocellular carcinoma. International journal of cancer, 145(7), 1860–1873. https://doi.org/10.1002/ijc.32248

• Fako, V., Martin, S. P., Pomyen, Y., Budhu, A., Chaisaingmongkol, J., Franck, S., Lee, J. M., Ng, I. O., Cheung, T. T., Wei, X., Liu, N., Ji, J., Zhao, L., Liu, Z., Jia, H. L., Tang, Z. Y., Qin, L. X., Kloeckner, R., Marquardt, J., Greten, T., … Wang, X. W. (2019). Gene signature predictive of hepatocellular carcinoma patient response to transarterial chemoembolization. International journal of biological sciences, 15(12), 2654–2663. https://doi.org/10.7150/ijbs.39534

• Ko, K. L., To, W. P., Mak, L. Y., Seto, W. K., Ning, Q., Fung, J., Lai, C. L., & Yuen, M. F. (2020). A large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearance. Journal of viral hepatitis, 27(4), 397–406. https://doi.org/10.1111/jvh.13237

• Mak, L. Y., Seto, W. K., Hui, R. W., Fung, J., Wong, D. K., Lai, C. L., & Yuen, M. F. (2019). Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval. Journal of viral hepatitis, 26(7), 818–827. https://doi.org/10.1111/jvh.13095

• To, W. P., Mak, L. Y., Wong, D. K., Fung, J., Liu, F., Seto, W. K., Lai, C. L., & Yuen, M. F. (2019). Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma. Journal of viral hepatitis, 26(12), 1473–1480. https://doi.org/10.1111/jvh.13191

• Mak, L. Y., Ko, M., To, E., Wong, D. K., Ma, J. H., Hui, T. L., Seto, W. K., Fung, J., Lai, C. L., & Yuen, M. F. (2019). Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients. Journal of gastroenterology and hepatology, 34(10), 1817–1823. https://doi.org/10.1111/jgh.14637

• Ma, W., Ho, D. W., Sze, K. M., Tsui, Y. M., Chan, L. K., Lee, J. M., & Ng, I. O. (2019). APOBEC3B promotes hepatocarcinogenesis and metastasis through novel deaminase-independent activity. Molecular carcinogenesis, 58(5), 643–653. https://doi.org/10.1002/mc.22956

• Chu, K., & Chok, K. (2019). Is the treatment outcome of hepatocellular carcinoma inferior in elderly patients?. World journal of gastroenterology, 25(27), 3563–3571. https://doi.org/10.3748/wjg.v25.i27.3563

• Mak, L. Y., Seto, W. K., Fung, J., & Yuen, M. F. (2019). New Biomarkers of Chronic Hepatitis B. Gut and liver, 13(6), 589–595. https://doi.org/10.5009/gnl18425

• Mak, L. Y., Liu, S. H., Yap, D. Y., Seto, W. K., Wong, D. K., Fung, J., Chan, T. M., Lai, C. L., & Yuen, M. F. (2019). In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue. Digestive diseases and sciences, 64(12), 3630–3641. https://doi.org/10.1007/s10620-019-05717-0

• Li, M. M., Tang, Y. Q., Gong, Y. F., Cheng, W., Li, H. L., Kong, F. E., Zhu, W. J., Liu, S. S., Huang, L., Guan, X. Y., Ma, N. F., & Liu, M. (2019). Development of an oncogenic dedifferentiation SOX signature with prognostic significance in hepatocellular carcinoma. BMC cancer, 19(1), 851. https://doi.org/10.1186/s12885-019-6041-2

• Huang, F. Y., Wong, D. K., Tsui, V. W., Seto, W. K., Mak, L. Y., Cheung, T. T., Lai, K. K., & Yuen, M. F. (2019). Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma. BMC cancer, 19(1), 789. https://doi.org/10.1186/s12885-019-6002-9

• Mak, L. Y., Seto, W. K., Fung, J., & Yuen, M. F. (2019). Novel developments of hepatitis B: treatment goals, agents and monitoring tools. Expert review of clinical pharmacology, 12(2), 109–120. https://doi.org/10.1080/17512433.2019.1567327

• Ma, K. W., She, W. H., Chan, A., Cheung, T. T., Fung, J., Dai, W. C., Lo, C. M., & Chok, K. (2019). Validated model for prediction of recurrent hepatocellular carcinoma after liver transplantation in Asian population. World journal of gastrointestinal oncology, 11(4), 322–334. https://doi.org/10.4251/wjgo.v11.i4.322

• She, W. H., Chok, K., Li, I., Ma, K. W., Sin, S. L., Dai, W. C., Fung, J., & Lo, C. M. (2019). Pneumocystis jirovecii-related spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema in a liver transplant recipient: a case report. BMC infectious diseases, 19(1), 66. https://doi.org/10.1186/s12879-019-3723-y

• Ma, K. W., Cheung, T. T., Leung, B., She, B., Chok, K., Chan, A., Dai, W. C., & Lo, C. M. (2019). Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: A meta-analysis. Medicine, 98(5), e14013. https://doi.org/10.1097/MD.0000000000014013

• Chok, K. S., Fung, J. Y., Dai, W. C., Sin, S. L., Ma, K. W., Chan, A. C., Cheung, T. T., & Lo, C. M. (2019). Donor ductal anomaly is not a contraindication to right liver lobe donation. Hepatobiliary & pancreatic diseases international : HBPD INT, 18(4), 343–347. https://doi.org/10.1016/j.hbpd.2019.06.001

• Ng, K., Cheung, T. T., Wong, T., Fung, J., Dai, J., Ma, K. W., She, W. H., & Lo, C. M. (2019). Long-term survival comparison between primary transplant and upfront curative treatment with salvage transplant for early stage hepatocellular carcinoma. Asian journal of surgery, 42(2), 433–442. https://doi.org/10.1016/j.asjsur.2018.08.008

• Chan, M. Y., Chok, K., Fung, J., Ng, S. L., Yiu, M. K., & Lo, C. M. (2019). Prospective Study on Sexual Dysfunction in Male Chinese Liver Transplant Recipients. American journal of men's health, 13(2), 1557988319835139. https://doi.org/10.1177/1557988319835139

• Lo RCL. An update on the histological subtypes of hepatocellular carcinoma. Hepatoma Res 2019;5:41. http://dx.doi.org/10.20517/2394-5079.2019.021

• Gong, L., Yan, Q., Zhang, Y., Fang, X., Liu, B., & Guan, X. (2019). Cancer cell reprogramming: a promising therapy converting malignancy to benignity. Cancer communications (London, England), 39(1), 48. https://doi.org/10.1186/s40880-019-0393-5

• Chow, F. C., & Chok, K. S. (2019). Colorectal liver metastases: An update on multidisciplinary approach. World journal of hepatology, 11(2), 150–172. https://doi.org/10.4254/wjh.v11.i2.150

• Chan, L. K., & Ng, I. O. (2019). Proteomic profiling in liver cancer: another new page. Translational gastroenterology and hepatology, 4, 47. https://doi.org/10.21037/tgh.2019.06.03